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Cancer-induced	bone	pain	is	reported	to	be	one	of	the	most	detrimental	aspects	of	the	
disease,	 often	 broadly	 categorized	 into	 two	 separate	 pain	 phenomena.	 Patients	 experience	
ongoing	pain,	a	dull	achy	persistent	background	pain	that	worsens	as	disease	progresses	which	
is	currently	treated	with	around	the	clock	mu	opioid	receptor	(MOR)	agonists	such	as	morphine.	
Patients	also	report	transient	episodes	of	severe	pain	that	is	spontaneous	but	often	triggered	by	
movement	 that	 “breaks	 through”	 around	 the	 clock	medication.	 Breakthrough	 pain	 is	 treated	
with	 additional	 rapid	 onset	MOR	 agonists	 that	 are	 hindered	 by	 dose-limiting	 side	 effects	 and	
often	misalign	with	treatment	for	patients.	The	failure	of	current	medications	to	effectively	treat	
patients	 and	 undesirable	 side	 effects	 of	 MOR	 agonists	 highlights	 the	 need	 to	 develop	 novel	
treatments.	 We	 examined	 the	 hypothesis	 that	 ongoing	 pain	 and	 breakthrough	 pain	 are	
mitigated	by	unique	populations	of	sensory	afferents.		
Utilizing	 a	 rat	 model	 of	 cancer-induced	 bone	 pain	 (CIBP)	 that	 implants	 MATBIII	
adenocarcinoma	cells	into	the	tibia	of	Fischer	rats,	we	demonstrate	that	IB4-binding	fibers	play	a	
critical	 role	 in	 transducing	 breakthrough	 pain,	 whereas	 TRPV1	 expressing	 fibers	 do	 not.		
Limitations	 of	 the	 chemo-ablative	 approach	 used	 to	 target	 these	 neurons	 directed	work	 to	 a	
	
	
mouse	model	of	CIBP	that	relies	on	implantation	of	Lewis	lung	carcinoma	cells	into	the	femur	of	
C57BL/6	mice.		Utilizing	Nav1.8-Cre	and	MrgD-Cre-ERT2	mouse	lines,	targeted	expression	of	the	
light	 sensitive	proton	pump	ArchT	allowed	 for	 the	 inhibition	of	 neurons	 in	 animals	with	CIBP.	
Using	 conditioned	 place	 preference	 to	 pain	 relief,	 we	 demonstrate	 that	 inhibition	 of	 Nav1.8	
fibers	 relieves	 ongoing	 pain,	 and	 silencing	 MrgD	 fibers	 in	 tumor-bearing	 animals	 results	 in	
conditioned	place	preference.	We	also	describe	a	potential	approach	to	measure	breakthrough	
pain	 in	 the	 mouse,	 but	 did	 not	 characterize	 it.	 This	 work	 provides	 evidence	 to	 target	 these	
populations	of	sensory	neurons	to	develop	treatments	in	an	effort	to	reduce	and	treat	cancer-
induced	ongoing	and	breakthrough	pain.	The	implication	of	non-peptidergic	neurons	to	convey	
components	of	cancer-induced	bone	pain	is	a	novel	finding	and	distinguishes	them	for	a	unique	
role	in	CIBP	from	other	work	in	the	pain	field.	
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CHAPTER	1	
INTRODUCTION	TO	CANCER-INDUCED	BONE	PAIN	
1.	Introduction	
1.1.	Preface,	Etiology	of	Cancer-Induced	Bone	Pain	
	 It	is	well	known	and	established	that	common	cancers	such	as	breast,	prostate	and	lung	
have	a	propensity	to	metastasize	to	the	bone	(Coleman	2006,	Lozano-Ondoua,	Symons-Liguori	
et	al.	2013,	Kane,	Hoskin	et	al.	2015).	 It	 is	estimated	that	nearly	70%	of	patients	 that	die	as	a	
result	of	their	cancer	have	bone	metastasis,	with	the	most	common	sites	of	cancer	metastasis	
being	the	vertebrae,	pelvis	 long	bones	and	ribs	 (Kane,	Hoskin	et	al.	2015).	Estimates	place	the	
incidence	of	patients	suffering	from	cancer	or	a	history	of	cancer	 in	America	at	14.5	million	 in	
2015	and	nearly	32.6	million	worldwide	 in	2012	 (Smith	and	Saiki	 2015).	 	Reports	also	 suggest	
that	 nearly	 all	 patients	 with	 myeloma,	 more	 than	 half	 with	 metastatic	 breast	 and	 prostate	
cancer	and	a	third	of	patients	with	lung	cancer	develop	metastasis	to	the	bone	(Gul,	Sendur	et	
al.	2016).		
Upon	 metastasis	 these	 lines	 of	 cancer	 often	 have	 differential	 effects	 on	 the	 bone	
following	 their	 establishment	 and	 development	 of	 unique	 tumor	microenvironments	 (Mantyh	
2014,	Mantyh	2014).	 The	origin	of	 these	 tumors	 induces	varying,	but	 characterized	effects	on	
the	bone.	For	example,	metastases	of	 lung	origin	 lean	towards	bone	degradation	or	osteolytic	
lesions,	breast	cancer	metastases	typically	induce	a	range	of	maladaptive	bone	remodeling	that	
results	 in	 osteolytic	 lesions	 as	 well	 as	 maladaptive	 osteoblastic	 lesions	 (Mantyh	 2006)).	
Metastases	 of	 prostate	 origin	 typically	 have	maladaptive	 bone	 deposition	 and	 remodeling,	 or	
osteoblastic	lesions	(Mantyh	2006).	The	maladaptive	bone	remodeling	that	occurs	in	patients	is	
often,	but	not	always	accompanied	by	pain	that	originates	from	the	sites	of	metastasis	and	bone	
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remodeling	(Mantyh	2014,	Mantyh	2014,	Kane,	Hoskin	et	al.	2015).	Nearly	two-thirds	of	patients	
with	 metastasis	 have	 been	 reported	 to	 experience	 severe	 pain	 (Mantyh	 2006).	 While	 more	
broadly,	34%	of	patients	who	are	hospitalized	with	cancer	and	45%	of	patients	enrolled	 in	 in-
home	care	report	pain	(Scarpi,	Calistri	et	al.	2014).	In	fact,	pain	originating	from	a	site	of	tumor	
growth	or	metastasis	is	typically	one	of	the	first	symptoms	that	draws	patients	to	the	clinic	and	
nearly	 half	 of	 patients	 with	 cancer	 report	moderate	 to	 severe	 pain	 (Halvorson,	 Kubota	 et	 al.	
2005,	Kane,	Hoskin	et	al.	2015,	Paice	2018).	
Pain	is	often	reported	by	patients	to	be	one	of	the	worst	or	most	feared	consequences	
of	 these	 ailments	 (Paice	 2018,	 Paice	 2018).	 Despite	 improvements	 in	 pain	 management	 and	
improved	understanding	of	CIBP,	patients	continue	to	suffer	from	inadequate	pain	management	
(Paice	2018,	Paice	2018).	From	the	perspective	of	the	field	as	well	as	patients,	this	is	worsened	
by	the	increased	survival	time	of	patients,	due	to	improvements	in	cancer	treatments,	patients	
live	 longer	 with	 these	 maladaptive	 bone	 pathologies	 (Lozano-Ondoua,	 Hanlon	 et	 al.	 2013,	
Lozano-Ondoua,	Symons-Liguori	et	al.	2013,	Kane,	Hoskin	et	al.	2015,	Paice	2018,	Paice	2018).	
Patients’	 reports	 typically	 describe	 two	 separate	 pain	 phenotypes,	 that	 as	 the	 disease	
progresses	 are	 both	 treated	with	 the	 same	 class	 of	 analgesics.	 The	 first	 and	more	 prominent	
pain	 phenotype	 is	 a	 dull-achy	 type	 of	 pain	 from	 the	 site	 of	 remodeling/metastasis	 that	 is	
constant	and	worsens	as	the	disease	progresses	and/or	time	goes	on.	Due	to	the	description	of	
the	pain	and	its	nature,	this	is	referred	to	as	ongoing	pain.		
This	is	treated	in	accordance	with	the	World	Health	Organization’s	“Ladder”	of	analgesia	
that	 begins	 with	 non-steroidal	 anti-inflammatory	 drugs	 (NSAIDs)	 to	 treat	 the	 pain	 patients	
experience.	This	 is	escalated	 in	 response	 to	 the	worsening	of	pain	 reported	by	 the	patient,	 to	
adding	adjuvant	treatments	in	addition	to	NSAIDs,	followed	by	“weak”	opioids	such	as	tramadol,	
codeine	 and	 buprenorphine,	 but	 ultimately	 escalates	 to	 around	 the	 clock	mu	 opioid	 receptor	
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(MOR)	agonists	such	as	morphine	(Sabino	and	Mantyh	2005,	Mantyh	2006,	Kane,	Hoskin	et	al.	
2015).	 The	 last	 step	 on	 the	 ladder	 allows	 for	 additional	 administration	 of	 adjuvant	 drugs	 to	
manage	 fear	 and	 anxiety,	 however	 this	 may	 introduce	 complications	 with	 chronic	 opioid	
regiments	(Bruera	and	Paice	2015,	Kane,	Hoskin	et	al.	2015)	.	
	This	 escalation	 occurs	 in	 an	 attempt	 to	mitigate	 background	 pain	 to	 a	 level	 that	 can	
allow	 patients	 to	 still	 retain	 a	 positive	 quality	 of	 life.	 However,	 some	 patients’	 doses	 are	
escalated	to	a	point	where	the	treatments	(high	doses	of	MOR	agonists)	detrimentally	affect	the	
patient’s	 quality	 of	 life	 themselves.	 Proper	management	 of	 this	 requires	 a	 skilled	 and	 vigilant	
team	of	medical	professionals	to	adequately	titrate	and	prescribe	analgesics	(Bruera	and	Paice	
2015).	 In	 addition	 to	 this,	 patients	 often	 have	 to	 be	 prescribed	 additional	 compensatory	
compounds,	 such	 as	 laxatives	 early	 in	 analgesic	 prescription	 to	manage	 the	more	 prominent	
side-effects	 of	 opioid	 therapy	 such	 as	 constipation	 (Bruera	 and	 Paice	 2015).	 Treating	 patients	
afflicted	 with	 CIBP	 can	 be	 difficult	 even	 after	 following	 well	 described	 practices,	 requiring	
multiple	visits	to	titrate	dosing	as	well	as	identifying	tolerable	MOR	agonist	agents	(Bruera	and	
Paice	 2015,	 Smith	 and	 Saiki	 2015).	 Another	 challenge	 is	 adequate	 education	 of	 clinicians	 in	
successful	 pain	 management.	 Reports	 suggest	 that	 clinicians	 in	 the	 most	 optimal	 position	 to	
manage	a	patient’s	pain,	receive	inadequate	training	to	do	so	(Smith	and	Saiki	2015).		Even	while	
practices	exist	and	continue	to	improve,	estimates	still	place	nearly	50%	of	patients	with	under	
managed	pain	(Smith	and	Saiki	2015).	Development	of	tolerance	to	MOR	agonists	that	patients	
likely	develop	also	 leads	to	escalation	of	doses	of	 treatments.	While	not	directly	assessing	the	
outcomes	 in	patients	with	CIBP,	 there	 is	mounting	evidence	that	MOR	agonists	 themselves	do	
not	effectively	treat	vary	forms	of	chronic	pain	(Morrone,	Scuteri	et	al.	2017).	Following	in	the	
footsteps	of	the	larger	pain	research	community,	these	limitations	of	MOR	agonists	drives	those	
of	us	working	to	find	better	treatments	for	advanced	and	difficult	pain	types,	and	to	question	if	
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it	 is	 responsible	 to	continue	 to	 rely	 so	heavily	on	 treatment	of	pain	with	chronic	 regiments	of	
MOR	agonists.	This	is	further	complicated	at	this	point	in	time	by	the	opioid	overuse	epidemic,	
which	correlative	studies	suggests	has	directly	affected	patients	suffering	from	CIBP,	resulting	in	
decreased	prescriptions	for	patients	who	have	no	alternative	to	manage	their	pain	(Paice	2018).	
Some	 clinical	 reports	 argue	 that	 treatment	 of	 ongoing	 pain	 with	 MOR	 agonists	 are	
sufficient	and	ample	at	 reducing	pain	and	 improving	quality	of	 life,	while	 it	 Is	widely	accepted	
that	a	better	alternative	is	necessary	for	patients	(Mantyh	2006,	Schmidt	2015,	Mercadante	and	
Bruera	2016).	Best	clinical	practice	aims	to	treat	each	individual	patient	while	maintaining	open	
dialogue	to	allow	changes	 in	 treatment	dependent	on	the	needs	of	 the	 individual	 (Bruera	and	
Paice	2015).	One	practice	used	in	the	clinic	known	as	“opioid	switching”,	a	practice	that	nearly	
80%	of	patients	will	require,	involves	the	rotation	or	switching	between	different	MOR	agonists	
to	achieve	therapeutic	levels	of	pain	relief	while	minimizing	side-effects	(Bruera	and	Paice	2015,	
Mercadante	 and	 Bruera	 2016).	 Some	 work	 suggests	 that	 this	 practice	 can	 reduce,	 but	 not	
eliminate	adverse	side	effects	in	as	many	as	50-90%	of	patients	(Mercadante	and	Bruera	2016).	
This	 is	 not	 completely	 understood,	 and	 attempts	 to	 underpin	 a	 genetic	 correlation	 have	
provided	 no	 target	 single	 nucleotide	 polymorphisms	 supporting	 a	 cause	 for	 the	 exacerbated	
pain	 from	 CIBP,	 or	 the	 need	 to	 switch	 certain	 individuals	 from	 one	MOR	 agonist	 to	 another	
(Scarpi,	 Calistri	 et	 al.	 2014).	 This	 leads	 to	 a	 best	 practice	 of	 tailoring	 dosing	 regiments	 and	
therapies	 to	 fit	 the	 needs	 of	 the	 individual	 rather	 than	 treating	 patients	 as	 a	whole,	 another	
detail	highlighting	why	CIBP	is	“one	of	the	most	difficult	chronic	pains	to	treat”	(Mantyh	2014,	
Mantyh	2014).	These	limitations	of	the	current	approach	to	treating	patients	with	CIBP	highlight	
why	research	continues	to	attempt	to	find	alternatives	to	MOR	agonists	to	treat	intense	pain.		
In	 addition,	 and	 perhaps	 alternatively	 to	 MOR	 agonists,	 patients	 are	 treated	 with	
radiotherapy,	 and	 agents	 that	 actively	 block	 cancer-induced	bone	 remodeling	 to	 stay	ongoing	
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pain	from	sites	of	pathological	bone	remodeling,	which	have	varying	degrees	of	success	(Kane,	
Hoskin	 et	 al.	 2015).	 Bisphosphonates	 have	 been	 demonstrated	 to	 bind	 to	 bone	 and	 actively	
block	osteoclast	induced	bone	destruction	through	osteoclast	induced	cell	death	(Drake,	Clarke	
et	 al.	 2008,	Mantyh	2014,	Mantyh	2014).	Osteoprotegerin	 (OPG)	 and	denosumab	both	 target	
and	 block	 the	 receptor	 activator	 of	 nuclear	 factor	 kappa	 B	 (RANK)	 and	 RANK-ligand	 (RANKL)	
pathway	that	induces	osteoclast	activation.	This	approach	has	been	demonstrated	to	effectively	
block	 pathological	 osteoclast	 induced	 bone-remodeling,	 which	 by	 blocking	 bone	 remodeling	
resolves	 some	 aspects	 of	 pain	 from	 sites	 of	metastasis,	 but	 these	 treatments	 have	 restrictive	
side-effects	of	their	own	(Mantyh	2014,	Mantyh	2014,	Gul,	Sendur	et	al.	2016).		
Studies	 indicate	 that	 these	compounds	 reduce	 skeletal	pain	and	delay	 skeletal	 related	
events	such	as	hypercalcemia	and	fracture,	some	of	the	factors	that	are	believed	to	induce	pain	
from	the	bone,	but	have	room	for	 improvement	(Coleman	2008,	Mantyh	2014,	Mantyh	2014).	
While	 effective	 at	 reducing	 pathological	 bone	 resorption	 in	 a	 number	 of	 skeletal	 diseases,	
bisphosphonates	 have	 been	 associated	 with	 several	 undesirable	 side-effects	 that	 can	 lead	 to	
discontinued	 use.	 The	 first	 being	 gastrointestinal	 disturbance	 including	 erosive	 esophagitis	 if	
taken	 improperly,	and	potentially	nausea,	dyspepsia,	abdominal	pain	and	gastritis	 (Kennel	and	
Drake	 2009).	 Initial	 exposure	 to	 bisphosphonates	may	 also	 induce	 temporary	 fever,	 however	
this	occurrence	reduces	after	multiple	exposures	and	 is	believed	to	be	temporary	 (Kennel	and	
Drake	2009).	Severe	suppression	of	bone	turn	over	and	the	requirement	for	adequate	vitamin	D	
and	 calcium	 supplementation	 are	 also	 considerations	 for	 patients	 undergoing	 chronic	
bisphosphonate	 therapy	 (Kennel	 and	 Drake	 2009).	 Lastly	 and	 perhaps	most	 apparent	 are	 the	
associated	 risks	 of	 renal	 dysfunction	 and	 osteonecrosis	 of	 the	 jaw,	 resulting	 in	 special	
considerations	to	be	taken	if	use	in	patients	is	required	(Coleman	2008,	Kennel	and	Drake	2009).		
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While	 preclinical	 evidence	 of	 Anti-nerve	 growth	 factor	 (NGF)	 antibodies	 provide	
evidence	that	the	treatment	blocks	measures	of	ongoing	bone	pain	in	both	models	of	CIBP	and	
osteoporosis,	 they	 fail	 to	 stop	 bone	 remodeling	 (Halvorson,	 Kubota	 et	 al.	 2005,	 Jimenez-
Andrade,	 Bloom	 et	 al.	 2010,	 Bloom,	 Jimenez-Andrade	 et	 al.	 2011,	 Suzuki,	 Millecamps	 et	 al.	
2018).	 At	 least	 one	 clinical	 trial	 investigating	 the	 effects	 of	 anti-NGF	 monoclonal	 antibody	
suggest	positive	effects	on	CIBP,	as	well	as	other	studies	suggesting	the	same	 in	osteoarthritis	
and	 lower	 back	 pain	 (Sopata,	 Katz	 et	 al.	 2015,	 Chang,	 Hsu	 et	 al.	 2016).	 Several	 studies	 that	
included	 anti-NGF	 treatment	 suggested	 a	 connection	 between	 long	 term	 use	 of	 anti-NGF	
treatment,	with	or	without	NSAID	co-administration,	and	rapid	 joint	destruction,	resulting	 in	a	
temporary	hold	on	clinical	studies	utilizing	this	approach	(Chang,	Hsu	et	al.	2016).	However,	this	
ban	 has	 since	 been	 lifted	 due	 to	 the	 potential	 for	 benefit	 in	 the	 clinical	 population	 with	
considerations	 and	 radiologic	 intervention,	 but	 no	 clinically/FDA	 approved	 anti-NGF	 agent	 is	
currently	available	(Chang,	Hsu	et	al.	2016).		
In	addition	to	ongoing	pain,	many	patients	with	skeletal	metastasis	experience	pain	that	
“breaks	 through”	around	the	clock	medication,	 typically	opioids,	managing	 their	ongoing	pain.	
Due	to	its	etiology	this	pain	phenomenon	is	referred	to	as	“breakthrough	pain”	(BTP).	Estimates	
put	the	percentages	of	patients	who	experience	BTP	while	already	experiencing	ongoing	pain	at	
40-80%,	however	confounds	 in	reports	exist	as	to	whether	or	not	proper	definition	of	BTP	has	
been	used	 in	 some	 studies	 examining	 the	pain	 type	 (Mercadante	 2015).	While	BTP	 can	occur	
spontaneously,	 it	 is	 much	 more	 often	 triggered,	 and	 likely	 more	 readily	 documented,	 in	
response	to	movement.	Unavoidable	movements	such	as	getting	out	of	bed	in	the	morning	or	
performing	 necessary	 tasks	 often	 can	 be	 enough	 to	 trigger	 a	 BTP	 episode.	 	 Equally	 as	
detrimental	but	likely	more	stressful,	unexpected	and	involuntary	movements	such	as	coughing	
or	 sneezing	 can	 result	 in	 initiation	of	a	BTP	experience	 (Mercadante	2015).	 It	 is	 reported	 that	
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these	BTP	experiences	can	occur	as	many	as	4	times	a	day,	 rate	as	high	as	7.4/10	on	the	pain	
intensity	 scale	 and	 last	 30-60	 minutes	 (Mercadante	 2015,	 Mercadante	 2018).	 Due	 to	 the	
unpredictable	 nature	 of	 BTP,	 patients	 often	 have	 to	 choose	 between	 pursuing	 activities,	 (i.e.	
maintaining	a	positive	quality	of	life)	or	avoiding	activities	that	might	produce	pain	(Mercadante	
2015).	
It	 is	 in	 part	 due	 to	 the	 unexpected	 nature	 of	 this	 pain	 type	 and	 the	 need	 to	 take	
analgesic	 regiments	 in	 response	 to	 the	 start	 of	 the	 pain,	 that	 current	 treatments	 fall	 on	 the	
patient	to	dose	in	response	to	sensation	of	pain.	If	you	can	imagine,	this	is	not	an	ideal	method	
of	 effectively	 treating	 intense	 pain	 and	 improving	 the	 quality	 of	 life	 of	 patients.	 Due	 to	 the	
pharmacokinetics	of	treatment	methods	(dosing	in	response	to	pain	initiation),	this	often	results	
in	patients	missing	the	window	to	adequately	treat	their	most	severe	pain	(Kane,	Hoskin	et	al.	
2015).	By	clinical	definition	BTP	must	be	a	pain	experience	that	breaks	through	onboard	opioid	
treatments,	 originally	 described	 in	 1990	 (Portenoy	 and	 Hagen	 1990,	 Mercadante	 2015).	
Although	this	 is	the	well-accepted	clinical	and	preclinical	definition,	until	recently	many	clinical	
based	 reports	 have	 not	 accurately	 adhered	 to	 this	 criteria,	 making	 the	 description	 of	 and	
evaluation	of	treatment	of	BTP	in	past	reports	to	some	extent	murky	(Mercadante	2015).	Recent	
reports	 address	 and	 acknowledge	 this	 limitation	 and	 highlight	 the	 need	 for	 more	 stringent	
inclusion/exclusion	 criteria	 in	 clinical	 reports	 (Mercadante	 2011,	 Mercadante	 2015).	 Previous	
treatments	of	BTP	involved	dosing	oral	morphine	at	 levels	proportional	to	those	being	used	to	
manage	patients’	ongoing	background	pain,	with	 little	to	no	scientific	evidence	to	support	this	
approach	 (Mercadante	 2011,	 Mercadante	 2015).	 While	 intravenous	 morphine	 with	 doses	 of	
between	 6	 and	 12	 mg,	 (also	 proportional	 to	 daily	 regiments	 of	 background	 medication)	
demonstrate	 rapid	 pain	 relief,	 it	 is	 confounded	 by	 the	 propensity	 of	 cognitive	 failure	 and	
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feasibility	of	 intravenous	delivery,	which	most	patients	cannot	comply	with	(Mercadante	2011,	
Mercadante	2012,	Sousa,	de	Santana	Neto	et	al.	2014,	Mercadante	2015).		
Due	 to	 the	 relatively	 slow	 pharmacokinetics	 of	 oral	 morphine	 treatment,	 analgesic	
application	has	shifted	towards	more	rapid	MOR	agonist	formulations	(Mercadante	2015).	The	
current	 mainstay	 to	 treat	 BTP	 is	 with	 rapid	 onset	 opioids,	 with	 varying	 methods	 of	 delivery,	
which	 have	 reportedly	 better	 outcomes	 for	 patients,	 however	 efficacy	 of	 these	 require	 ideal	
patient	 responsiveness	 (Mercadante	2015).	 Transmucosal	 fentanyl	 and	 lozenges,	 lollipops	 and	
other	means	to	rapidly	and	dose-dependently	deliver	additional	MOR	agonists	are	available	to	
patients	 (Mercadante	 2015).	 A	 recent	 report	 attempted	 to	 compare	 new	 analgesics	 used	 to	
treat	 BTP	 to	 the	 traditional	 oral	 morphine,	 finding	 that	 reported	 and	 well	 conducted	 clinical	
experiments	suggest	that	out	of	the	available	treatments,	the	most	effective	agents	are	fentanyl	
products,	 although	 admitting	 oral	morphine	 has	 its	 place	 for	 treatment	 of	 predictive	 episodic	
BTP	(Mercadante	2018).	
Relying	on	additional	MOR	agonists	to	treat	BTP	is	limited	in	a	number	of	ways.	The	first	
hurdle	in	treatment	likely	lies	with	the	nature	of	dosing	in	response	to	the	sensation	of	pain,	as	
previously	 mentioned,	 which	 can	 result	 in	 patients	 misaligning	 therapy	 with	 their	 pain	
experience	(Kane,	Hoskin	et	al.	2015).	 In	this	sense,	a	medication	with	alternative	mechanisms	
of	 action	 to	 MOR	 agonists	 that	 would	 allow	 for	 around	 the	 clock	 dosing	 would	 be	 ideal.	
Alternative	 mechanisms	 to	 MOR	 agonists	 are	 needed	 as	 evidence	 reports	 that	 even	 at	 high	
doses	of	MOR	agonists,	patients	with	advanced	disease	and	pain,	continue	to	experience	BTP,	
demonstrating	that	MOR	agonists	fail	to	effectively	treat	BTP	(Bennett	2010,	Havelin,	Imbert	et	
al.	 2017).	 One	 possible	 explanation	 to	 this	 is	 that	 the	 sensory	 fibers	 transducing	 BTP	may	 be	
mechanistically	 or	 inherently	 different	 from	 those	 that	 respond	 to	 MOR	 agonists	 and	
successfully	manage	ongoing	pain	 (Havelin,	 Imbert	et	al.	2017).	Due	to	 the	regiments	patients	
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are	 already	 on,	 there	 is	 the	 realistic	 limitation	 of	 dosing	 to	 effect	 due	 to	 the	 adverse	 and	
potentially	 life	 threatening	 side	 effects	 of	 MOR	 agonists.	 Side	 effects	 such	 as	 nausea,	
constipation,	somnolence,	dizziness	and	risk	of	falls,	mental	confusion	and	potential	respiratory	
depression,	 all	 limit	 the	 improvement	 of	 quality	 of	 life	 these	 patients	 experience	 despite	 any	
benefits	 to	pain	 relief	 they	may	experience	 (Bruera	 and	Paice	2015,	Kane,	Hoskin	et	 al.	 2015,	
Mercadante	2015).		
A	non-opioid	option	with	opioid	sparing	effects	would	greatly	benefit	the	quality	of	life	
of	these	patients.	These	limitations	and	current	failures	of	treatments	demonstrate	that	at	the	
level	 of	 the	 patient	 we	 have	 not	 developed	 a	 treatment	 that	 sufficiently	 manages	 CIBP	 or	 a	
treatment	 that	 simultaneously	 allows	 them	 to	 return	 to	 the	 quality	 of	 life	 they	 desire.	 	 To	
develop	such	a	class	or	agent	of	analgesics,	the	field	has	relied	heavily	on	animal	models	of	CIBP	
that	 allow	 us	 to	 isolate	 the	 site	 where	 CIBP	 is	 generated	 and	 therefore	 study	 the	 effects	 of	
tumor	modulation	of	local	tissue	and	neuroanatomical	changes	induced	by	this	chronic	pain	in	a	
controlled	manner.		
	
1.2.	Contributions	of	Preclinical	Models	to	the	Neurobiology	of	Bone	Pain	
The	section	below	is	work	that	 is	published	as	a	review	article	 in	Osteoporosis	Reports	
(Havelin	and	King	2018).	It	has	been	slightly	modified	for	this	dissertation.	
	
1.2.1.	Introduction	
Ultimately	 a	most	 optimal	 treatment	may	be	 a	 dual	 acting	 therapy	 that	 has	 alternate	
molecular	 targets	 that	 treat	 pain	 while	 also	 slowing	 the	 growth	 of	 cancer.	 Preclinical	 studies	
over	the	past	20	years	have	implicated	a	number	of	molecular	targets,	as	well	as	some	agents	to	
target	them,	however	few	if	any	of	these	have	made	it	to	the	clinic	to	positively	impact	patient’s	
10	
	
quality	 of	 life.	 These	 will	 be	 discussed	 in	 Chapter	 1.3	 after	 a	 brief	 explanation	 of	 preclinical	
models	 and	 pain	 signaling	 to	 emphasize	 contributions	 preclinical	 models	 have	 made	 to	 our	
understanding	of	mechanisms	driving	CIBP.		
Bone	 and	 joint	 pain	 can	 occur	 in	 response	 to	 numerous	 conditions	 including	 trauma,	
infection,	 inflammation,	 autoimmune	 disease,	 genetic	 driven	 disease	 states,	 joint	 and	 bone	
pathology	associated	with	aging,	and	cancer.	Bone	and	joint	associated	pain	can	be	acute	(e.g.	
due	 to	 trauma),	 recurring,	 or	 chronic	 in	 nature.	 Indeed,	 musculoskeletal	 pain	 such	 as	
osteoarthritis	is	the	most	common	form	of	chronic	pain	and	disability	worldwide.	It	is	important	
to	 recognize	 that	 bone	 and	 joint	 pain	 is	 very	 complex,	with	multiple	 types	 of	 pain	 as	well	 as	
multiple	 etiologies	 that	 may	 require	 different	 treatment	 strategies	 for	 complete	 pain	
management.	 Some	 patients	 also	 report	 development	 of	 persistent	 background	 pain	 and/or	
breakthrough	 pain	 episodes	 that	 are	 resistant	 to	 currently	 available	 medications	 (Hawker,	
Stewart	et	al.	2008,	Paice	and	Ferrell	2011,	Hawker	and	Stanaitis	2014,	Mercadante	2015).	This	
indicates	a	requirement	for	development	of	therapies	targeting	multiple	mechanisms	underlying	
the	various	aspects	of	bone	and	joint	pain	for	more	comprehensive	pain	management	for	these	
patients.	 Development	 of	 such	 therapeutic	 options	 requires	 better	 understanding	 of	
mechanisms	underlying	the	multiple	aspects	of	bone	and	joint	pain	needed	for	better	care	for	
these	patients.	
	
1.2.2.	Overview	of	the	Pain	Pathway	
Signals	from	events	that	may	damage	tissue	(e.g.	twisted	joint,	stressful	impact)	or	from	
actual	 damaged	 tissue	 activate	 specialized	 sensory	 neurons	 known	 as	 nociceptors.	 Both	 bone	
and	joint	tissue	are	innervated	by	these	specialized	neurons	which	allow	for	the	transduction	of	
painful	 stimuli	 to	 aid	 in	 preventing	 further	 damage	 to	 tissue	 and	 repeating	 potentially	 tissue	
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damaging	 behaviors	 (Jimenez-Andrade,	 Mantyh	 et	 al.	 2010,	 Alliston,	 Hernandez	 et	 al.	 2017,	
Eitner,	Hofmann	et	al.	2017,	Ivanusic	2017).	Multiple	classes	of	nociceptors	have	been	studied	to	
date,	 differentiated	 by	 their	 cell	 body	 and	 axon	 size,	 their	 myelination	 patterns,	
electrophysiological	 characteristics	 such	 as	 conduction	 velocity	 and	 response	 thresholds,	 and	
the	 characteristics	 of	 stimuli	 that	 they	 respond	 to	 (Schaible	 and	 Schmidt	 1983,	 Schaible	 and	
Schmidt	1983,	Cavanaugh,	Lee	et	al.	2009,	Woller,	Eddinger	et	al.	2018).	Evidence	that	different	
classes	 of	 sensory	 neurons	 contain	 observable	 differences	 in	 cytochemical	markers	 as	well	 as	
terminate	 in	different	anatomical	 locations	with	the	spinal	cord	dorsal	horn	have	existed	since	
the	 1980’s	 and	1970s	 (Hunt	 and	Rossi	 1985).	 Interestingly,	 the	observations	 that	 peptide	 rich	
and	peptide	lacking	c-fibers	have	slightly	different	innervation	patterns	in	the	periphery,	and	the	
theory	that	these	nociceptors	may	indeed	transmit	unique	nociceptive	signals	is	not	new	(Hunt	
and	 Rossi	 1985).	 Critical	 evaluation	 of	 these	 two	 fiber	 types	 by	 Molliver	 and	 colleagues	
demonstrated	unique	neurochemical	markers	between	 the	populations	as	well	as	 termination	
patters	 in	 the	spinal	 cord	dorsal	horn	 (Molliver,	Radeke	et	al.	1995).	Elegant	work	by	Molliver	
and	 colleagues	 demonstrated	 that	 throughout	 development	 expression	 patterns	 of	 TrkA,	 the	
receptor	 for	NGF,	 is	 downregulated	 to	 a	 smaller	 population	of	 neurons	 that	 go	on	 to	 express	
classic	 markers	 of	 peptidergic	 fibers	 (i.e.	 calcitonin	 gene-related	 peptide,	 [CGRP])	 (Molliver,	
Radeke	 et	 al.	 1995,	 Molliver,	 Wright	 et	 al.	 1997).	 Neurons	 in	 the	 dorsal	 root	 ganglia	 that	
downregulate	 TrkA	 begin	 to	 express	 c-Ret,	 a	 receptor	 for	 glial	 cell	 line-derived	 neurotrophic	
factor	 (GDNF)	 (Molliver,	Wright	 et	 al.	 1997).	 Additionally,	 this	 work	 demonstrated	 that	 while	
TrkA	 expressing	 neurons	 require	 NGF	 for	 continued	 survival,	 c-Ret	 expressing	 cells	 require	
GDNF,	and	the	two	cell	populations	do	not	survive	 in	the	presence	of	the	others	neurotrophic	
factor	(Molliver,	Wright	et	al.	1997).	Reports	have	also	suggested	that	following	dissection	and	
growth	 in-vitro	 and	 injury	 the	 non-peptidergic	 population	 of	 cells	 potentially	 undergo	 a	
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phenotypic	switch	or	regression	(Wang,	Molliver	et	al.	2011).	 In-vitro	the	non-peptidergic	cells	
once	 again	 require	 NGF	 to	 survive,	 and	 in-vivo	 following	 injury	 they	 begin	 to	 express	 the	
transient	 receptor	 potential	 vanilliod	 1	 (TRPV1)	 protein,	 a	 classical	marker	 of	 the	 peptidergic	
population	(Wang,	Molliver	et	al.	2011).		Table	1.1	contains	some	common	nomenclature	that	is	
used	somewhat	interchangeably	when	discussing	these	two	fiber	types.	
	
These	classic	observations	have	been	repeated,	supported	and	expanded	upon	through	
the	 use	 of	 modern	 tools.	 Recent	 RNA	 sequencing	 data	 indicate	 that	 multiple	 classes	 of	
nociceptors	 exist	 (Usoskin,	 Furlan	 et	 al.	 2015).	 Distinct	 RNA	 transcription	 profiles	 and	 protein	
expression	 in	 conjunction	 with	 behavioral	 experiments	 demonstrate	 specific	 nociceptive	
responses	from	nociceptor	populations	that	have	distinct	molecular	characteristics	(Zylka,	Rice	
et	 al.	 2005,	 Cavanaugh,	 Lee	 et	 al.	 2009,	 Scherrer,	 Imamachi	 et	 al.	 2009,	 King,	Qu	 et	 al.	 2011,	
Okun,	DeFelice	et	al.	2011,	Barabas,	Kossyreva	et	al.	2012,	Usoskin,	Furlan	et	al.	2015,	Havelin,	
Imbert	et	al.	2017).	Studies	such	as	these	demonstrate	that	different	fiber	populations	not	only	
exist	 but	 convey	 distinct	 sensory	 information	 depending	 on	 modality	 (thermal,	 chemical,	
mechanical)	as	well	as	areas	of	innervation	(cutaneous	vs	deep	tissue)	as	outlined	in	the	labeled	
line	 hypothesis	 of	 sensory	 processing	 (Cavanaugh,	 Lee	 et	 al.	 2009,	 Scherrer,	 Imamachi	 et	 al.	
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2009,	King,	Qu	et	al.	2011,	Okun,	DeFelice	et	al.	2011,	Barabas,	Kossyreva	et	al.	2012,	Havelin,	
Imbert	et	al.	2017).	
Sensory	 fibers	 mediating	 pain	 and	 itch	 project	 to	 the	 spinal	 cord,	 where	 projections	
terminate	 in	 the	superficial	 lamina	of	 the	dorsal	horn,	 lamina	 I	and	 II	 (Link,	Pulliam	et	al.	 ,	Ma	
2010,	Abraira	and	Ginty	2013,	Bourane,	Duan	et	al.	2015,	Duan,	Cheng	et	al.	2017,	Todd	2017).	
Upon	 activation	 by	 noxious	 stimulation,	 terminal	 endings	 of	 the	 nociceptors	 release	 small	
molecule	 (eg.	 glutamate)	 and	peptidergic	 (e.g.	 substance	 P,	 CGRP)	 neurotransmitters	 into	 the	
synaptic	cleft.	Of	interest	to	our	work,	the	two	major	populations	of	nociceptors	often	referred	
to	 as	 the	 “non-peptidergic”	 and	 “peptidergic”	 have	 been	 demonstrated	 to	 use	 these	 signals.	
These	neurotransmitters	act	on	receptors	located	on	interneurons	within	the	spinal	cord	as	well	
as	 projection	 neurons	 that	 project	 along	 specialized	 tracts	 (e.g.	 the	 anterolateral	 tract)	 to	
various	regions	of	the	brain	such	as	the	thalamus,	periaqueductal	grey,	lateral	parabrachial	area	
and	regions	within	the	medullary	reticular	formation	(Link,	Pulliam	et	al.	,	Ma	2010,	Abraira	and	
Ginty	2013,	Bourane,	Duan	et	al.	2015,	Duan,	Cheng	et	al.	2017,	Todd	2017).	There	has	been	a	
great	deal	of	progress	 in	gaining	a	better	understanding	of	 the	circuitry	mediating	nociception	
within	the	spinal	cord	(Link,	Pulliam	et	al.	,	Ma	2010,	Abraira	and	Ginty	2013,	Bourane,	Duan	et	
al.	2015,	Duan,	Cheng	et	al.	2017,	Todd	2017).		
While	some	of	the	second	order	neurons	within	superficial	dorsal	horn	of	the	spinal	cord	
project	 signals	 directly	 to	 the	 brain,	 not	 all	 neurons	 are	 involved	 in	 directly	 transmitting	
information	to	the	brain	(Todd	2017).	Additionally,	within	lamina	I-II,	roughly	90-95%	neurons	in	
lamina	 I	 and	 nearly	 all	 neurons	 in	 lamina	 II	 are	 characterized	 as	 interneurons	 (Todd	 2017).	
Interneurons	 that	 modulate	 pain	 signals	 intuitively	 consist	 of	 both	 inhibitory	 neurons	 that	
release	 gamma-aminonutyric	 acid	 (GABA)	 and	 glycine,	 and	 excitatory	 interneurons	 that	 are	
predominately	 glutamatergic	 (Todd	 2017).	 	 Various	 studies	 examining	 the	 role	 of	 these	
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interneurons	 indicate	 that	 they	play	a	key	 role	 in	processing	 the	 incoming	 signal,	with	 several	
interneuronal	populations	responding	to	multiple	modalities	of	input	(e.g.	chemical,	mechanical,	
thermal,	touch,	itch)	(Abraira	and	Ginty	2013,	Duan,	Cheng	et	al.	2014,	Bonin,	Wang	et	al.	2016,	
Koch,	Acton	et	al.	2018).	Although	studies	have	begun	to	explore	the	role	of	subpopulations	of	
spinal	inhibitory	and	excitatory	interneurons	in	mediating	pain,	itch	and	mechanical	allodynia,	a	
full	understanding	of	the	complex	interactions	and	circuitry	is	not	complete	(Koch,	Acton	et	al.	
2018).	Little	is	known	regarding	processing	of	sensory	information	from	deep	tissues	such	as	the	
joint	and	the	bones.	 It	 is	very	 likely	 that	gaining	a	better	understanding	of	 the	processing	and	
integration	of	signals	within	the	spinal	cord	will	be	essential	in	developing	improved	treatments	
that	 address	 the	 multiple	 components	 of	 bone	 and	 joint	 pain	 such	 as	 movement-associated	
pain,	breakthrough	pain,	and	persistent	background	aches	and	pains.		
Of	importance,	multiple	regions	within	the	brain	including	cortical	regions	(e.g.	anterior	
cingulate	 cortex,	 somatosensory	 cortex,	 prefrontal	 cortex,	 insula,	 parietal	 lobe),	 the	
diencephalon	(thalamus),	and	the	limbic	regions	(e.g.	amygdala)	are	implicated	in	processing	the	
incoming	signal	and	contribute	to	the	perception	of	pain	(Tracey	2017).	Notably,	these	different	
brain	 regions	may	 contribute	 to	 different	 components	 of	 the	 complex	 sensation	 of	 pain	 that	
includes	 both	 sensory	 and	 emotional	 components	 (Navratilova,	 Atcherley	 et	 al.	 2015,	
Navratilova,	Morimura	et	al.	2016).	Clinical	and	preclinical	studies	are	making	important	gains	in	
our	understanding	of	how	these	different	brain	regions	contribute	to	the	affective	(unpleasant)	
and	sensory	(intensity,	location)	aspects	of	pain	(Porreca	and	Navratilova	2017).	How	these	and	
other	 regions	 interact	 and	 how	 they	 may	 be	 altered	 in	 the	 conditions	 of	 chronic	 pain	 (e.g.	
arthritis,	 low	 back	 pain)	 are	 under	 investigation	 (Kuner	 and	 Flor	 2016,	 Davis	 and	 Seminowicz	
2017).	 Moreover,	 key	 changes	 in	 brain	 volume,	 functional	 connections,	 and	 processing	 are	
observed	 using	 imaging	 studies	 (Mansour,	 Farmer	 et	 al.	 2014,	 Smith,	 López-Solà	 et	 al.).	 In	
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patients	 with	 chronic	 back	 pain,	 studies	 have	 reported	 diminished	 cortical	 grey	 matter	 and	
impaired	 emotional	 decision-making	 (Apkarian,	 Sosa	 et	 al.	 2004).	 These	 observations	 are	
mimicked	 in	a	preclinical	model	of	nerve	 injury	 in	which	chronic	pain	disrupts	normal	 function	
and	anatomy	of	 the	prefrontal	 cortex,	partially	 reversed	by	different	molecules	with	analgesic	
properties	 (Shiers,	Pradhan	et	al.	2018).	This	observation	has	been	expanded	 to	other	chronic	
pain	states	 including	chronic	osteoarthritis	 (Mansour,	Farmer	et	al.	2014,	Smith,	López-Solà	et	
al.	2017).		
	
1.2.3.	Initiation	of	Pain	Signals	from	the	Bone	and	Joint:	
Early	studies	 in	the	cat	demonstrated	that	the	knee	 joint	 is	 innervated	by	sympathetic	
fibers	 as	 well	 as	 sensory	 afferent	 fibers,	 primarily	 fine	 myelinated	 A-delta	 fibers	 and	
unmyelinated	(slow	conducting	C-fibers)	sensory	afferent	neurons	(Langford	and	Schmidt	1983).	
Both	 A-delta	 and	 C-fibers	 demonstrated	 responses	 to	 mechanical	 stimulation	 at	 higher	
thresholds	 compared	 to	 other	 tissues	 such	 as	 skin,	 with	 some	 fibers	 that	 respond	 only	 to	
stimulation	 in	 the	 noxious	 range	 (Schaible	 and	 Schmidt	 1983).	 Electrophysiological	 studies	
characterizing	 movement-induced	 activation	 of	 sensory	 fibers	 innervating	 the	 joint	 further	
classified	 these	 fibers	 into	 4	 subtypes:	 fibers	 activated	 by	 non-noxious	 movement;	 fibers	
activated	 both	 by	 non-noxious	 and	 noxious	 movement;	 fibers	 activated	 only	 by	 noxious	
movement,	and	fibers	that	failed	to	respond	to	movement	(Schaible	and	Schmidt	1983).		
These	data	 led	 to	 the	 conclusion	 that	 the	 sensory	afferent	 fibers	 innervating	 the	 joint	
contribute	to	deep	pressure	sensation	and	nociception,	and	likely	signal	that	the	joint	is	about	to	
leave	 the	normal	working	 range	 (Schaible	and	Schmidt	1983).	Subsequent	electrophysiological	
characterization	 of	 the	 A-delta	 and	 C-fibers	 innervating	 the	 knee	 joint	 in	 the	 setting	 of	 acute	
inflammation	revealed	altered	firing	properties	in	the	context	of	injury.	Fiber	populations	from	
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inflamed	knee	joints	demonstrated	increased	activity	in	the	absence	of	any	stimulation	or	joint	
movement	(spontaneous	activity).	In	addition,	they	demonstrated	lower	response	thresholds	to	
mechanical	 stimulation	 (hypersensitivity),	 and	 increased	 activity	 in	 response	 to	 mechanical	
stimulation	 from	 probing	 the	 joint	with	 calibrated	 von	 Frey	 filaments	 and	 to	 joint	movement	
(Coggeshall,	 Hong	 et	 al.	 1983,	 Grigg,	 Schaible	 et	 al.	 1986,	 Schaible,	 Schmidt	 et	 al.	 1987).	 In	
addition,	 silent	 sensory	 fibers	 that	 normally	 do	 not	 demonstrate	 activity	 during	 non-noxious	
movement	 of	 the	 joint,	 became	 active	 following	 exposure	 to	 knee	 joint	 injection	 of	
kaolin/carrageenan,	 a	model	 of	 acute	 experimental	 arthritis	 in	 the	 cat	 (Schaible	 and	 Schmidt	
1985).	 Findings	 such	 as	 these	 have	 highlighted	 the	 potential	 of	 sensory	 neurons	 to	 undergo	
maladaptive	change	in	their	response	to	both	natural	and	artificial	stimuli.	
Little	 was	 known	 about	 the	 protein	 expression	 patterns	 and	 identity/anatomy	 of	 the	
sensory	 nerves	 involved	 in	 transducing	pain	 from	 the	bone	 in	 naïve	 animals	 let	 alone	disease	
treated	 animals	 (i.e.	 nociceptive,	 autonomic,	 large	 diameter,	 etc.).	 Several	 studies	 examining	
innervation	of	the	bone	using	a	combination	of	IHC	and	transgenic	animals	indicate	that	bone	as	
well	as	the	surrounding	periosteum	is	well	innervated	by	small-diameter	peptidergic	C-fibers,	A-
delta	fibers,	and	sympathetic	fibers	(Mach,	Rogers	et	al.	2002,	Jimenez-Andrade,	Mantyh	et	al.	
2010,	 Guedon,	 Longo	 et	 al.	 2016).	 Several	 reports	 suggest	 key	 differences	 in	 patterns	 of	
innervation	 of	 the	 bone	 and	 other	 deep	 tissue	 compared	 to	 skin.	 Initial	 work	 using	 staining	
methods	(Mach,	Rogers	et	al.	2002)	was	replicated	utilizing	a	transgenic	animal	that	selectively	
expressed	 eGFP	 under	 control	 of	 the	mas-related	 G-coupled	 protein	 sub	 family	 D	 expressing	
(MrgD)	 promoter	 developed	by	 Zylka	 et	 al.	 2005,	 that	 serves	 as	 a	marker	 for	 non-peptidergic	
nociceptors	(Zylka,	Rice	et	al.	2005).	Analysis	of	tissue	from	these	animals	demonstrated	a	lack	
of	eGFP+	fiber	innervation	to	the	bone	and	periosteum	thus	a	lack	of	MrgD+	or	nonpeptidergic	
nociceptors,	but	dense	 innervation	within	skin	of	 the	same	animals	 (Mach,	Rogers	et	al.	2002,	
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Jimenez-Andrade,	Mantyh	et	al.	2010).	 Studies	 that	directly	 compared	 innervation	of	 skin	and	
bone	 using	 these	 mice	 demonstrated	 that	 whereas	 skin	 is	 innervated	 by	 both	 peptidergic	
(CGRP+)	 and	 non-peptidergic	 populations	 of	 C-fibers,	 bone	 shows	 evidence	 of	 innervation	 by	
peptidergic	 and	 sympathetic,	 but	 not	 non-peptidergic	 C-fibers	 (Mach,	 Rogers	 et	 al.	 2002,	
Jimenez-Andrade,	Mantyh	et	al.	2010).	 Jimenez-andrade	et.	al	2010	also	demonstrated	 lack	of	
purinergic	receptor	P2X3	(P2X3)	IHC	staining	in	the	bone	and	periosteum,	another	marker	of	the	
stereotypical	 non-peptidergic	 nociceptor	 population	 (Jimenez-Andrade,	 Mantyh	 et	 al.	 2010).	
Additional	 recent	 immunohistochemical	 evidence	 in	 the	 rat	 has	 also	 demonstrated	 TRPV1	
expressing	 fibers	 in	 marrow,	 which	 can	 be	 sensitized	 by	 application	 of	 capsaicin	 (Morgan,	
Nencini	et	al.	2019).	This	has	led	to	the	proposal	that	bone	and	joints	are	not	innervated	by	the	
non-peptidergic	population	of	C-fibers	in	mice	(Mantyh	2014).	However,	evidence	regarding	the	
presence	of	non-peptidergic	C-fibers	innervating	the	bone	has	been	reported	in	rat	studies	using	
retrograde	tracers	injected	into	the	intramedullary	space	of	the	bone	(Ivanusic	2007,	Kaan,	Yip	
et	al.	2010,	Ivanusic	2017).		
Such	 discrepant	 findings	 suggest	 the	 possibility	 that	 there	may	 be	 a	 subpopulation	 of	
non-peptidergic	fibers	that	innervate	the	bone	that	have	not	been	directly	assessed	in	previous	
studies.	Alternative	 explanations	 include	 the	possibility	 of	 differences	 in	 the	methods	used	 to	
examine	innervation.	The	processes	of	decalcification	of	the	bone	may	have	altered	binding	sites	
for	markers	 of	 non-peptidergic	 fibers	 such	 as	 isolectin	 B4	 (IB4)	 or	 P2X3	 diminishing	 potential	
visualization	 of	 fibers	 innervating	 the	 bone	 and	 leading	 to	 false	 negative	 findings	 (Jimenez-
Andrade,	Mantyh	et	al.	2010).	However,	IB4	binding	has	been	reported	in	muscle	that	had	been	
processed	 for	decalcification	 in	 the	same	manner	as	bone	that	did	not	show	these	markers	of	
non-peptidergic	fibers	(Jimenez-Andrade,	Mantyh	et	al.	2010).	In	addition,	MrgD	expressing	and	
IB4	binding	 fibers	were	not	observed	 in	periosteum	whole	mount	 tissue	 that	did	not	undergo	
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decalcification	whereas	in	side	by	side	control	tissue,	both	were	expressed	in	the	skin	(Jimenez-
Andrade,	Mantyh	et	al.	2010).	These	observations	indicate	that	the	decalcification	process	does	
not	 explain	 the	 absence	 of	 these	 markers	 of	 non-peptidergic	 fibers	 within	 the	 bone.	
Alternatively,	as	bone	is	a	site	of	perfusion,	it	is	possible	that	injection	of	the	retrograde	tracers	
may	have	leaked	to	other	sites	resulting	in	false	positive	findings.	It	is	also	of	importance	to	note	
the	difficulty	to	process	calcified	tissue,	especially	following	the	establishment	and	degradation	
of	 tissue	 due	 to	 cancer.	 Let	 alone	 locate	 fibers	 of	 small	 to	 medium	 diameter	 neurons	 when	
processing	 slices	of	 this	 tissue.	Methods	continue	 to	 improve	 to	allow	such	analysis,	 including	
here	at	the	University	of	New	England’s	histology	core.	
Finally,	 it	 is	 possible	 that	 there	 are	 species	 differences	 in	 innervation	 or	 population	
(peptidergic	 vs	non-peptidergic)	 separation	and	 identity	 that	 causes	 these	discrepant	 findings.	
Indeed,	 differences	 between	 rats	 and	 mice	 related	 to	 expression	 of	 these	 specific	 molecular	
markers	of	neuronal	subtypes	have	been	reported	(Price	and	Flores	2007).	 In	the	mouse	these	
populations	 have	 been	 demonstrated	 to	 be	mostly	 non-overlapping	 in	 the	DRG	 (Molliver	 and	
Snider	1997,	Molliver,	Wright	et	al.	1997,	Cavanaugh,	Lee	et	al.	2009,	Scherrer,	Imamachi	et	al.	
2009,	 Thakur,	 Rahman	 et	 al.	 2012,	 Usoskin,	 Furlan	 et	 al.	 2015),	 whereas	 in	 the	 rat	 these	
populations	show	a	~45%	overlap	 in	expression	 in	the	DRG,	and	these	expression	profiles	vary	
between	DRG	 and	 trigeminal	 ganglia	 (Price	 and	 Flores	 2007).	 In	 addition	 to	 these	 differences	
between	 rats	 and	 mice,	 distribution	 of	 these	 fiber	 populations	 have	 been	 reported	 to	 differ	
across	 different	 strains	 of	 mice	 (Laedermann,	 Pertin	 et	 al.	 2014).	 Future	 studies	 examining	
potential	 differences	 in	 innervation	 of	 bone	 and	 joint	 across	multiple	 species	 is	warranted	 to	
better	understand	whether	patterns	of	innervation	of	bone	is	conserved.		
In	 addition	 to	 these	 populations	 of	 nociceptors,	 some	 recent	 studies	 have	 implicated	
low	 threshold	 mechanoreceptors	 (C-LTMRs)	 in	 mediating	 mechanical	 pain	 to	 normally	 non-
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noxious	stimuli	in	conditions	of	injury	and	chronic	pain	(Rutlin,	Ho	et	al.	2014,	Zimmerman,	Bai	
et	al.	2014,	Abraira,	Kuehn	et	al.	2017).	The	C-LTMRs	have	been	most	studied	within	the	skin.	
Whether	 this	population	 innervates	bone	or	 joint	or	mediates	pain	associated	with	 trauma	or	
pathology	 that	generates	chronic	pain	 is	unknown	and	difficult	 to	assess	due	 to	 the	nature	of	
joint	 and	bone	 tissue	 accessibility.	 Improved	understanding	of	 subpopulations	 innervating	 the	
bone	and	surrounding	tissues	as	well	as	how	they	may	contribute	to	diverse	aspects	of	bone	and	
joint	 pain	 are	 needed	 to	 develop	 a	 more	 comprehensive	 understanding	 of	 mechanisms	
underlying	the	multiple	components	of	bone	and	joint	pain.		
	
1.2.4.	Site	of	Injury	or	Pathology:	
Inflammation.	Tissue	damage	leads	to	an	innate	immune	response	that	results	in	release	
of	 molecules	 including	 chemokines,	 cytokines,	 and	 growth	 factors	 from	 local	 tissue	 (e.g.	
fibroblasts,	 chondrocytes),	 blood,	 and	 local	 and	 migrating	 inflammatory	 cells	 (Mantyh	 2014,	
Krustev,	 Rioux	 et	 al.	 2015,	 Jeon,	 David	 et	 al.	 2018,	 Syx,	 Tran	 et	 al.	 2018).	 These	 factors	may	
promote	disease	progression	and	pathology	in	disease	states	such	as	arthritis	or	cancer-induced	
bone	 pain.	 Pro-inflammatory	 cytokines	 such	 as	 tumor	 necrosis	 factor-alpha	 (TNF-alpha),	
Interleukin	 6	 (IL-6)	 and	 IL1-beta	 have	 been	 implicated	 in	 bone	 resorption	 by	 increasing	
osteoclast	 activity	 (Braun	 and	 Schett	 2012).	 In	 addition,	 these	 cytokines	 produce	 peripheral	
sensitization	of	nociceptive	fibers,	resulting	in	decreased	thresholds	for	activation	and	amplified	
signaling	(Cook,	Christensen	et	al.	2018).	Growth	factors	NGF,	vascular	endothelial	growth	factor	
(VEGF)	and	insulin-like	growth	factor	(IGF)	are	also	 implicated	in	development	of	bone	or	 joint	
pathology	 in	 disease	 states	 such	 as	 arthritis	 and	 cancer-induced	 bone	 pain.	 VEGF	 has	 been	
implicated	 in	 angiogenesis	 associated	 with	 arthritis	 and	 skeletal	 metastases	 (Felson	 2005,	
Mantyh	2014).		
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NGF	 has	 been	 implicated	 in	 peripheral	 sensitization	 through	 mechanisms	 such	 as	
upregulation	 of	 key	 channels	 such	 as	 sodium	 channels	 and	 transducers	 that	 regulate	 neural	
activity	 and	 by	 phosphorylation	 of	 transducers	 such	 as	 TRPV1	 within	 neurons	 leading	 to	
enhanced	activity	and	increased	neuronal	excitability	(Chang,	Hsu	et	al.	2016,	Denk,	Bennett	et	
al.	2017).	In	addition,	NGF	has	been	shown	to	mediate	pathological	sprouting	of	nociceptive	and	
sympathetic	 fibers	within	 the	 bone	 and	 joint	 across	 various	 rodent	models	 of	 bone	 and	 joint	
pain	 including	 cancer-induced	 bone	 pain	 (Jimenez-Andrade,	 Bloom	 et	 al.	 2010),	 arthritis	
(Jimenez-Andrade,	 Mantyh	 et	 al.	 2012)	 and	 fracture	 (Jimenez-Andrade,	 Martin	 et	 al.	 2007,	
Chartier,	Thompson	et	al.	2014).	Building	upon	these	preclinical	studies,	therapies	such	as	anti-
TNF-alpha,	 anti-IL6	 and	 anti-NGF	 antibodies	 are	 in	 clinical	 use	 or	 in	 clinical	 trials	 for	 pain	
associated	with	bone	or	joint	pathology	has	not	been	investigated.	However,	the	role	of	many	of	
these	 inflammatory	 signaling	 molecules	 has	 not	 been	 assessed	 in	 models	 of	 ongoing	 pain	
assessment	or,	primarily	due	to	a	lack	of	models,	BTP.	
Neuropathic	Pain.	In	addition	to	the	development	of	inflammation,	neuropathic	changes	
have	also	been	reported	in	animal	models	of	bone	and	joint	pain	(Thakur,	Rahman	et	al.	2012,	
Falk,	 Bannister	 et	 al.	 2014,	 Falk	 and	 Dickenson	 2014,	Mantyh	 2014,	 Thakur,	 Dickenson	 et	 al.	
2014).	 Studies	 in	 rat	 and	 mouse	 models	 of	 cancer-induced	 bone	 pain	 and	 chemical-induced	
osteoarthritis	 joint	 pain	 have	 demonstrated	 expression	 of	 activated	 transcription	 factor	 3	
(ATF3),	 a	 neural	 marker	 of	 nerve	 damage,	 in	 cell	 bodies	 within	 the	 dorsal	 root	 ganglion	
innervating	 the	 bone	 or	 joint	 (Peters,	 Ghilardi	 et	 al.	 2005,	 Sabino	 and	 Mantyh	 2005,	 Csont,	
Bereczki	 et	 al.	 2007,	 Thakur,	 Rahman	 et	 al.	 2012).	 Pathological	 changes	 to	 sensory	 and	
sympathetic	nerve	 fibers	within	the	bone	and	 joint	have	been	demonstrated	across	models	of	
cancer	 bone	 pain,	 arthritis	 pain,	 and	 fracture	 pain	 (Jimenez-Andrade,	 Martin	 et	 al.	 2007,	
Jimenez-Andrade,	Bloom	et	al.	2010,	Jimenez-Andrade,	Mantyh	et	al.	2012,	Chartier,	Thompson	
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et	 al.	 2014).	 These	 studies	 describe	 development	 of	 neuromas	 and	disorganized	 structures	 of	
fibers	similar	to	those	reported	following	traumatic	nerve	injury	in	patients	and	animal	models	
of	nerve-injury	 induced	neuropathic	pain.	Finally,	pharmacological	 studies	 in	animal	models	of	
bone	 and	 joint	 pain	 have	 demonstrated	 that	 knee	 joint	 arthritis	 pain	 and	 cancer	 bone	 pain	
associated	 with	 markers	 of	 nerve	 damage	 are	 resistant	 to	 pain	 alleviating	 effects	 of	 anti-
inflammatory	drugs	 such	as	NSAIDs	 (e.g.	 ketorolac,	 diclofenac)	 (Okun,	 Liu	 et	 al.	 2012,	 Thakur,	
Dickenson	et	al.	2014,	Remeniuk,	Sukhtankar	et	al.	2015).		
In	 contrast,	 these	 pain	 states	were	 found	 to	 be	 responsive	 to	 drugs	 typically	 used	 to	
treat	 neuropathic	 pain	 within	 the	 clinical	 setting,	 duloxetine,	 pregabalin	 and	 gabapentin	
(Thakur,	 Dickenson	 et	 al.	 2014,	 Havelin,	 Imbert	 et	 al.	 2016).	 Importantly,	 these	 studies	
demonstrate	 that	 anti-inflammatory	 drugs	may	 be	 effective	 in	 some	 aspects	 of	 pain	whereas	
they	 are	 ineffective	 on	 others,	 results	 echoed	 by	 clinical	 observations	 of	 the	 need	 to	 elevate	
patients	 with	 CIBP	 to	 analgesics	 using	 molecular	 targets	 that	 differ	 from	 inflammatory	
mediators.	 In	 a	 rat	model	 of	 advanced	 osteoarthritis	 in	which	 both	 evoked	measures	 of	 joint	
pain	 and	 non-evoked	 ongoing	 pain	 are	 observed,	 the	 NSAID	 diclofenac	 effectively	 blocked	
weight	asymmetry	whereas	it	failed	to	block	persistent	ongoing	joint	pain	(Okun,	Liu	et	al.	2012)	
whereas	 duloxetine	 blocks	 both	 evoked	 and	 ongoing	 joint	 pain	 (Havelin,	 Imbert	 et	 al.	 2016).	
Similarly,	 in	 a	 rat	 model	 of	 CIBP,	 diclofenac	 was	 demonstrated	 to	 effectively	 block	 tactile	
hypersensitivity,	 a	 measure	 of	 referred	 evoked	 pain,	 but	 not	 ongoing	 pain	 (Remeniuk,	
Sukhtankar	 et	 al.	 2015).	 Specific	 to	 peripheral	 neurons,	 treatment	 with	 anti-NGF	 antibody	
relieved	 many	 of	 the	 measurable	 pain	 behaviors	 in	 mice	 with	 CIBP	 where	 as	 anti-P2X3	
antibodies	 only	 reversed	 referred	 tactile	 hypersensitivity	 (Guedon,	 Longo	 et	 al.	 2016).	 Such	
observations	 indicate	 that	 there	 are	 mechanistic	 differences	 between	 different	 clinically	
important	 aspects	 of	 bone	 and	 joint	 pain.	 Such	 complexity	 highlights	 the	 need	 for	 more	
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comprehensive	analysis	of	the	multiple	aspects	of	bone	or	joint	pain	when	examining	potential	
molecular	 mechanisms	 of	 pathological	 chronic	 pain	 and	 for	 effectiveness	 of	 potential	
therapeutic	targets.		
	
1.2.5.	Sensitization	
Many	animal	and	clinical	studies	have	demonstrated	that	sensitization	of	peripheral	and	
central	neurons	develops	in	the	context	of	chronic	bone	or	joint	pain	(Falk	and	Dickenson	2014,	
Arendt-Nielsen,	Egsgaard	et	al.	2015,	Eitner,	Hofmann	et	al.	2017).	The	international	association	
for	 the	 study	 of	 pain	 (IASP)	 defines	 sensitization	 as	 “Increased	 responsiveness	 of	 nociceptive	
neurons	 to	 their	 normal	 input,	 and/or	 recruitment	 of	 a	 response	 to	 normally	 subthreshold	
inputs”.	They	note	that	sensitization	may	include	a	decrease	in	activation	threshold,	increase	in	
suprathreshold	responses,	spontaneous	discharges	of	neurons,	and	 increases	 in	receptive	field	
of	neurons.	They	further	clarify	that	sensitization	 is	a	neurophysiological	term	and	can	only	be	
applied	when	both	 input	and	output	of	the	neural	system	being	studied	(e.g.	peripheral	 input,	
spinal	 signaling)	 are	 known.	 It	 is	 emphasized	 that	 clinically,	 sensitization	may	only	be	 inferred	
indirectly	 from	 observations	 such	 as	 exacerbated	 pain	 from	 a	 known	 painful	 response	
(hyperalgesia)	 or	 a	 painful	 response	 from	 a	 previously	 non-painful	 stimulus	 (allodynia).	
Temporal	summation	is	also	used	within	the	clinical	literature	as	a	sign	of	sensitization	(Arendt-
Nielsen,	 Egsgaard	 et	 al.	 2015).	 Sensitization	 can	 be	 measured	 in	 the	 periphery,	 termed	
peripheral	sensitization	defined	by	IASP	as	“Increased	responsiveness	and	reduced	threshold	of	
nociceptive	neurons	 in	the	periphery	to	the	stimulation	of	 their	 receptive	 fields”.	Sensitization	
can	also	be	measured	at	sites	within	the	central	nervous	system	such	as	the	spinal	cord,	termed	
central	sensitization	defined	by	IASP	as	“Increased	responsiveness	of	nociceptive	neurons	in	the	
central	nervous	system	to	their	normal	or	subthreshold	afferent	input.”		
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This	 has	 been	 described	 in	 patients	 with	 moderate	 to	 severe	 knee	 osteoarthritis	
(Arendt-Nielsen,	Egsgaard	et	al.	2015).	 Further,	 in	patients	with	knee	osteoarthritis	associated	
with	 spread	 of	 allodynia	 and	 temporal	 summation,	 functional	 magnetic	 resonance	 imaging	
demonstrated	 that	 whereas	 direct	 painful	 stimulation	 at	 the	 osteoarthritic	 site	 did	 not	
distinguish	between	sensitized	and	non-sensitized	patients,	stimulation	at	an	area	of	spreading	
sensitization	 resulted	 in	 increased	signals	within	brain	 regions	associated	with	pain	processing	
(Pujol,	 Martinez-Vilavella	 et	 al.	 2017).	 Stimulation	 of	 an	 area	 associated	 with	 spreading	
sensitization	 also	 produced	 activation	 of	 brain	 regions	 not	 associated	 with	 pain	 processing,	
extending	to	the	auditory,	visual,	and	ventral	sensorimotor	cortices	(Pujol,	Martinez-Vilavella	et	
al.	 2017).	 Such	 studies	will	 be	 critical	 in	 gaining	a	better	understanding	of	 changes	associated	
with	 development	 of	 central	 sensitization	 that	 contribute	 to	 worsening	 of	 pain	 and	 to	
medication	resistant	pain	states	associated	with	bone	and	joint	pain.	
There	are	many	well	written	overviews	of	mechanisms	contributing	to	development	of	
peripheral	 sensitization	 (Schaible	 2018,	 Syx,	 Tran	 et	 al.	 2018)	 and	 central	 sensitization	 (Woolf	
2011,	 Falk,	 Bannister	 et	 al.	 2014,	 Falk	 and	 Dickenson	 2014,	 Schaible	 2018).	 Much	 has	 been	
learned	 about	 the	 impact	 of	 many	 of	 the	 factors	 that	 are	 released	 by	 local	 tissues,	 such	 as	
adenosine	 triphosphate	 (ATP),	 adenosine	 diphosphate	 (ADP),	 endothelins,	 bradykinin,	 and	
growth	factors	(Jimenez-Andrade,	Bloom	et	al.	2010,	Mantyh	2014,	Schaible	2018,	Syx,	Tran	et	
al.	2018,	Woller,	Eddinger	et	al.	2018).	These	factors	have	been	shown	to	act	both	directly	on	
neurons	 to	 activate	 them	 and	 to	 alter	 the	 properties	 of	 the	 neurons.	 These	 actions	 including	
lowering	 of	 activation	 thresholds	 and	 increased	 in	 responses	 are	 key	 characteristics	 of	
peripheral	 sensitization	 (Jimenez-Andrade,	Mantyh	 et	 al.	 2010,	 Syx,	 Tran	 et	 al.	 2018,	Woller,	
Eddinger	 et	 al.	 2018).	 Several	 factors	 including	proinflammatory	 cytokines	 (e.g.	 IL-1	beta,	 TNF	
alpha,	 IL-6)	 have	 been	 shown	 to	 be	 catabolic	 and	 may	 enhance	 bone	 resorption	 promoting	
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underlying	pathology	(Lee,	Ellman	et	al.	2013).	Mechanisms	underlying	peripheral	sensitization	
include	 translation	 and	 trafficking	 of	 transducer	 channels	 as	 well	 as	 phosphorylation	 of	
transducer	 channels	 such	 as	 TRPV1	 resulting	 in	 altered	 activation	 thresholds	 and	 increased	
transfer	of	cations	allowing	for	enhanced	depolarization	of	the	neurons	and	amplified	signaling	
(Jimenez-Andrade,	 Mantyh	 et	 al.	 2010,	 Syx,	 Tran	 et	 al.	 2018,	 Woller,	 Eddinger	 et	 al.	 2018).	
Similarly,	 increased	translation	and	trafficking	of	sodium	channels	 resulting	 in	amplified	action	
potentials	and	increased	numbers	and	phosphorylation	of	calcium	channels	result	 in	enhanced	
neurotransmitter	release	from	afferent	terminals	within	the	spinal	cord	(Devor	2006,	Bao	2015).	
In	addition,	pathophysiological	changes	in	neurons	such	as	pathological	sprouting	and	formation	
of	neuromas	may	contribute	to	ectopic	discharge	and	amplified	signaling	from	the	bone	or	joint	
(Jimenez-Andrade,	Mantyh	et	al.	2010).	
Ongoing	afferent	input	has	been	suggested	to	result	in	spinal	sensitization	(Devor	2009,	
Latremoliere	and	Woolf	2009,	Woolf	2011).	Various	studies	in	animal	models	of	cancer-induced	
bone	pain	and	osteoarthritis	have	demonstrated	development	of	central	sensitization	including	
lowered	 thresholds	 for	 activation,	 amplification	 of	 signal,	 and	 widening	 of	 the	 receptor	 field	
(Thakur,	 Rahman	 et	 al.	 2012,	 Thakur,	 Dickenson	 et	 al.	 2014),	 as	 well	 as	 activation	 of	 spinal	
neurons	 in	 response	 to	normally	non-noxious	stimuli	 such	as	movement	of	 the	 tumor	bearing	
hind	 limb	 (Schwei,	 Honore	 et	 al.	 1999)	 or	 arthritic	 joint	 (Havelin,	 Imbert	 et	 al.	 2016).	 Various	
mechanisms	have	been	implicated	in	mediating	spinal	sensitization,	including	activation	of	glia,	
upregulation	 and	 excitatory	 signaling	 by	 dynorphin,	 and	 diminished	 tonic	 inhibition	 by	
GABAergic	interneurons	(Coull,	Beggs	et	al.	2005,	De	Koninck	2007,	Lai,	Luo	et	al.	2008,	Gao	and	
Ji	2010,	Trang,	Beggs	et	al.	2011,	Beggs	and	Salter	2013,	Clark,	Old	et	al.	2013,	 Ji,	Berta	et	al.	
2013,	 Mapplebeck,	 Beggs	 et	 al.	 2016).	 Several	 studies	 have	 demonstrated	 a	 role	 for	 spinal	
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microglia	 and	 elevated	 pro-inflammatory	 cytokines	 in	 mediating	 cancer-induced	 bone	 pain	
(Zhou,	Liu	et	al.	2016)	and	in	animal	models	of	osteoarthritis	(Tran,	Miller	et	al.	2017).		
In	addition	to	release	of	pro-inflammatory	cytokines,	spinal	microglia	mediated	release	
of	 the	 brain	 derived	 growth	 factor	 (BDNF)	 has	 been	 implicated	 in	 mediating	 spinal	 changes	
resulting	 in	 disinhibition	 and	 spinal	 sensitization	 (Coull,	 Beggs	 et	 al.	 2005,	 Trang,	 Beggs	 et	 al.	
2011,	 Beggs	 and	 Salter	 2013).	 These	 changes	have	been	described	 in	 animal	models	 of	 nerve	
injury	 as	 well	 as	 opioid-induced	 hypersensitivity.	 Release	 of	 BDNF	 is	 proposed	 to	 increase	
chloride	channels	 (KCCL)	 leading	 to	disruption	of	 the	gradient	balance	of	 chloride	 ions	 (Trang,	
Beggs	 et	 al.	 2011,	 Beggs	 and	 Salter	 2013).	 This	 is	 proposed	 to	 result	 in	 GABA	 activation	 of	
normally	 inhibitory	 channels	 become	 excitatory,	 thereby	 facilitating	 sensitization	 and	
hyperexcitability	 (Coull,	 Beggs	 et	 al.	 2005,	 De	 Koninck	 2007,	 Prescott,	Ma	 et	 al.	 2014,	 Bonin,	
Wang	et	al.	2016).	Whether	such	changes	are	implicated	in	chronic	bone	and	joint	pain	has	not	
been	well	studied.	The	role	of	these	changes	 in	mediating	evoked	hypersensitivities	compared	
to	persistent	ongoing	pain	has	not	been	systematically	studied.	Upregulation	of	dynorphin	has	
also	 been	 implicated	 in	 spinal	 sensitization	 in	 preclinical	models	 of	 nerve	 injury-induced	 pain	
through	activation	of	non-opioid	receptors	such	as	the	bradykinin	receptor	(Lai,	Luo	et	al.	2008).	
Upregulation	of	dynorphin	has	been	 reported	 in	a	mouse	model	of	 cancer-induced	bone	pain	
(Schwei,	 Honore	 et	 al.	 1999).	 However,	 further	 investigation	 regarding	 the	 role	 of	 spinal	
dynorphin	in	mediating	chronic	bone	or	joint	pain	has	not	been	investigated.		
	
1.2.6.	Descending	Pain	Modulation	
Another	important	aspect	of	pain	processing	is	the	ability	for	the	brain	to	modulate	pain	
signals	 through	 descending	 pain	 pathways	 that	 can	 amplify	 (descending	 pain	 facilitatory	
pathways)	 or	 diminish	 (descending	 pain	 inhibitory	 pathways)	 the	 pain	 signal	 (reviewed	 by	
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(Suzuki,	 Rahman	et	 al.	 2004,	Ossipov,	Dussor	 et	 al.	 2010)).	 Key	 sites	 implicated	 in	 descending	
pain	 modulation	 include	 the	 anterior	 cingulate	 cortex,	 the	 periaqueductal	 grey,	 and	 the	
rostroventromedial	medulla	(RVM)	(Suzuki,	Rahman	et	al.	2004,	Ossipov,	Dussor	et	al.	2010).	In	
the	uninjured/non-pain	 state,	 pain	 can	be	modulated	 in	 response	 to	physical	 or	psychological	
stress.	Much	has	been	learned	about	how	stress	can	activate	these	descending	pain	modulatory	
pathways	 to	 dampen	 pain	 or	 induce	 analgesia	 through	 endogenous	 opioid	 and	 cannabinoid	
signaling	 within	 the	 brain	 (Ossipov,	 Dussor	 et	 al.	 2010).	 Following	 injury,	 a	 time-dependent	
increase	 in	 net	 descending	 pain	 facilitation	 occurs,	 wherein	 descending	 facilitatory	 pathways	
promote	enhanced	spinal	cord	activity	 to	noxious	and	non-noxious	stimuli	 (Ossipov,	Dussor	et	
al.	 2010,	 Falk,	 Bannister	 et	 al.	 2014)	 as	 well	 as	 behavioral	 responses	 showing	 enhanced	
responsiveness	 to	 noxious	 and	 non-noxious	 stimuli	 modeling	 hyperalgesia	 and	 allodynia,	
respectively	 (Burgess,	 Gardell	 et	 al.	 2002,	 Qu,	 King	 et	 al.	 2011,	 King,	 Qu	 et	 al.	 2012,	 Havelin,	
Imbert	et	al.	2016,	Bannister,	Qu	et	al.	2017).		
	
1.2.7.	Conclusion	
Much	has	been	learned	regarding	biological	mechanisms	contributing	to	bone	and	joint	
pain.	 The	 continued	 improvement	 and	 development	 of	 animal	 models	 that	 more	 accurately	
represent	the	human	condition	will	continue	to	advance	the	field	and	allow	basic	researchers	to	
identify	 translational	 proteomic,	 cellular	 and	 systems	 to	 better	 treat	 pain.	 In	 addition,	 the	
relatively	recent	advent	of	specific	genetic	tools	including	transgenic	animals	with	alterations	to	
“pain-specific”	genes	(i.e.	knock-ins	and	knock-outs),	reporter	genes,	and	development	of	virally	
deliverable	tools	to	induce	genetic	alterations	allow	dissection	and	analysis	of	molecular	targets	
and	 microcircuitry	 underlying	 specific	 and	 distinct	 aspects	 of	 chronic	 pain.	 Optogenetic	 and	
chemogenetic	tools	offer	increased	ability	for	spatial	and	temporal	precision	of	the	investigation	
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of	key	cell	subtypes	and	circuits	within	the	CNS.	Fluorescent	proteins	that	serve	as	a	surrogate	
for	neuronal	 firing/activity	 such	as	GCaMP6	and	 the	 continued	 incorporation	of	 light	 sensitive	
ion	channels	and	pumps	that	allow	for	selective	activation	or	 inhibition	of	cells	are	 immensely	
powerful	tools	working	their	way	to	the	forefront	of	the	pain	field.	In	addition,	improvements	in	
imaging	techniques	both	at	the	site	of	pathology	(Felson	2005)	and	brain	imaging	assessing	brain	
activity	and	changes	in	processing	in	chronic	pain	patients	will	guide	future	studies	on	molecular	
and	circuit	changes	that	are	associated	with	chronic	pain.		
Such	analyses	will	open	new	potential	targets	as	genomic	and	proteomic	analyses	reveal	
novel	 targets	 at	 the	 site	 of	 pathology	 or	 the	 neural	 circuitry	 driving	 chronic	 pain.	 In	 addition,	
brain	imaging	will	allow	for	potential	insights	into	development	of	comorbidities	associated	with	
chronic	 pain	 such	 as	 development	 of	 depression,	 anxiety	 and	 altered	 cognitive	 processing	
(Borsook,	Hargreaves	et	al.	2011,	Parks,	Geha	et	al.	2011,	Tetreault,	Mansour	et	al.	2016,	Bajic,	
Craig	et	al.	2017,	Colon,	Bittner	et	al.	2017,	Peng,	Steele	et	al.	2018).	Beyond	the	development	
of	exciting	new	tools	there	remain	complexities	that	go	beyond	the	scope	of	this	review	of	work,	
such	as	integral	contributions	by	the	immune	system	and	the	endocrine	system.	Continued	and	
growing	 analysis	 of	 genetic	 susceptibility	 to	 increased	 or	 decreased	 pain	 sensitivity,	 and	
epigenetic	 modifications	 that	 result	 from	 chronic	 pain	 will	 guide	 our	 understanding	 of	 the	
predisposition	 of	 different	 races/ethnicities/sexes	 to	 chronic	 pain	 and	 the	 potential	
effectiveness	or	insensitivity	to	specific	pain	treatments.		
	
1.3.	Preclinical	Models	of	Cancer-Induced	Bone	Pain	
	 Several	variations	of	animal	models	exist	to	examine	CIBP	in	preclinical	studies.	Much	of	
the	 initial	work	done	to	examine	the	mechanisms	underlying	CIBP	was	performed	 in	a	murine	
model	 that	 utilizes	 an	 injection	 of	 a	 primary	 tumor	 line	 into	 the	 femur,	 and	 to	 date	 most	
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published	work	still	uses	this	approach.	The	first	published	piece	of	working	using	this	approach	
was	performed	by	Clohisy	et	al.	1995,	where	injection	of	the	2472	sarcoma	cells	into	the	femur	
of	 osteoclast	 deficient	 mice	 resulted	 in	 the	 upregulation	 of	 macrophage	 colony-stimulating	
factor	 and	 a	 pathological	 increase	 in	 osteoclast	 activity	 and	 morphology	 that	 coincided	 with	
osteolysis	 (Clohisy,	 Ogilvie	 et	 al.	 1995).	 It	 is	 important	 to	 note	 that	 unless	 using	
immunocompromised	 animals	 it	 is	 necessary	 to	 use	 syngeneic	 cell	 lines	with	 the	 species	 and	
strain	 of	 animal	 being	 used.	 Work	 immediately	 following	 this	 expanded	 on	 this	 observation	
looking	 at	 the	 differences	 between	 the	 2472	 sarcoma	 cell	 line	 and	 G3.26	melanoma	 cell	 line	
(Clohisy,	Ogilvie	et	al.	1996).	Investigation	here	demonstrated	that	whereas	the	sarcoma	cell	line	
induced	osteoclast	pathology	and	bone	destruction,	the	melanoma	line	grew	but	failed	to	alter	
osteoclast	 numbers	 or	 structure	 and	 no	 change	 in	 bone	 remodeling	 was	 reported	 (Clohisy,	
Ogilvie	et	al.	1996).	Further	support	that	this	approach	resulted	in	maladaptive	bone	remodeling	
resulted	when	a	human	breast	cancer	cell	line	MDA-MB-45s,	induced	an	increase	in	the	number	
and	 size	 of	 osteoclasts	 in	 a	 mouse	 model	 of	 cancer-induced	 bone	 loss,	 as	 well	 as	 induced	
osteoclasts	to	increase	bone	resorption	(Clohisy,	Palkert	et	al.	1996).	In	general,	these	bodies	of	
work	demonstrated	bone	remodeling	that	mimicked	in	the	clinical	observations,	leading	to	this	
approach	to	be	heavily	utilized	to	study	CIBP.	
	 Following	the	initial	establishment	of	this	approach,	work	by	Dr.	Patrick	Mantyh	adapted	
this	with	the	intent	to	examine	mechanisms	underlying	CIBP.	His	work	examined	alterations	to	
the	peripheral	and	central	nervous	system	and	corresponding	emergence	of	behaviors	that	are	
still	 used	 as	 measures	 of	 pain.	 This	 work	 and	 previous	 work	 by	 Clohisy	 and	 colleagues	
demonstrated	pain	measures	were	 induced	by	tumor	growth	within	the	bone	as	they	are	only	
observed	 in	 the	 mice	 that	 received	 cells	 implanted,	 and	 upon	 improvement	 of	 the	 surgical	
implantation	of	cells,	sealed	directly	 into	the	femur	(Schwei,	Honore	et	al.	1999).	Schwei	et	al.	
29	
	
1999	was	 the	 first	 paper	 published	 in	 the	 series	 of	 work	 by	 Dr.	Mantyh	 and	 established	 this	
approach	 as	 a	 clinically	 relevant	 method	 to	 evaluate	 CIBP.	 An	 initial	 clinically	 relevant	
observation	 being	 that	 this	 approach	 resulted	 in	 tumor	 induced	 drastic	 bone	 remodeling	 and	
prolonged	 growth	 resulted	 in	 invasion	 of	 the	 tumor	 into	 the	 periosteum	 of	 the	 femur,	
observations	 that	 had	 not	 been	 documented	 in	 the	 previous	 work	 by	 Clohisy	 and	 colleagues	
(Schwei,	Honore	et	al.	1999).	
This	was	furthered	by	a	direct	comparison	between	pain	models	within	Dr.	Mantyh’s	lab	
in	 the	 subsequent	 publication	 of	 Honore	 et	 al	 2000	 suggesting	 that	 difficulty	 in	 treating	 CIBP	
might	 be	 due	 to	 its	 apparent	 “unique”	 neurochemical	 footprint,	 a	 combination	 of	 oxidative	
stress	 within	 the	 spinal	 cord,	 increased	 expression	 of	 dynorphin	 within	 the	 spinal	 cord,	 and	
increased	glial	cell	hypertrophy	(Honore,	Rogers	et	al.	2000).	In	an	effort	to	compare	the	efficacy	
of	 morphine	 in	 treating	 CIBP	 vs	 inflammatory	 pain	 this	 group	 also	 demonstrated	 that	
comparable	to	observations	in	the	clinic,	higher	doses	of	morphine	are	required	to	temper	pain	
measurements	in	this	model	of	CIBP	(Luger,	Sabino	et	al.	2002).	This	work	was	soon	echoed	by	
Wacnik	 et	 al.	 2003	 who	 also	 demonstrated	 that	 in	 advanced	 CIBP,	 the	 required	 doses	 of	
morphine	were	 nearly	 2.5	 times	 as	 high	 (measured	 be	 ED50)	 when	 compared	 to	 a	model	 of	
carrageenan	induced	muscular	pain	to	reverse	movement-related	hyperalgesia	as	measured	by	
grip	 strength	 (Wacnik,	 Kehl	 et	 al.	 2003).	 These	 works	 notably	 only	 observed	 acute	 effects	 of	
morphine	 at	 potentially	 behavior	 altering	 doses	 (30	mg/kg	 and	 ED50	 23.9	mg/kg	 Luger	 et	 al.	
2002	and	Wacnik	et	al.	2003	respectively)	and	didn’t	compare	efficacy	of	morphine	in	a	chronic	
regiment	to	observe	the	effects	of	morphine	tolerance	development	or	whether	an	increase	in	
dosing	would	be	necessary	to	manage	pain	as	the	cancer	progressed.		
Work	by	King	et	al.	2007	demonstrated	that	mini-pump	implantation	to	deliver	varying	
doses	 of	 morphine	 not	 only	 failed	 to	 attenuate	 CIBP	 behaviors	 3-5	 days	 after	 implant,	 but	
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exacerbated	measures	 of	 pain.	 Alarmingly	 this	 work	 also	 demonstrated	 that	 this	 regiment	 of	
morphine	also	induced	an	increase	in	tumor-induced	bone	destruction	after	as	short	a	time	as	3-
5	days	of	chronic	morphine	exposure,	and	this	effect	was	blocked	by	naloxone	indicating	these	
observations	to	be	opioid	receptor	mediated	(King,	Vardanyan	et	al.	2007).	These	are	two	of	the	
fundamental	 challenges	 within	 the	 clinic	 when	 treating	 CIBP	 in	 patients,	 as	 patients	 are	 on	
regiments	 of	 increasing	 opioids	 for	 long	 durations	 of	 time	 (Luger,	 Sabino	 et	 al.	 2002).	
Interestingly	 Peters	 et	 al.	 2005	 demonstrated	 that	 chronic	 administration	 of	 gabapentin,	 also	
attenuated	 flinching	 as	 a	 measure	 of	 ongoing	 pain,	 as	 well	 as	 palpation	 induced	 increase	 in	
flinching,	 a	 proposed	 behavioral	 measure	 of	 pain	 exacerbated	 by	 movement	 of	 the	 cancer-
afflicted	limb	(Peters,	Ghilardi	et	al.	2005).	These	observations	demonstrate	that	not	only	does	
CIBP	 have	 a	 unique	 neurochemical	 footprint,	 but	 an	 interesting	 response	 to	 various	
pharmacological	 agents,	 implicating	 the	 potential	 for	 multiple	 mechanisms	 driving	 this	 pain	
state.	
A	similar	 rat	model	exists	 to	study	CIBP,	where	the	major	difference	 (excluding	cancer	
cell	line	utilized)	is	that	primary	tumor	cells	are	sealed	and	restricted	to	the	tibia	rather	than	the	
femur.	 The	 first	 report	 of	 this	 approach	 was	 in	 2002	 by	 Medhurst	 and	 colleagues	 using	 the	
MRMT-1	 rat	mammary	 gland	 carcinoma	 cells.	 They	 reported	 tumor-induced	bone	destruction	
indicated	by	both	radiographic	analysis	and	microcomputed	tomography	(Medhurst,	Walker	et	
al.	 2002).	 These	 observations	 are	 not	 only	 similar	 to	 results	 in	 the	 mouse	 model,	 but	 more	
importantly.	 similar	 to	 clinical	 observations	 of	 osteolytic	 bone	 loss	 in	 many	 breast	 cancer	
patients	with	skeletal	metastasis	(Mantyh	2002,	Mantyh,	Clohisy	et	al.	2002).		A	corresponding	
decrease	in	mechanical	thresholds,	a	relative	decrease	in	wheel	running,	altered	weight	bearing	
away	 from	the	cancer	afflicted	 limb	and	 increased	glial	 fibrillary	acidic	protein	 (GFAP)	 staining	
ipsilateral	to	the	cancer-afflicted	limb	in	the	dorsal	horn	was	reported	(Medhurst,	Walker	et	al.	
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2002).	 	This	initial	characterization	established	a	model	that	allowed	future	analysis	and	use	of	
rats	 that	would	 allow	 additional	 techniques	 that	 could	 not	 be	 achieved	 in	 the	mouse	 due	 to	
technical	 challenges,	 such	as	electrophysiological	 recordings	 in	awake	animals,	 and	behavioral	
assays	that	may	be	more	reliable	in	the	rat.		
Recent	novel	methods	used	to	measure	ongoing	pain	in	models	has	allowed	us	to	assess	
the	 role	 of	 pain	 in	 a	 non-evoked	 way	 (King,	 Vera-Portocarrero	 et	 al.	 2009,	 Navratilova	 and	
Porreca	2014).	Within	the	rat	model	of	CIBP,	Remenuik	et	al.	2015	demonstrated	that	peripheral	
blockade	 of	 sensory	 fibers	 (by	 lidocaine)	 to	 the	 cancer-afflicted	 tibia	 in	 rats	 resulted	 in	
conditioned	place	preference	(CPP)	to	the	lidocaine	paired	chamber	indicating	pain	relief	along	
with	an	increase	in	dopamine	release	in	the	nucleus	accumbens	indicating	that	relief	of	CIBP	as	
other	pain	states	is	rewarding	(Remeniuk,	Sukhtankar	et	al.	2015).	These	two	observations	not	
only	 demonstrate	 that	 generation	 and	 likely	 maintenance	 of	 ongoing	 pain	 from	 the	 cancer	
afflicted	limb	in	rats	requires	sensory	neuron	activity,	but	holds	measures	that	blockade	of	the	
pain	signal	has	a	rewarding	behavioral	effect	and	a	physiological	response	in	the	reward	centers	
of	 the	brain.	These	 two	measures	went	 further	 to	demonstrate	 that	while	administration	of	a	
systemic	NSAID	reverses	tactile	hypersensitivity,	it	fails	to	induce	CPP	to	pain	relief	or	dopamine	
release	 in	 the	 nucleus	 accumbens	 (Remeniuk,	 Sukhtankar	 et	 al.	 2015).	 However,	 systemic	
morphine	successfully	blocks	peripheral	nerve	block	 induced	CPP	and	dopamine	release	 in	the	
nucleus	 accumbens,	 suggesting	 that	 morphine	 successfully	 manages	 ongoing	 pain	 and	 tactile	
hypersensitivity,	 recapitulating	 clinical	 reports	 that	 NSAIDs	 fail	 to	 manage	 advanced	 CIBP	
whereas	opioids	have	some	effect	(Bruera	and	Paice	2015,	Kane,	Hoskin	et	al.	2015).	
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1.4.	Known	Mechanisms	Driving	Cancer-Induced	Bone	Pain	
The	following	is	meant	to	expand	on	the	previous	section	and	discuss	with	slightly	more	
detail	some	of	the	key	findings	in	preclinical	models	of	CIBP	that	led	to	the	specific	direction	of	
the	work	included	in	this	dissertation.	
Evidence	from	the	earliest	bodies	of	work	investigating	these	preclinical	models	of	CIBP	
have	uncovered	many	important	factors	involved	in	CIBP.	As	mentioned	previously	Schwei	et.	Al	
1999,	 described	 evidence	 that	 implied	 the	 neurochemical	 changes	 observed	 in	 their	 mouse	
model	to	be	“unique”	from	other	models	of	pain,	or	perhaps	more	of	a	hybrid	signature	when	
compared	to	previous	results	from	inflammatory	and	neuropathic	pain	models	(Schwei,	Honore	
et	al.	1999).	Non-noxious	stimulation	that	consisted	of	a	2-minute	hind	limb	movement,	induced	
c-fos	expression	and	neurokinin-1	receptor	 (NK-1)	 internalization	 in	 the	superficial	dorsal	horn	
of	 the	 spinal	 cord	 ipsilateral	 to	 the	 implantation	 of	 the	 tumor,	 as	 well	 as	 deep	 lamina	 c-fos	
expression	 (Schwei,	Honore	et	al.	1999).	 	Beyond	this	 these	animals	displayed	 increased	GFAP	
staining	ipsilateral	to	the	tumor,	and	dynorphin	and	c-fos	expression	in	deep	lamina	of	the	spinal	
cord	dorsal	horn.	These	 findings	were	replicated	 in	a	 follow	up	publication	 from	Honore	et	al.	
2000	 that	 directly	 compared	 neurochemical	 changes	 between	 models	 of	 inflammation	 and	
neuropathic	pain	(Honore,	Rogers	et	al.	2000).	
Honore	et	al.	2000	and	Luger	et	al.	2001	demonstrated	that	both	the	bone	destruction	
and	neurochemical	changes	induced	by	the	tumor	were	blocked	by	OPG,	an	effective	osteoclast	
“decoy”	 that	 inhibits	 osteoclast	 function	 as	 previously	 mentioned	 through	 the	 RANK-RANKL	
activation	pathway	(Honore,	Rogers	et	al.	2000,	Luger,	Honore	et	al.	2001).	These	observations	
paired	well	with	previous	results	from	Clohisy	and	colleagues	that	demonstrated	OPG	effectively	
reduces	the	number	of	osteoclasts	at	the	site	of	an	osteolytic	tumor,	effectively	blocking	them	
from	 degrading	 bone.	 This	 effectively	 demonstrated	 that	 osteoclasts	 are	 required	 for	 bone	
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degradation,	 and	bone	degradation	plays	 a	 key	 role	 in	 the	 generation	of	 pain	 from	 the	bone,	
connecting	 this	 preclinical	 model	 to	 the	 clinic	 (Clohisy	 and	 Ramnaraine	 1998,	 Clohisy,	
Ramnaraine	 et	 al.	 2000).	 This	 highlighted	 the	 role	 for	 osteoclasts	 direct	 involvement	 in	
degrading	 the	 bone	 and	 emphasized	 the	 role	 for	 bone	 destruction	 and	 osteoclasts	 in	 driving	
neurochemical	 changes	 and	 pain	 in	 this	 model.	 Investigation	 of	 different	 cell	 lines	 and	 their	
potential	impact	on	CIBP	behavior	and	osteoclast	reprogramming	by	Sabino	et	al.	2003	(Sabino,	
Luger	 et	 al.	 2003)	 demonstrated	 that	 in	 immunocompromised	mice	 the	 injection	 of	 sarcoma,	
melanoma	and	colon	cancer	cell	lines	resulted	in	different	patterns	of	pathology	(Sabino,	Luger	
et	al.	2003).		
Perhaps	most	 remarkably	with	 respect	 to	bone	 remodeling,	 a	 similar	 observation	was	
recorded	to	Clohisy	and	colleagues’	earlier	work	with	a	melanoma	cell	line	(G3.26	derived	from	
C57BL6	 mouse)	 in	 this	 model	 and	 approach	 (Clohisy,	 Ogilvie	 et	 al.	 1996).	 The	 previously	
categorized	 sarcoma	 line	 (2472)	 replicated	 findings	 of	 the	 generation	 of	 unevoked	
flinching/guarding	behaviors	and	an	 increase	 in	pain	behaviors	during	 forced	ambulation	on	a	
rotarod	apparatus	and	palpation-evoked	guarding.	Whereas	melanoma	 (B16-F10	derived	 from	
C57/bl6)	and	colon	(NCI	derived	from	Balb/c	mice)	cell	lines	failed	to	induce	unevoked	guarding	
behaviors	and	have	differential	effects	on	ambulation	and	palpation-evoked	behaviors	(Sabino,	
Luger	 et	 al.	 2003).	 Beyond	 this,	 normally	 non-noxious	 palpation	 of	 the	 hind	 limb	 of	 animals	
injected	with	 all	 cell	 lines	 demonstrated	 increased	 c-fos	 expression	 in	 the	deep	 lamina	of	 the	
spinal	 cord,	 but	 only	 sarcoma	 and	melanoma	 cell	 lines,	 not	 colon,	 induced	 pathological	 c-fos	
expression	 in	 the	 superficial	 lamina	 of	 the	 spinal	 cord	 dorsal	 horn.	 Demonstrating	 a	 unique	
pattern	 of	 sensitization	 that	 correlated	 to	 palpation-induced	 guarding	 of	 the	 hind	 limb.	
Interestingly,	 GFAP	 expression	 was	 also	 demonstrated	 to	 be	 upregulated	 in	 animals	 injected	
with	the	sarcoma	and	colon	cell	 lines	(but	not	melanoma),	reflecting	cancer-induced	alteration	
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of	ambulatory	pain	scores	(Sabino,	Luger	et	al.	2003).	Evidence	such	as	this	demonstrates	that	
the	effects	of	different	primary	tumors	within	the	bone	can	have	unique	neurochemical	as	well	
as	 behavioral	 changes,	 further	 exemplifying	 the	 heterogeneity	 of	 CIBP	 (Sabino,	 Luger	 et	 al.	
2003).		
Little	was	known	about	the	actual	identity	or	anatomy	of	the	sensory	nerves	involved	in	
transducing	 pain	 from	 the	 femur	 in	 naïve	 animals	 let	 alone	 disease	 treated	 animals	 (i.e.	
nociceptive,	 autonomic,	 large	 diameter,	 etc.).	 Early	 work	 in	 the	 mouse	 utilizing	
immunohistochemical	(IHC)	staining	demonstrated	that	innervation	in	naïve	bone	as	well	as	the	
periosteum	was	primarily	CGRP	and	tyrosine	hydroxylase	(TH)	positive	with	additional	staining	
suggesting	the	presence	of	A-delta	 fibers	 (Mach,	Rogers	et	al.	2002).	These	observations	were	
accompanied	by	a	notable	 lack	of	 IB4-binding	fibers	(Mach,	Rogers	et	al.	2002).	This	work	was	
replicated	 utilizing	 a	 transgenic	 animal	 that	 selectively	 expressed	 eGFP	 under	 control	 of	 the	
MrgD	promoter	originally	developed	to	visualize	non-peptidergic	nociceptors	without	the	need	
for	staining	and	the	caveats	 introduced	by	different	methodological	approaches	 (Zylka,	Rice	et	
al.	2005).	Analysis	of	tissue	from	these	animals	demonstrated	a	lack	of	eGFP+	fiber	innervation	
to	 the	 bone,	 thus	 a	 lack	 of	 MrgD+	 or	 non-peptidergic	 nociceptors	 in	 the	 bone,	 but	 dense	
innervation	within	skin	of	 the	same	animals	 (Jimenez-Andrade,	Mantyh	et	al.	2010).	However,	
dense	 innervation	 of	 CGRP+	 fibers	 was	 observed	 within	 the	 bone	 and	 periosteum,	 again	
consistent	with	previous	experiments	identifying	peptidergic	nociceptors	in	the	periosteum	and	
bone	 (Jimenez-Andrade,	Mantyh	 et	 al.	 2010).	 This	 study	 also	 demonstrated	 lack	 of	 P2X3	 IHC	
staining	 in	 the	 bone	 and	 periosteum	 in	 mice,	 another	 marker	 of	 the	 stereotypical	 non-
peptidergic	nociceptor	population.		
This	 lent	 further	 evidence	 to	 the	 ideology	 in	 mice	 the	 innervation	 of	 the	 bone	 and	
periosteum	 is	 primarily	 peptidergic,	 CGRP+	 fibers,	 and	 that	 these	 native	 populations	 undergo	
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sprouting	 that	may	be	contributing	directly	 to	ongoing	and	spontaneous	pain	originating	 from	
this	site.	Counter	intuitively,	additional	investigation	within	this	model	demonstrated	that	while	
in	 the	 early	 stages	 of	 cancer	 cell	 growth	within	 the	 bone	 pathological	 sprouting	 is	 observed,	
denervation	occurs	in	the	distal	end	of	the	femur	at	late	stages	of	disease	progression,	perhaps	
highlighting	a	role	for	active	damage	to	neurons	within	the	bone	and	periosteum,	and	a	role	for	
neuronal	 damage	 to	 contribute	 to	 the	 pain	 generated	 from	 the	 cancer-afflicted	 hind	 limb	
(Peters,	 Ghilardi	 et	 al.	 2005).	 Of	 note	 the	 peptidergic	 population	 of	 nociceptors	 also	 reliably	
express	 the	 TRPV1,	 and	 one	 body	 of	work	 in	 the	 dog	 demonstrated	 ablation	 of	 TRPV1	 fibers	
improved	 several	 outcomes	 in	 companion	 dogs	 affected	 by	 bone	 cancer	 and	 CIBP	 (Brown,	
Agnello	et	al.	2015).		
Work	 that	 immediately	 followed	 this	 sought	 to	 observe	 fiber	 anatomy	 following	 the	
implantation	of	cancer	cells	into	the	femur.	Jimenez	et	al	2010,	demonstrated	that	not	only	was	
pathological	 sprouting	 observed	 following	 cancer	 cell	 implantation	 but	 that	 the	 fibers	
undergoing	pathological	sprouting	were	primarily	CGRP+,	TrkA+	and	neurofilament	protein	200	
(NF-200+)	 (Jimenez-Andrade,	 Bloom	 et	 al.	 2010).	 As	 mentioned	 previously,	 this	 pathological	
sprouting	was	blunted	by	administration	of	an	NGF-sequestering	antibody,	 and	observed	pain	
behaviors	also	decreased,	however	bone	pathology	remained	unaffected	by	the	NGF-antibody.	
Bloom	et	al.	2011	demonstrated	similar	sprouting	in	TrkA+	fibers	in	the	periosteum,	a	 location	
close	proximity	to	the	tumor	cells,	stromal	cells	and	bone	remodeling,	this	too	was	blocked	by	
the	 NGF	 sequestering	 antibody	 (Bloom,	 Jimenez-Andrade	 et	 al.	 2011).	 These	 findings	 were	
supported	by	additional	results	in	experiments	that	utilized	a	TrkA	receptor	antagonist,	further	
highlighting	the	role	for	NGF-induced	changes	in	peripheral	nerve	structure	and	CIBP	(Ghilardi,	
Freeman	 et	 al.	 2011).	 It	 is	 not	 clear	 whether	 blockade	 of	 bone	 remodeling	 by	 OPG	 blocks	
pathological	 sprouting	 of	 fibers.	 Both	 of	 these	 key	 bodies	 of	 work	 demonstrated	 a	 role	 for	
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neuronal	 plasticity	 induced	 by	 the	 presence	 of	 NGF	 following	 bone	 remodeling	 and	 tumor	
growth.		
In	 an	 attempt	 to	 compare	 effects	 of	 mitigating	 pain	 on	 the	 peptidergic	 and	 non-
peptidergic	 populations	 work	 was	 performed	 in	 both	 the	 mouse	 and	 the	 rat.	 As	 previously	
mentioned	work	in	the	rat	utilizing	retrograde	labeling	from	the	tibia	 implicated	the	possibility	
that	some	fibers	innervating	the	bone	were	in	fact	non-peptidergic	(Ivanusic	2009).	Work	from	
Mantyh’s	 group	 demonstrated	 the	 two	 fiber	 types	 likely	 have	 differential	 roles	 in	 CIBP	 by	
performing	 a	 side	 by	 side	 comparison	 using	 an	 NGF-sequestering	 antibody	 and	 an	 antibody	
targeting	the	P2X3	protein	in	the	mouse	(Guedon,	Longo	et	al.	2016).	As	previously	observed	the	
NGF-antibody	blocked/reversed	pain	behaviors	both	in	the	skin	and	measures	of	pain	from	the	
bone	 in	 the	 mouse	 model	 of	 CIBP,	 whereas	 the	 P2X3	 antibody	 only	 blocked	 the	 tactile	
hypersensitivity	 that	 reliably	 develops	 in	 these	 models	 of	 CIBP	 (Guedon,	 Longo	 et	 al.	 2016).	
Perhaps	 in	 line	with	the	differing	observations	of	fiber	type	innervation	of	the	bone	in	the	rat,	
Kaan	et	al.	2010	used	a	P2X2/P2X3	antagonist	and	demonstrated	that	while	bone	pathology	was	
unaltered	 by	 drug	 treatment,	mechanical	 allodynia	 and	 phosphorylated	 extracellular	 receptor	
kinase	 (pERK)	 expression	 in	 DRG	 were	 reversed	 (Kaan,	 Yip	 et	 al.	 2010).	 Wu	 et	 al	 2012	 also	
demonstrated	that	antagonism	of	the	P2X3	receptor	transiently	blocked	cancer-induced	tactile	
hypersensitivity	(Wu,	Xu	et	al.	2012).		
While	this	work	was	informative	to	the	peripheral	identity	of	cell	types	innervating	the	
femur,	and	 the	potential	 for	altering	each	 fiber	 types	 transduction	of	pain,	observation	of	 the	
cellular	bodies	of	these	neurons	within	the	DRG	of	animals	has	added	some	specifics	to	the	story	
of	CIBP.	Peters	et	al	2005	investigated	the	anatomical	location	of	cells	that	may	be	undergoing	
damage	 following	 cancer	 cell	 implantation.	While	 compared	 to	 sham	 treated	 animals,	 cancer	
cell	implantation	resulted	in	an	upregulation	of	the	neuronal	damage	marker	ATF3	in	L1,	L2	and	
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L3	DRG,	with	a	distinct	lack	of	ATF3	expression	in	other	DRG	(Peters,	Ghilardi	et	al.	2005).	This	
work	was	 run	 in	 comparison	 to	 femoral	nerve	 transection,	which	displayed	similar	patterns	 in	
DRG	of	ATF3	expression,	and	sciatic	nerve	transection	which	displayed	a	shifted	pattern	of	ATF3	
expression	towards	the	L3-L5	DRG	(Peters,	Ghilardi	et	al.	2005).	Intuitively	implicating	the	role	of	
innervation	 from	 the	 femoral	 nerve,	 which	 contains	 fibers	 from	 cell	 bodies	 within	 L2	 DRG.	
Additionally,	marked	galanin	expression	and	immune	cell	activation/migration	was	observed	in	
the	L2	DRG	of	cancer	treated	animals	when	compared	to	sham	(Peters,	Ghilardi	et	al.	2005).		
Sevcki	et	al	2004,	demonstrated	an	 interesting	 link	between	bone	destruction	and	the	
development	 of	 ATF3	 expression,	 demonstrating	 that	 bisphosphonate	 blockade	 of	 bone	
destruction	results	in	a	decrease	in	cell	bodies	within	the	DRG	expressing	ATF3	(Sevcik,	Luger	et	
al.	2004).	Interestingly	work	by	King	et	al.	2007	demonstrated	an	upregulation	of	ATF3	in	L4	DRG	
compared	to	shams,	demonstrating	that	establishment	and	growth	of	the	cells	within	the	femur	
reliably	induce	neuronal	damage	in	sensory	neurons	and	this	coincides	with	c-fos	expression	in	
the	L4	spinal	cord	segment	by	Sabino	et	al	2003	(Sabino,	Luger	et	al.	2003,	King,	Vardanyan	et	al.	
2007).	Notably	ATF3	expression	was	exacerbated	by	exposure	 to	chronic	mini-pump	delivered	
morphine,	 an	 observation	 that	 coincided	 with	 enhanced	 bone	 destruction	 as	 previously	
mentioned	(King,	Vardanyan	et	al.	2007).	Ivanusic	et	al.	2009	who	performed	a	characterization	
of	retrograde	labeling	to	identify	the	DRG(s)	in	which	the	cell	bodies	innervating	the	tibia	in	the	
rat,	reported	that	the	tibia	and	periosteum	contain	terminals	of	cells	primarily	within	the	L2-L5	
DRG.	This	report	also	contained	information	that	the	diameter	of	these	cells	ranged	from	small	
(likely	 C-fibers)	 to	 larger	 (A-delta)	 cell	 bodies,	 with	 more	 positive	 cells	 being	 small	 diameter	
neurons	 (Ivanusic	 2009).	 	 In	 addition	 to	 this,	 tumor	 growth	 and	 perhaps	 CIBP	 as	 a	 result,	
increases	 the	 presence	 of	 CGRP	 RNA	 and	 protein	 in	 the	 DRG	 of	mice	 (King,	 Vardanyan	 et	 al.	
2007,	Isono,	Suzuki	et	al.	2011).	An	effect	exacerbated	in	the	presence	of	chronic	morphine,	and	
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diminished	by	the	lack	of	activated	prostaglandin	E2	(PGE2)	(King,	Vardanyan	et	al.	2007,	Isono,	
Suzuki	et	al.	2011).	
	This	 addition	 to	 the	 literature	 gave	 the	 anatomical	 location	 of	 sensory	 nerves	
innervating	the	femur	in	these	mice	and	tibia	of	the	rat,	as	well	as	likely	the	identity	of	the	cells	
generating	 and	 maintaining	 pain	 signals,	 an	 important	 contribution	 to	 future	 work	 that	
would/will	allow	for	targeted	proteomic	and	genomic	investigation	of	sensory	neurons	following	
cellular	implant.	
Evidence	 that	 tumor	 cells	 alter	 cellular	 signaling	 of	 osteoclasts	 and	 immune	 cells	 has	
also	been	demonstrated	in	both	the	mouse	and	rat	model	of	CIBP.	Work	as	early	as	Clohisy	et	al.	
1995	 has	 demonstrated	 the	 likelihood	 of	 tumor	 cells	 inducing	 cellular	 changes	 within	 close	
proximity	 to	 their	 growth.	 Remeniuk	 et	 al.	 2018	 demonstrated	 that	 in	 animals	 that	 received	
tumor	 implant,	 markedly	 increased	 levels	 of	 interleukin-6	 were	 found	 in	 bone	 exudate	 and	
plasma,	 an	 observation	 closely	 following	measures	 of	 clinical	 patients	 with	metastatic	 breast	
cancer	(Remeniuk,	King	et	al.	2018).	The	authors	of	this	paper	found	that	acute	administration	
of	 an	 IL-6	 antagonist	 temporarily	 reversed	 tactile	 hypersensitivity,	 while	 having	 no	 effect	 on	
ongoing	 pain	 measured	 by	 CPP	 to	 pain	 relief.	 However,	 chronic	 administration	 of	 the	 IL-6	
antagonist	beginning	at	the	time	of	tumor	implantation	resulted	in	blockade	of	the	development	
of	 tactile	 hypersensitivity,	 ongoing	 pain	 as	 well	 as	 bone	 remodeling,	 a	most	 promising	 result	
with	clinical	translation	indeed.	Isono	et	al.	2011	demonstrated	that	microsomal	prostaglandin	E	
synthase-1	(mPGES-1)	knock	out	mice,	that	lack	the	ability	to	activate	PGE2	showed	diminished	
pain	 behaviors	 along	 with	 tumor	 growth	 potentially	 due	 to	 a	 lack	 of	 RANKL	 activation,	
implicating	a	role	of	cancer-induced	activation	of	the	gene	in	order	to	produce	certain	aspects	of	
CIBP	(Isono,	Suzuki	et	al.	2011).	
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Electrophysiological	 recordings	 from	 spinal	 cord	 dorsal	 horn	 neurons	 in	 cancer	 cell	
injected	 rats	 has	 demonstrated	 that	 as	 pain	 behaviors	 develop	 and	 bone	 destruction	 occurs,	
central	 sensitization	 occurs,	 however	 it	 did	 so	 in	 a	manner	 unique	 from	 previously	 observed	
neuropathy	models	(Urch,	Donovan-Rodriguez	et	al.	2003).	CIBP	caused	hyperexcitability	in	wide	
dynamic	range	cells	 in	the	spinal	cord	 in	response	to	a	number	of	nociceptive	stimuli,	changes	
that	 remained	 even	 when	 a	 chronic	 morphine	 regiment	 was	 given	 to	 rats	 (Urch,	 Donovan-
Rodriguez	et	al.	2003,	Urch,	Donovan-Rodriguez	et	al.	2005).	Interestingly	the	hyperexcitablity	of	
dorsal	horn	neurons	evoked	by	A-delta	and	C-fibers	 in	the	periphery	in	the	rat	was	blocked	by	
administration	of	the	P2X3	antagonist,	an	interesting	contradiction	to	the	observed	role	in	mice	
for	 the	 non-peptidergic	 fibers	 (Kaan,	 Yip	 et	 al.	 2010).	 The	 reactivity	 and	 sensitization	 that	 is	
recorded	 from	 superficial	 dorsal	 horn	 neurons	 not	 only	 agrees	 with	 the	 known	 innervation	
patterns	 of	 the	 spinal	 cord	 from	 previously	 reported	 evidence,	 but	 coincides	with	 retrograde	
labeling	from	the	tibia.	Both	Kaan	et	al.	2010	and	Ivanusic	2009	report	the	identity	of	cell	bodies	
within	 DRG	 that	 innervate	 the	 tibia	 in	 the	 rat,	 and	 demonstrate	 co-labeling	 for	 stereotypical	
nociceptive	markers,	 eg.	 SP,	 CGRP	 and	notably	 IB4,	 in	 contrast	 to	 results	 noted	 in	 the	mouse	
(Ivanusic	2009,	Kaan,	Yip	et	al.	2010)	.	
These	examples	and	efficacy	of	approaches	varies	between	measurable	pain	behaviors,	
i.e.	 certain	 approaches	 treat	 tactile	 hypersensitivity	 but	 fail	 to	manage	 supposed	measures	of	
ongoing	 pain,	 and	 vice	 versa.	 Acute	 administration	 of	 a	 p38-MAPK	 inhibitor	 reversed	 cancer-
induced	 increases	 in	 flinching	 and	decreased	 cancer-induced	hind	 limb	guarding,	 but	 failed	 to	
ameliorate	 cancer-induced	 tactile	 hypersensitivity	 (Sukhtankar,	 Okun	 et	 al.	 2011).	 Chronic	
administration	of	 the	 kappa	opioid	 receptor	 (KOR)	 agonist	U50-488	has	 similar	 effects,	where	
U50-488	reversed	these	measures	although	to	a	lesser	extent	(Edwards,	Havelin	et	al.	2018).	
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While	these	additions	to	the	body	of	literature	surrounding	CIBP	have	been	informative,	
few	 have	 resulted	 in	 the	 development	 of	 novel	 improvements	 in	 the	 clinic.	 One	 potential	
limitation	of	 the	 translation	of	 these	 findings	are	 the	methods	used	 to	evaluate	 their	efficacy.	
While	 behaviors	 such	 as	 shifted	 weight	 bearing,	 evoked	 tactile	 hypersensitivity,	 increased	
flinching/guarding	 and	 impaired	 limb	use	have	been	 the	mainstay	 for	 nearly	 20	 years	 of	 CIBP	
preclinical	work,	 it	 is	not	necessarily	clear	that	reversal	of	these	behaviors	 is	truly	due	relief	of	
ongoing	pain.	A	dramatic	 implication	of	work	published	by	King	et	al.	2009,	where	the	authors	
demonstrated	 compounds	 that	 alleviate	 tactile	 hypersensitivity	 in	 preclinical	 models	 do	 not	
necessarily	 always	 alleviate	 ongoing	 pain,	 similar	 to	 observations	 form	 the	 clinic	 (King,	 Vera-
Portocarrero	et	al.	2009).		While	some	work	is	likely	more	convincing	than	others,	e.g.	blockade	
of	 neuronal	 sprouting	 by	 NGF-antibodies	 that	 may	 have	 clinical	 efficacy,	 and	 blockade	 of	
osteoclast	induced	bone	remodeling	which	does	show	clinical	efficacy,	other	approaches	may	be	
more	 limited	 in	 their	 translatability.	Recently	 the	development	and	successful	 implementation	
of	CPP	to	ongoing	pain	relief	in	models	of	CIBP	has	provided	a	novel	and	non-evoked	measure	of	
pain	relief	that	may	serve	for	screening	of	more	effective	therapeutics	(Remeniuk,	Sukhtankar	et	
al.	2015,	Remeniuk,	King	et	al.	2018).	This,	 in	addition	to	the	 lack	of	a	model	of	BTP	that	truly	
involves	a	non-painful	stimulus	are	truly	two	hindrances	to	the	field.	In	the	case	of	BTP,	this	has	
been	a	detriment	to	the	field	in	the	development	and	screening	of	novel	analgesics	to	treat	BTP,	
as	 little	 is	 known	 about	 the	 underlying	 neurophysiology	 of	 BTP.	 In	 the	 following	 I	 share	 the	
results	 of	 our	 group	 in	 developing	 a	 novel	model	 of	 BTP	 in	 a	 rat	model	 of	 CIBP	 along	with	 a	
unique	role	for	the	non-peptidergic	IB4-binding	fibers	in	being	critical	to	BTP.	Following	this,	due	
to	limitations	of	the	techniques	used	in	our	rat	work,	we	sought	to	expand	and	clarify	the	role	of	
unique	populations	of	sensory	fibers	in	ongoing	pain	and	BTP	in	the	mouse	using	an	optogenetic	
approach	that	would	allow	us	to	transiently	silence	peripheral	fibers	rather	than	ablate	them.	
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CHAPTER	2	
MEDIATION	OF	MOVEMENT-INDUCED	BREAKTHROUGH	CANCER	PAIN	BY	IB4-BINDING	
NOCICEPTORS	IN	RATS	
	
The	section	below	is	work	that	is	published	as	a	primary	research	article	in	The	Journal	
of	Neuroscience	(Havelin,	Imbert	et	al.	2017).	It	has	been	slightly	modified	for	this	dissertation.	
	
2.1.	Abstract	
Cancer-induced	bone	pain	 (CIBP)	 is	 characterized	by	moderate	 to	 severe	ongoing	pain	
that	commonly	requires	the	use	of	opiates.	Even	when	ongoing	pain	is	well	controlled,	patients	
can	suffer	breakthrough	pain	(BTP),	episodic	severe	pain	that	“breaks	through”	the	medication.	
We	 developed	 a	 novel	 model	 of	 cancer-induced	 BTP	 using	 female	 rats	 with	 mammary	
adenocarcinoma	cells	sealed	within	the	tibia.	We	previously	demonstrated	that	rats	with	bone	
cancer	 learn	 to	 prefer	 a	 context	 paired	 with	 saphenous	 nerve	 block	 to	 elicit	 pain	 relief	 (i.e.,	
conditioned	 place	 preference,	 CPP),	 revealing	 the	 presence	 of	 ongoing	 pain.	 Treatment	 with	
systemic	morphine	abolished	CPP	to	saphenous	nerve	block	demonstrating	control	of	ongoing	
pain.	 Here,	 we	 show	 that	 pairing	 BTP	 induced	 by	 experimenter-induced	 movement	 of	 the	
tumor-bearing	 hind	 limb	 with	 a	 context	 produces	 conditioned	 place	 aversion	 (CPA)	 in	 rats	
treated	 with	 morphine	 to	 control	 ongoing	 pain,	 consistent	 with	 clinical	 observation	 of	 BTP.	
Preventing	movement-induced	afferent	input	by	saphenous	nerve	block	prior	to,	but	not	after,	
hind	limb	movement	blocked	movement-induced	BTP.	Ablation	of	isolectin	B4	(IB4)	binding,	but	
not	TRPV1+,	sensory	afferents	eliminated	movement-induced	BTP	suggesting	that	input	from	IB4	
binding	 fibers	 mediates	 BTP.	 Identification	 of	 potential	 molecular	 targets	 specific	 to	 this	
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population	of	fibers	may	allow	for	development	of	peripherally	restricted	analgesics	that	control	
BTP	and	improve	quality	of	life	in	patients	with	skeletal	metastases.		
	
2.2.	Introduction	
Pain	 is	 the	most	 feared	 consequence	of	 cancer	 (Breivik,	Cherny	et	 al.	 2009,	Paice	and	
Ferrell	2011).	Metastatic	bone	pain	 is	 characterized	by	moderate-to-severe	persistent	ongoing	
pain	associated	with	tumor	growth,	nerve	destruction	and	bone	remodeling.	As	many	as	40-80%	
of	 these	 patients	 also	 experience	 breakthrough	 pain	 (BTP),	 transient	 episodes	 of	 severe	 to	
excruciating	 pain	 occurring	 in	 the	 presence	 of	medication	 controlling	 background	 cancer	 pain	
(Portenoy	 and	 Hagen	 1989,	 Portenoy	 and	 Hagen	 1990,	 Mercadante	 2015).	 BTP	 is	 frequently	
reported	 for	 15-30	 min	 following	 voluntary	 or	 involuntary	 movements,	 such	 as	 changing	
position	or	coughing,	with	as	many	as	4-6	episodes	reported	within	a	day	dramatically	reducing	
patients’	 quality	 of	 life	 (Haugen,	Hjermstad	 et	 al.	 2010,	Mercadante	 2015).	 Treatment	 of	 BTP	
typically	requires	rapid	onset	opioids	that	while	often	effective,	are	confounded	by	uncertainty	
of	 dosing	 requirements	 for	 safe	 and	 effective	 treatment	 of	 individual	 patients	 (Mercadante	
2011,	Mercadante	2015).	Further	complicating	treatment,	BTP	takes	place	on	a	background	of	
medication,	 primarily	 opioid,	 controlled	 ongoing	 pain.	 Increasing	 the	 opioid	 dose	 results	 in	 a	
high	 likelihood	 of	 adverse	 side	 effects,	 further	 diminishing	 these	 patients’	 quality	 of	 life	
(Mercadante	2015).	 The	discovery	of	 safe	 and	effective	medications	 to	 treat	BTP	 is	 an	urgent	
unmet	medical	need.		
The	 observation	 that	 BTP	 occurs	 in	 the	 setting	 of	 opioid	 medication	 that	 sufficiently	
controls	 ongoing	 pain	 suggests	 that	 these	 pain	 states	 are	 mechanistically	 distinct	 (Bennett	
2010).	Analgesic	actions	of	drugs	such	as	morphine	occur	at	mu	opioid	receptors	(MOR)	that	are	
located	 within	 the	 periphery,	 spinal	 cord	 and	 brain.	 One	 possibility	 is	 that	 movement	 may	
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recruit	 additional	 fibers	 that	 are	 not	 blocked	 by	 peripheral	MOR	 agonists	 at	 doses	 that	 block	
persistent	background	pain.	In	the	setting	of	pain-induced	central	sensitization,	such	signals	may	
elicit	 excruciating	 BTP	 (Mantyh	 2013,	 Falk	 and	 Dickenson	 2014,	Mantyh	 2014),	 that	 requires	
fast-acting	opioids	that	likely	exert	their	effects	at	supraspinal	sites.		
While	recent	RNAseq	studies	have	described	as	many	as	11	subpopulations	of	sensory	
fibers	 (Usoskin,	 Furlan	 et	 al.	 2015),	 two	 broad	 classes	 of	 fibers	 that	 have	 been	 widely	
characterized	are	TRPV1	expressing	fibers	IB4	binding	neurons	(Molliver	and	Snider	1997,	Snider	
and	McMahon	 1998,	 Basbaum,	 Bautista	 et	 al.	 2009,	Wang	 and	 Zylka	 2009).	 Previous	 studies	
have	 demonstrated	 that	 long-lasting	 desensitization	 of	 TRPV1	 expressing	 sensory	 fibers	
produces	 insensitivity	 to	 thermal	 stimulation	 and	 ongoing	 pain,	 without	 altering	 tactile	
hypersensitivity,	 in	 models	 of	 neuropathic	 and	 inflammation-induced	 pain	 (Yaksh,	 Farb	 et	 al.	
1979,	 Ossipov,	 Bian	 et	 al.	 1999,	 Okun,	 DeFelice	 et	 al.	 2011).	 Others	 have	 demonstrated	 that	
ablation	of	MrgD	expressing	or	IB4	binding	fibers	blocks	tactile	hypersensitivity	without	altering	
thermal	responses	(Joseph,	Chen	et	al.	2008,	Cavanaugh,	Lee	et	al.	2009,	Ye,	Dang	et	al.	2012).	
Given	 the	 mechanical	 component	 of	 movement-evoked	 BTP,	 we	 tested	 the	 hypothesis	 that	
blocking	 nociceptive	 input	 from	 IB4	 binding	 fibers	 will	 block	movement-evoked	 BTP	 whereas	
blocking	nociceptive	input	from	TRPV1	expressing	fibers	will	not	block	movement-evoked	BTP.		
Evaluation	 of	 BTP	 and	 cancer-induced	 ongoing	 pain	 has	 been	 limited	 by	 the	 lack	 of	
available	 preclinical	 models.	 We	 recently	 reported	 capturing	 ongoing	 cancer	 pain	 through	 a	
learning	paradigm	assessing	motivation	to	seek	a	context	associated	with	pain	relief	(Remeniuk,	
Sukhtankar	et	al.	2015).	Here,	we	developed	a	novel	measure	of	BTP	by	assessing	the	motivation	
to	avoid	a	context	associated	(conditioned	place	avoidance,	CPA)	with	pain	following	movement	
of	 the	 tumor-bearing	 hind	 limb.	 Critically,	 this	 model	 assessed	 CPA	 in	 rats	 with	 morphine-
controlled	ongoing	bone	cancer	pain,	simulating	movement	triggered	BTP	in	patients.		
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2.3.	Materials	and	methods	
2.3.1.	Animal	Care	
Female	 and	 male	 Fischer	 F344/NhSD	 (Harlan	 Laboratories	 Inc,	 Indianapolis,	 IN,	 USA)	
weighing	125-150g	were	chosen	based	on	their	histocompatibility	with	the	MAT	BIII	tumor	line.	
The	rats	were	maintained	on	a	12-hour	light/dark	cycle	with	food	and	water	available	ad	libitum.	
All	experiments	were	performed	 in	accordance	with	 the	policies	and	 recommendations	of	 the	
International	 Association	 for	 the	 Study	 of	 Pain,	 National	 Institutes	 of	 Health,	 and	 the	
Institutional	Animal	Care	and	Use	Committee	of	the	University	of	Arizona	and	University	of	New	
England.		
	
2.3.2.	Cell	Line	Maintenance		
The	 Fischer	 rat	mammary	 adenocarcinoma	 cell	 line	 13762	MAT	 BIII	 (ATCC,	 CRL	 1666,	
RRID:CVCL_3475,	Manassas,	VA)	was	maintained	 in	McCoy’s	media	with	L-Glutamine	 (CellGro,	
Manassas,	 VA)	 with	 10%	 fetal	 bovine	 serum	 (ATCC,	 Manassas,	 VA)	 and	 1%	
penicillin/streptomycin	 at	 37°C	 in	 a	 5%	 CO2	 atmosphere.	 Prior	 to	 surgical	 implantation,	 cells	
were	washed	with	phosphate-buffered	saline	and	detached	with	0.05%	trypsin-EDTA	 (CellGro,	
Manassas,	 VA).	 The	 cells	 were	 spun	 at	 2300	 rpm	 for	 3	 minutes	 and	 re-suspended	 at	 a	
concentration	of	2	x	105	cells/	µL	in	McCoy’s	serum	free	media.		
	
2.3.3.	Surgical	Procedures	and	Drug	Treatment	
Intratibial	 Surgery	 and	 Cancer	 Implantation.	 This	 surgical	 procedure	 was	 performed	
according	 to	 previously	 published	 methods	 (Remeniuk,	 Sukhtankar	 et	 al.	 2015).	 Briefly,	 rats	
were	anaesthetized	under	gas	anesthesia	(2%	isoflurane	O2	mixture).	The	right	hind	limb	of	the	
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rat	was	 shaved	and	disinfected	with	70%	ethanol	 and	betadine.	 The	animal	was	placed	on	 its	
back	and	a	1	cm	 incision	was	made	horizontally	across	the	femoral-tibial	 region	to	expose	the	
patellar	tendon,	and	surrounding	skin	retracted	to	expose	the	proximal	end	of	the	tibia.	A	small	
hole	was	drilled	between	the	lateral	and	medial	condyles	into	the	intramedullary	canal	followed	
by	 insertion	of	a	5	 cm,	28-gauge	guide	cannula	 (Plastics	One)	attached	 to	Tygon	 tubing	 (Cole-
Palmer)	 to	 a	 25	 µL	 syringe	 (Hamilton,	 Reno,	 NV),	 with	 location	 verified	 by	 x-ray	 imaging	
(Faxitron,	Tucson,	AZ).	Injection	of	5	µL	of	MAT	BIII	cells,	or	cell	free	McCoy’s	serum	free	media	
(vehicle),	 was	 followed	 by	 sealing	 the	 drilled	 hole	 with	 bone	 cement	 (Stryker	 Orthopaedics,	
Simplex	 P	 Bone	Cement,	Mahwah,	NJ).	 The	 area	was	 flushed	with	 sterile	 saline	 and	 the	 knee	
joint	 was	 reinforced	with	 a	 vicryl	 5-0	 suture	 (Ethicon,	 Cornelia,	 GA)	 placed	 across	 the	 drilled	
area.	Each	rat	 received	1	mg/ml	of	gentamicin	sulfate	 (Sparhawk	Laboratories	 Inc,	Lenexa,	KS)	
via	subcutaneous	(s.c.)	injection	and	was	allowed	to	recover	from	anesthesia	prior	to	return	to	
the	 housing	 colony.	 Animals	 did	 not	 receive	 treatment	 with	 analgesics	 following	 tumor	
implantation	 as	 treatment	with	 NSAIDs,	 specifically	 COX	 inhibitors,	 as	well	 as	morphine	 have	
been	 demonstrated	 to	 impact	 aspects	 of	 disease	 progression	 including	 tumor	 growth	 and	
tumor-induced	bone	remodeling	(Sabino,	Ghilardi	et	al.	2002,	Sabino,	Ghilardi	et	al.	2002,	King,	
Vardanyan	et	al.	 2007).	 For	ethical	 considerations,	 all	 experiments	were	 terminated	within	14	
days	of	tumor	inoculation	into	the	tibia.	A	total	of	83	tumor-bearing	rats	and	50	sham	rats	were	
used	across	all	studies.	
Morphine	 Pellet	 Implantation.	 Effects	 of	morphine	 on	 tumor-induced	 bone	 pain	were	
assessed	 by	 insertion	 of	 morphine	 or	 placebo	 pellets	 11	 days	 post-intratibial	 surgery	 and	
behavioral	 testing	 20-24	 hours	 post-pellet	 implantation,	 12	 days	 post	 intratibial	 surgery.	
Morphine	sulfate	 (75	mg)	or	placebo	pellets,	generously	provided	by	 the	National	 Institute	on	
Drug	 Abuse	 (NIDA)	 Drug	 Supply	 Program,	 were	 inserted	 (s.c.)	 under	 gas	 anesthesia	 (2%	
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isoflurane	O2	mixture)	on	the	side	contralateral	to	tibia	surgery	of	the	rat	in	front	of	the	pelvic	
region.	The	region	was	shaved	and	disinfected	with	70%	ethanol	and	betadine.	A	1	cm	incision	
was	made	 into	the	skin,	and	a	pocket	created	with	forceps	 in	between	the	skin	and	muscle.	A	
single	pellet	was	inserted	into	the	pocket	region,	and	the	incision	closed	using	a	surgical	wound	
clip.	Rats	received	1	mg/mL	(s.c.)	of	gentamicin	sulfate	(Sparhawk	Laboratories	Inc,	Lenexa,	KS)	
and	were	allowed	to	recover	from	anesthesia	prior	to	return	to	the	housing	colony.	For	CPP	and	
CPA	 experiments,	 pellets	were	 implanted	 immediately	 following	 assessment	 of	 baseline	 (pre-
conditioning)	time	spent	in	the	conditioning	chambers.		
Intrathecal	 Catheterization	 and	 Spinal	 Drug	 Delivery.	 Rats	 underwent	 surgical	
implantation	of	an	intrathecal	catheter	for	drug	administration	at	the	level	of	the	lumbar	spinal	
cord	a	minimum	of	7	days	prior	 to	 intra-tibial	 surgeries	 to	allow	sufficient	 recovery	 time	 from	
the	intrathecal	surgeries.	Intrathecal	catheters	were	surgically	implanted	as	previously	described	
(Yaksh	 and	 Rudy	 1976,	 Yaksh,	 Farb	 et	 al.	 1979,	 King,	Qu	 et	 al.	 2011).	 Rats	were	 anesthetized	
under	gas	anesthesia	(2%	isoflurane	O2	mixture)	while	secured	in	a	stereotaxic	frame	(Stoelting,	
Wood	 Dale,	 IL).	 The	 atlanto-occipital	 membrane	 was	 exposed,	 punctured,	 and	 a	 section	 of	
polyethylene-10	tubing	(PE-10)	6.5	cm	in	length	was	passed	caudally	from	the	cisterna	magna	to	
the	lumbar	enlargement	for	a	single	spinal	administration	of	the	appropriate	drug	or	vehicle.	To	
determine	 the	 effect	 of	 eliminating	 input	 from	 TRPV1	 expressing	 fibers,	 rats	 received	 spinal	
administration	of	capsaicin	(20	µg/10	µl	10%	Tween,	10%	Ethanol,	80%	saline)	followed	by	10	µl	
saline	flush	or	equivolume	vehicle	(10%	Tween,	10%	Ethanol,	80%	saline)	vehicle	followed	by	10	
µl	 saline	 flush.	 To	 determine	 the	 effect	 of	 eliminating	 input	 from	 IB4-binding	 fibers,	 separate	
groups	 of	 rats	 received	 spinal	 administration	 of	 IB4-Saporin	 (IB4-SAP,	 Advanced	 Targeting	
Systems,	3.2	µg	/20	µl	saline)	or	the	control,	blank-SAP	(Advanced	Targeting	Systems,	3.2	µg	/20	
µl	saline)	followed	by	a	10	µl	flush	of	saline.	Movement	of	an	air	bubble	placed	between	drug	
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solution	 and	 saline	 was	 used	 to	 monitor	 progress	 of	 the	 injection.	 Immediately	 following	
injection,	 catheters	 were	 slowly	 removed	 from	 the	 spinal	 cord	 and	 the	 wound	 closed.	 Any	
animals	 displaying	 motor	 impairment	 or	 paralysis	 during	 recovery	 (<10%	 total	 rats)	 were	
immediately	 euthanized.	 Animals	 were	 routinely	 checked	 throughout	 the	 experiment	 to	
monitor	 health.	 Following	 behavioral	 testing,	 rats	 were	 euthanized	 and	 tissue	 collected	 for	
immunohistochemical	 verification	 of	 elimination	 of	 TRPV1	 or	 IB4	 immunofluorescence	 in	 the	
spinal	dorsal	horn	of	capsaicin	or	IB4-SAP	treated	rats,	respectively.		
Immunofluorescent	Analysis	of	Effect	of	Spinal	Capsaicin	or	IB4-SAP	on	TRPV1,	SP,	CGRP	
and	IB4	Immunofluorescence	in	the	Spinal	Dorsal	Horn.	To	verify	that	these	treatments	produced	
selective	ablations	of	targeted	nociceptor	terminals,	tissue	was	collected	for	immunofluorescent	
staining	 and	 semi-quantitative	 image	 analysis	 D21	 post	 intrathecal	 administration	 of	 IB4-
saporin,	blank-SAP,	capsaicin,	or	 the	vehicle	 for	capsaicin.	Rats	were	deeply	anesthetized	with	
Beuthanasia-D	(Henry	Schein	Animal	Health,	Dublin,	OH)	and	underwent	intracardiac	perfusion	
through	 the	 left	 ventricle	 with	 PBS	 containing	 heparin	 (100	 U/mL)	 followed	 by	 4%	 PFA	
containing	 PBS,	 pH	 7.4.	 The	 L3-L4	 spinal	 cord	 segments	 were	 immediately	 dissected	 out	 and	
post-fixed	 in	 10%	 formalin	 overnight.	 The	 spinal	 cord	 was	 then	 moved	 into	 a	 30%	 sucrose	
solution	at	4oC	for	12	to	24	hours	for	cryoprotection.	Spinal	cords	were	embedded	in	OCT	(VWR,	
Radnor,	PA)	and	frozen	on	dry	ice	for	sectioning.	Sections	were	cut	on	a	cryostat	(Leica,	Wetzlar,	
Germany)	at	30	microns,	collected	onto	positively	charged	slides	(Azer	Scientific,	Morgantown,	
PA),	 and	 allowed	 to	 dry	 before	 storage	 at	 -80oC.	 Sections	 were	 rinsed	 3	 times	 with	 PBS	
containing	0.05%	Tween	(PBST)	to	remove	OCT,	then	non-specific	binding	proteins	were	blocked	
by	 30	 min	 incubation	 with	 5%	 normal	 donkey	 serum	 (EMD	 Millipore,	 Billerica,	 MA)	 and	 1%	
bovine	 serum	 albumin	 (Amresco,	 Solon,	 OH)	 in	 PBST.	 This	 blocking	 solution	 was	 also	 the	
antibody	diluent.	Primary	antibodies	and	Alexa	488-conjugated	IB4	were	incubated	overnight	at	
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4°C	as	follows:	IB4-AF488	1:500	(Molecular	Probes	Cat#	I21411	also	I21411	RRID:AB_2314662);	
goat	anti-TRPV1	1:100	(AF3066,	R&D	Systems,	Minneapolis,	MN);	rabbit	anti-Substance	P	1:500	
(ImmunoStar	Cat#	20064	RRID:AB_572266,	Hudson,	WI);	rabbit	anti-CGRP	1:2000	(ImmunoStar	
Cat#	 24112	 RRID:AB_572217).	 The	 TRPV1	 antibody	 was	 validated	 in	 rat	 DRG	 tissue	 by	
competition	experiments	with	the	TRPV1	antigen	peptide	that	completely	abolished	binding	of	
the	TRPV1	antibody	as	well	as	verifying	that	the	antibody	detected	a	protein	of	the	appropriate	
molecular	 weight	 in	 western	 blots	 (Isensee,	 Wenzel	 et	 al.	 2014).	 Both	 the	 CGRP	 and	 SP	
antibodies	are	widely	used	and	cited	in	the	literature,	with	504	citations	for	the	SP	antibody	and	
110	 citations	 for	 the	 CGRP	 antibody	 verifying	 that	 these	 antibodies	 are	 widely	 used	 in	 peer-
reviewed	 journals	 (https://www.citeab.com/),	proposed	as	 the	most	 reliable	way	 to	 identify	a	
suitable	 antibody	 (Helsby,	 Leader	 et	 al.	 2014).	 Sections	 were	 rinsed	 3	 times	 with	 PBST	 and	
incubated	 in	 the	dark	 for	1	hour	at	RT	with	appropriate	cross-adsorbed	secondary	antibodies:	
Donkey	 anti-goat	 Alexa	 Fluor	 568	 1:1000	 (A-11057,	 Life	 Technologies,	 Carlsbad,	 CA);	 donkey	
anti-rabbit	Alexa	Fluor	568	1:1000	(ab175692,	Abcam,	Cambridge,	MA);	donkey	anti-goat	Alexa	
Fluor	488	1:1000	(ab150133,	Abcam).	Sections	were	rinsed	with	PBS	3	times	and	mounted	with	
DAPI-containing	Fluoroshield	(ab104139,	Abcam).	Primary	and/or	secondary	antibody	omission	
controls	under	identical	staining	conditions	resulted	in	no	fluorescent	signal.		
Images	were	acquired	using	a	Leica	TCS	SP5	confocal	laser	scanning	microscope	using	a	
20x/0.7	NA	plan	apo	objective	 lens.	Excitation	 light	was	generated	at	488	nm	by	an	argon	gas	
laser	or	561	nm	by	a	diode	pumped	solid	 state	 laser	 through	a	double	dichroic	beam	splitter,	
and	emission	was	detected	sequentially	via	photomultiplier	 tubes	 to	avoid	cross-talk	between	
fluorophores.	Z-stack	images	were	collected	with	a	0.71	um	step	size,	and	maximum	projections	
generated	 for	 subsequent	 analysis.	 All	 z-stack	 images	 within	 each	 staining	 condition	 were	
acquired	in	a	single	session	using	the	same	laser	intensity	settings.	Images	were	analyzed	using	
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FIJI	 image	analysis	software	(Schindelin,	Arganda-Carreras	et	al.	2012).	Confocal	z-stack	images	
captured	using	 the	Leica	confocal	 software	were	opened	using	 the	Bioformats	plug-in.	 Images	
were	rotated	on	the	X/Y	axis	so	that	the	dorsal	portion	of	the	spinal	dorsal	horn	is	located	at	the	
top	 of	 the	 image	 and	 a	 Z	 projection	 image	 was	 created	 using	 maximum	 intensity	 for	 2D	
visualization	 of	 the	 stack.	 The	 split	 channels	 function	 was	 used	 to	 create	 red	 (TRPV1,	 SP	 or	
CGRP)	or	green	(IB4)	fluorescent	images.	Regions	of	interest	(ROI)	were	selected	from	a	file	and	
arranged	 to	 calculate	 ratios	of	 the	mean	grey	 value	of	 pixels	within	 the	ROI	 for	 1)	 an	 area	of	
lamina	1	and	the	same	area	in	the	deep	dorsal	horn	(L1/L1con)	and	2)	an	area	of	lamina	2	and	
the	 same	 area	 in	 the	 deep	 dorsal	 horn	 (L2/L2con)	 (See	 Fig	 4).	 This	 allowed	 for	 an	 internal	
reference	to	normalize	intensity	ratings	for	comparison	across	sections.	The	number	of	sections	
analyzed	 for	 TRPV1	 analyses	 are	 reported	 in	 table	 1.	 These	 numbers	 include	 sections	 from	
TRPV1/IB4,	SP/IB4	and	CGRP/IB4	co-stains	as	 there	were	no	significant	differences	 in	 intensity	
ratings	for	IB4-fluorescence	across	these	three	immunofluorescent	conditions.	Average	intensity	
ratios	 across	 sections	were	 used	 to	 calculate	means	 and	 SEM	 across	 samples	 from	 individual	
animals.	Ratios	were	calculated	across	spinal	dorsal	horn	images	from	3	control	rats,	4	capsaicin	
treated	rats	for	SP	and	CGRP,	3	for	TRPV1	and	2	IB4-SAP	treated	rats.	
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2.3.4.	Behavioral	Measures	
Behavioral	Measure	of	tactile	hypersensitivity.	Rats	were	placed	into	elevated	chambers	
with	a	wire	mesh	 floor	and	allowed	 to	acclimate	 for	30	min.	Paw	withdrawal	 thresholds	were	
determined	 in	 response	to	probing	with	calibrated	von	Frey	 filaments	with	spaced	 increments	
ranging	from	0.5	to	15	g.	Each	filament	was	applied	to	the	middle	of	the	plantar	surface	of	the	
paw	using	the	"up	and	down"	method	and	analyzed	using	a	Dixon	nonparametric	test	(Chaplan,	
Bach	et	al.	1994).	
Behavioral	measure	of	impaired	limb	use.	Limb	use	was	assessed	as	previously	described	
(Luger,	Honore	et	al.	2001).	The	animal	was	placed	in	an	empty	pan	and	observed	while	walking.	
Sample	1 Sample	2 Sample	3 Sample	4
TRPV1
Control 8 14 15
IB4-SAP 6 9
Capsaicin 11 12 17
SP
Control 13 15 15
IB4-SAP 9 9
Capsaicin 9 12 17 18
CGRP
Control 12 13 16
IB4-SAP 10 13
Capsaicin 7 13 17 18
IB4
Control 35 41
IB4-SAP 15 31
Capsaicin 27 36 40 41
Table	2.1.	Numbers	of	Sections	Analyzed	for	Staining	Intensity
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Usage	of	 the	 treated	 limb	was	 rated	on	 the	 following	 scale:	0=complete	 lack	of	use,	1=partial	
non-use,	2=limping	and	guarding,	3=limping	and	4=normal	walking.	
Behavioral	 measure	 of	 BTP	 using	 CPA.	 Analysis	 of	 movement-induced	 BTP	 was	
performed	using	CPA	to	a	chamber	associated	with	movement	triggered	BTP.	Within	the	clinical	
setting,	voluntary	or	involuntary	movement	has	been	reported	to	trigger	episodes	of	BTP	lasting	
approximately	 30	 min	 following	 the	 movement	 (Haugen,	 Hjermstad	 et	 al.	 2010,	 Mercadante	
2015).	 Therefore,	 we	 hypothesized	 that	 placing	 the	 rat	 into	 the	 chamber	 following	 a	 2-min	
period	of	movement	of	 the	 tumor-bearing	hind	 limb	would	produce	a	 transient	period	of	BTP	
and	 that	 association	 of	 the	 BTP	 with	 the	 novel	 context	 produces	 motivation	 to	 avoid	 the	
chamber	 on	 test	 day	 resulting	 in	 CPA.	 CPA	 was	 assessed	 in	 a	 three-chamber	 apparatus	 with	
chambers	 distinguishable	 by	 visual,	 tactile	 and	 odor	 cues.	 One	 pairing	 chamber	 within	 the	
apparatus	had	striped	walls,	a	smooth	floor,	and	pink-lemonade	chap	stick	(Lipsmackers)	applied	
to	the	ceiling.	The	other	pairing	chamber	within	the	apparatus	had	uniformly	gray	walls,	a	rough	
floor,	and	vanilla	chap	stick	(Lipsmackers)	applied	to	the	ceiling.	The	neutral	chamber	had	white	
walls,	 a	 smooth	 floor,	no	 chap	 stick,	 and	a	 LED	 light	 (Sylvanna,	 LED/DOTS/BLACK/1X12/BL)	on	
the	 ceiling	 to	 diminish	 time	 spent	 in	 the	 middle	 chamber	 and	 encourage	 exploration	 of	 the	
pairing	 chambers.	 The	 boxes	 were	 cleaned	 (Sparkleen,	 Fisherbrand)	 between	 each	 baseline,	
conditioning,	and	testing	session.	Each	rat	underwent	baseline,	conditioning	and	testing	 in	the	
same	CPP	apparatus.	
Both	tumor-bearing	and	sham	control	rats	underwent	a	one-day	pre-conditioning	period	
(D11	post-surgery)	where	they	were	placed	in	the	three-chamber	apparatus	with	open	access	to	
all	 chambers	 for	 15	 min.	 Behavior	 was	 video	 recorded	 and	 time	 spent	 in	 each	 chamber	
determined	by	video	tracking	software	(Anymaze,	Stoelting,	Wood	Dale,	 IL).	Any	rats	spending	
less	 than	180	 seconds	 in	a	 single	 chamber	were	 removed	 from	 the	 study	 (<25%	 total	 animals	
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tested).	On	conditioning	day	(D12),	rats	were	paired	with	an	enclosed	chamber	(striped	or	grey)	
for	30	min	with	no	treatment	to	minimize	potential-accidental	movement	of	the	tumor-bearing	
hind	limb.	Four	hours	later,	rats	underwent	2	minutes	of	movement	to	the	cancer-bearing	limb	
and	 were	 placed	 in	 the	 opposite	 chamber.	 This	 treatment	 was	 previously	 demonstrated	 to	
induce	spinal	FOS	and	NK-1	receptor	internalization	in	tumor	bearing	mice	but	not	sham	treated	
mice	 (Schwei,	Honore	et	al.	1999).	Hind	 limb	movements	were	completed	 in	a	 separate	 room	
from	the	conditioning	chambers	to	prevent	other	rats	from	being	unnecessarily	exposed	to	signs	
of	 distress	 from	 the	 rats	 during	 the	 hind	 limb	movement.	 Both	 sham	 and	 tumor-bearing	 rats	
vocalized	during	the	treatment.	On	the	test	day	(D13),	rats	were	once	again	placed	in	the	three-
chamber	 apparatus	with	 open	 access	 to	 all	 chambers.	 Behavior	was	 video	 recorded	 and	 time	
spent	 in	 each	 of	 the	 pairing	 chambers	 was	 determined	 by	 Anymaze	 video	 tracking	 software.	
Difference	 scores	were	calculated	as	 the	preconditioning	baseline	 (BL)	 scores	 subtracted	 from	
test	 scores	 (test	 -	 BL).	 A	 negative	 score	 indicates	 aversion,	 and	 a	 positive	 score	 indicates	
preference.		
Morphine’s	 effects	 on	 BTP.	 To	 determine	 whether	 movement-induced	 CPA	 breaks	
through	ongoing	morphine	 treatment	 that	controls	ongoing	pain	 (Remeniuk,	Sukhtankar	et	al.	
2015),	the	ability	of	morphine	infusion	across	20-24	hours	to	block	movement-induced	CPA	was	
determined.	On	day	11	following	injection	of	cancer	cells	into	the	tibia,	rats	underwent	baseline	
analysis	 of	 time	 spent	 in	 each	 of	 the	 conditioning	 chambers	 as	 described	 above	 followed	 by	
implantation	of	extended	release	morphine	or	placebo	pellets.	Pellets	were	surgically	implanted	
(s.c.)	on	the	 lower	back	1	 inch	above	the	pelvic	bone	under	 isoflurane	anesthesia	 immediately	
after	 pre-conditioning	 baselines	 were	 performed.	 The	 following	 day	 (conditioning	 day),	
movement	of	the	tumor-bearing	hind	limb	was	performed	20-24	hours	into	morphine	infusion.	
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Measure	 of	 sensory	 input	 on	movement-induced	 BTP.	 To	 determine	whether	 blocking	
sensory	 input	 blocks	 movement-induced	 BTP,	 rats	 underwent	 the	 3-day	 CPA	 conditioning	
protocol	as	described	above.	In	the	morning	of	conditioning	day,	rats	received	saphenous	saline	
(350	ml)	and	no	hind	paw	movement	of	the	tumor	bearing	hind	limb,	and	were	then	confined	to	
the	 appropriate	 conditioning	 chamber.	 Afternoon	 conditioning	 occurred	 4	 hours	 later.	 To	
determine	 if	 saphenous	 lidocaine	 blocks	 movement-induced	 BTP,	 rats	 received	 saphenous	
lidocaine	(4%	w/v,	350	µl)	10	min	prior	to	the	2	min	movement	of	the	tumor	bearing	hind	limb	
and	 confinement	 within	 the	 opposite	 conditioning	 chamber.	 To	 determine	 whether	 blocking	
sensory	input	after	hind	limb	movement	blocks	movement-induced	BTP,	afternoon	conditioning	
consisted	of	hind	 limb	movement	 for	2	min	followed	10	min	 later	by	saphenous	 lidocaine	and	
confinement	to	the	opposite	conditioning	chamber.	All	saphenous	injections	were	performed	as	
previously	 described	 (Remeniuk,	 Sukhtankar	 et	 al.	 2015).	 Rats	 were	 anaesthetized	with	 a	 2%	
isoflurane	 O2	 mixture.	 To	 produce	 an	 effective	 peripheral	 nerve	 block,	 lidocaine	 was	
administered	over	the	saphenous	nerve	in	a	single	s.c.	injection	(4%	wt/vol,	350	µL).	Equivolume	
saline	was	given	as	a	vehicle	control.	
	
2.3.5.	Radiograph	Analysis	of	Disease	Progression	
Bones	 were	 rated	 according	 to	 a	 4-point	 scale.	 0:	 represented	 a	 normal,	 non-tumor	
bearing	 bone	 with	 no	 bone	 remodeling;	 1:	 represented	 slight	 signs	 of	 bone	 remodeling;	 2:	
represented	diffuse	bone	loss	or	pitting	without	full	cortical	bone	loss;	and	3:	represented	clear	
pitting	and	full	cortical	bone	loss.	
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2.3.6.	Statistical	Analysis		
All	 statistical	analysis	was	performed	and	all	 graphs	were	made	using	GraphPad	Prism	
6.0.	 Group	 differences	 in	 tactile	 sensory	 thresholds	 were	 analyzed	 across	 time	 by	 a	 two-way	
analysis	of	variance	(ANOVA).	Post-hoc	analysis	of	time-dependent	changes	following	treatment	
was	performed	using	 the	Bonferroni’s	multiple	comparisons	 test	wherein	each	time-point	was	
compared	 to	pre-treatment	 values	within	 each	 group.	A	probability	 level	 of	 0.05	was	used	 to	
establish	 significance.	 For	 CPA,	 the	 effects	 of	 treatment	 (cancer	 vs	 control)	 and	 conditioning	
chamber	were	analyzed	by	a	2-way	analysis	of	variance	(ANOVA).	Sidack’s	multiple	comparison	
tests	were	used	for	post	hoc	analysis	of	pre-conditioning	(BL)	vs	post-conditioning	values	within	
each	treatment	group.	Group	differences	were	analyzed	by	ANOVA	using	the	difference	scores	
that	were	calculated	as	post-conditioning	 (test)	–	preconditioning	 (BL)	 time	spent	 in	 the	drug-
paired	chamber.	A	negative	value	indicates	CPA	whereas	a	positive	value	indicates	CPP.	Post-hoc	
analysis	was	performed	using	Dunnett’s	multiple	comparison’s	test.	Where	appropriate,	analysis	
was	performed	to	determine	whether	the	difference	score	was	significantly	different	from	zero	
using	 a	 one-sample	 t-test.	 Group	 differences	 in	 intensity	 ratios	 for	 immunofluorescence	were	
determined	using	one-way	ANOVAs	followed	by	Dunnett’s	multiple	comparison’s	test.	F	values	
and	degrees	of	freedom	for	all	ANOVAs	are	presented	in	Table	2.2	and	2.3.				
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Figure	 2.1:	 Tumor-induced	 Bone	 Remodeling,	 Referred	 Pain	 and	 Impaired	 Limb	 Use.	 A.	
Representative	 radiographs	 demonstrate	 significant	 bone	 loss	 in	male	 and	 female	 rats	with	
fractures	 developing	 within	 D12	 post-injection.	 B.	 Time-dependent	 development	 of	 tactile	
hypersensitivity	and	C.	 impaired	 limb	use,	*p<0.05,	**p<0.01,	 ***p<0.001	vs	pre-surgery	BL.	
Graphs	are	mean	±	SEM,	n=8.	 
	
	
2.4.	Results	
2.4.1.	Tumor-induced	Bone	Loss,	Tactile	Hypersensitivity,	and	Impaired	Limb	Use	
Intratibial	injection	of	rat	breast	cancer	cells	produced	bone	remodeling	with	bone	loss	
apparent	 by	D12	 post-surgery	 in	 both	male	 and	 female	 rats	 (Fig.	 2.1A).	 Corresponding	 tactile	
hypersensitivity	and	 impaired	 limb	use	was	observed	 in	both	male	and	female	rats	 (Fig.	1B,	C,	
respectively).	No	overt	differences	 in	pain	behaviors	were	observed	between	male	and	female	
rats.	All	subsequent	experiments	were	performed	in	female	Fischer	344/NhSD	rats.		
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2.4.2.	Movement-induced	Pain	Induces	CPA	That	Breaks	Through	Morphine	Infusion	
To	 determine	whether	movement	 of	 the	 tumor-bearing	 hind	 limb	 induces	 a	 transient	
increase	 in	 pain	 intensity	 consistent	 with	 reports	 of	 BTP,	 rats	 underwent	 a	 single-trial	
conditioning	protocol	as	outlined	by	the	flow-chart	(Fig.	2.2A).	Movement	of	the	tumor	bearing	
hind	 limb	 significantly	 reduced	 time	 spent	 in	 the	 movement-paired	 chamber	 indicating	 CPA	
selectively	in	the	tumor-bearing	rats	(Fig.	2.2A,	**p<0.01	vs	sham).	Sham	treated	control	rats	did	
not	show	any	difference	 in	 time	spent	 in	 the	conditioning	chambers	 following	movement	 (Fig.	
2.2A;	p>0.05	vs	0).		
To	determine	whether	movement	induced	BTP	was	observed	in	morphine	treated	rats,	
rats	 underwent	 a	 single-trial	 conditioning	 protocol	 as	 outlined	 by	 the	 flow-chart	 (Fig.	 2.2B).	
Continuous	administration	of	morphine	across	24	hours	failed	to	block	movement-induced	CPA	
(Fig.	 2.2B),	 indicating	 that	 movement-induced	 pain	 breaks	 through	 morphine	 previously	
demonstrated	 to	block	 tumor-induced	ongoing	pain	 (Remeniuk,	 Sukhtankar	 et	 al.	 2015).	 Both	
placebo	and	morphine	treated	tumor-bearing	rats	spent	significantly	decreased	amounts	of	time	
in	the	movement-paired	chamber	compared	to	sham	rats	(Fig.	2.2B,	*p<0.05	vs	sham-placebo,	
***p<0.001	 vs	 sham-morphine).	 The	 degree	 of	 CPA	 did	 not	 differ	 between	 the	 placebo	 and	
morphine	 treated	 tumor	 bearing	 rats	 (p>0.05,	 Bonferroni	 t-test).	 Sham	 controls	 did	 not	
demonstrate	a	decrease	in	time	spent	in	the	movement-paired	chamber	irrespective	of	placebo	
or	morphine	treatment	(Fig.	2.2B,	p>0.05	vs	0).	
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2.4.3.	 Blockade	 of	 Sensory	 Afferent	 Input	 from	 Tibia	 Prevents,	 But	 Does	 Not	 Reverse	
Movement-induced	BTP	
To	determine	whether	 saphenous	 lidocaine	 induced	peripheral	 nerve	block	prevented	
movement-induced	BTP,	 rats	underwent	a	single-trial	 conditioning	protocol	as	outlined	by	 the	
flow-chart	(Fig.	2.3A).	Pretreatment	with	saline	did	not	alter	movement-induced	CPA	in	tumor-
bearing	rats	(Fig.	2.3A,	*p<0.05	vs	sham	saline).	In	contrast,	pretreatment	with	lidocaine	10	min	
prior	 to	 movement	 of	 the	 cancer-bearing	 hind	 limb	 produced	 CPP	 (Fig.	 2.3A,	 ***p<0.001	 vs	
sham	 lidocaine),	 likely	 indicating	alleviation	of	 tumor-induced	ongoing	pain.	Sham	control	 rats	
did	 not	 alter	 time	 spent	 in	 the	 movement-paired	 chamber	 following	 saline	 or	 lidocaine	
treatment	10	min	prior	to	hind	limb	movement	(Fig.	2.3A,	p>0.05	vs	0).	
To	 determine	 whether	 saphenous	 lidocaine	 induced	 peripheral	 nerve	 block	 following	
movement	blocked	BTP,	 rats	underwent	a	 single-trial	 conditioning	protocol	as	outlined	by	 the	
flow-chart	 (Fig.	 2.3B).	Blockade	of	 afferent	 input	 from	 the	 tibia	by	 lidocaine	administration	 to	
the	saphenous	nerve	10	min	following	hind	limb	movement	did	not	reverse	movement-induced	
CPA	(Fig.	2.3B).	Cancer	treated	rats	show	equivalent	decreases	in	time	spent	 in	the	movement	
treated	chamber	 following	saline	or	 lidocaine	administration	10	min	 following	movement	 (Fig.	
3B,	**p<0.01	vs	sham-saline;	*p<0.05	vs	sham-lidocaine).	Sham	rats	did	not	demonstrate	CPA	to	
the	 movement-paired	 chamber	 irrespective	 of	 saline	 or	 lidocaine	 treatment	 10	 min	 post-
movement	(Fig.	3B,	p>0.05	vs	0).			
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2.4.4.	 Spinal	 Capsaicin	 Eliminates	 TRPV1,	 SP,	 CGRP	 Immunofluorescence	 and	 IB4-SAP	
Diminishes	IB4	Immunofluorescence	in	the	Spinal	Cord	Dorsal	Horn	
Immunofluorescent	imaging	was	focused	on	lamina	corresponding	to	lamina	I	–	IV/V	as	
indicated	 in	 the	map	 (Fig.	 2.4A).	 High	 resolution	 images	 of	 lamina	 I-II	 demonstrate	 that	 DAPI	
immunofluorescence	 (blue)	 does	 not	 overlap	with	 IB4	 (green	 Fig.	 2.4B-D))	 or	 TRPV1	 (red,	 Fig.	
2.4B);	SP	(red,	Fig.	2.4C)	or	CGRP,	Fig.	2.4D).	A	representative	image	demonstrating	the	regions	
of	 interest	used	to	calculate	intensity	ratios	for	 immunofluorescence	in	lamina	I	(TRPV1,	SP,	or	
CGRP;	 L1)	 and	 lamina	 2	 (IB4;	 L2)	 and	 the	 corresponding	 control	 regions	 (L1con,	 L2con)	 in	 the	
deep	dorsal	horn	(Fig.	2.4E).	Representative	images	demonstrating	co-immunofluorescent	stains	
for	TRPV1	 (red)/IB4	 (green)	 (Fig.	2.4F);	SP/IB4	 (Fig.	4G);	and	CGRP/IB4	 (Fig.	2.4H)	 in	 the	spinal	
dorsal	 horn	 from	 control	 treated	 rats	 demonstrate	 similar	 immunofluorescent	 patterns	 to	
previous	reports	 (Yaksh,	Farb	et	al.	1979,	Vulchanova,	Olson	et	al.	2001,	Cavanaugh,	Lee	et	al.	
2009).	 Immunofluorescence	 for	 TRPV1,	 SP	 and	 CGRP	 appear	 in	 the	 lamina	 I	 region	 and	 IB4	
immunofluorescence	 is	 observed	 in	 lamina	 II	 region	 of	 the	 spinal	 cord	 dorsal	 horn.	
Representative	 images	of	 co-immunofluorescent	 stains	 for	 TRPV1	 and	 IB4	 in	 the	 spinal	 dorsal	
horn	 of	 an	 IB4-SAP	 treated	 rat	 (Fig.	 4I)	 demonstrate	 that	 IB4-SAP	 diminished	 IB4	
immunofluorescence	 as	 reported	 in	 previous	 publications	 (Vulchanova	 et	 al.,	 2001).	
Representative	 images	 from	 spinal	 dorsal	 horns	 of	 capsaicin	 treated	 rats	 demonstrate	
elimination	of	terminals	expressing	TRPV1	(Fig.	2.4J),	SP	(Fig.	2.4K)	and	CGRP	(Fig.	2.4L)	without	
significant	alteration	of	IB4	immunofluorescence.		
Intensity	ratios	of	 immunofluorescence	confirmed	that	IB4-SAP	significantly	diminished	
IB4	immunofluorescence	compared	to	control	samples	(Fig.	4M,	*p<0.05	vs	control).	IB4-SAP	did	
not	 alter	 immunofluorescence	 for	 TRPV1	 immunofluorescence	 (Fig.	 2.4M).	 TRPV1	 intensity	
ratios	 confirm	 that	 capsaicin	 eliminated	 TRPV1	 immunofluorescence,	with	 values	 dropping	 to	
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96.21	 ±12.22	%	of	 the	 internal	 control	 ROI	 (Fig.	 2.4N,	 **p<0.01	 vs	 control).	 Capsaicin	 did	 not	
alter	 the	 immunofluorescence	 of	 IB4	 (Fig.	 2.4N,	 p>0.05	 vs	 control).	 SP	 intensity	 ratios	
demonstrate	 that	 capsaicin	 eliminates	 SP	 values	 (Fig.	 2.4O,	 **p<0.01	 vs	 control),	 with	 mean	
intensity	ratio	dropping	to	124.71	±	11.19	%	of	the	control	ROI,	a	value	not	different	from	100%	
(p>0.05	 vs	 null	 hypothesis).	 Capsaicin	 did	 not	 alter	 IB4	 immunofluorescence	 compared	 to	
control	 treated	 samples	 (Fig.	 2.4O,	p>0.05	vs	 control).	CGRP	 intensity	 ratios	demonstrate	 that	
capsaicin	 significantly	diminishes	CGRP	values	compared	 to	control	 treated	samples	 (Fig.	2.4P,	
*p<0.05	vs	control),	although	the	values	remain	significantly	elevated	compared	to	100%	control	
ROI	(p<0.05	vs	null	hypothesis.	IB4-SAP	did	not	alter	immunofluorescence	of	CGRP	compared	to	
control	treated	samples	(Fig.	2.4P).	
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Figure	 2.4.	 Capsaicin	 Eliminates	 TRPV1,	 SP	 and	 CGRP	 Immunofluorescent	 Staining	 and	 IB4-SAP	
Diminishes	IB4	Immunofluorescence	in	the	Spinal	Dorsal	Horn.	
63	
	
	
	
2.4.5.	Functional	Blockade	of	IB4-binding,	not	TRPV1-expressing	Fibers	Blocks	BTP	
The	effects	of	capsaicin-induced	elimination	of	TRPV1+	fibers	or	IB4-SAP	ablation	of	IB4	
binding	fibers	on	tumor-induced	tactile	hypersensitivity	were	measured	as	outlined	by	the	flow-
chart	(Fig.	2.5A).	Cancer-induced	tactile	hypersensitivity	was	blocked	by	spinal	administration	of	
IB4-SAP,	 but	 not	 spinal	 capsaicin	 (Fig.	 2.5A).	 Cancer-treated	 rats	 that	 had	 received	 spinal	
administration	 of	 vehicle	 or	 SAP	 developed	 tactile	 hypersensitivity	 by	 D12	 post-cancer	
implantation	 (Fig.	 2.5A,	 ***p<0.001	 vs	 BL).	 Tumor-bearing	 rats	 treated	 with	 spinal	 capsaicin	
Figure 2.4. (continued). Capsaicin Eliminates TRPV1, SP and CGRP Immunofluorescent Staining and IB4-
SAP Diminishes IB4 Immunofluorescence in the Spinal Dorsal Horn. A. Spinal map from The Rat Brain in
Stereotaxic Coordinates, Fourth Edition, Paxinos and Watson (Paxinos andWatson, 1998). B.Representative
40x image inset from panel F of DAPI (blue), IB4 (green) conjugate fluorescence and TRPV1 (red)
immunofluorescence, indicating a lack of overlap between IB4, TRPV1 and DAPI signal in a control animal.
Images were collected using a single optical section. C. Representative 40x image inset from panel G. of
DAPI (blue), IB4 (green) conjugate fluorescence and SP (red) immunofluorescence, indicating a lack of
overlap between IB4 SP and DAPI signal in a control animal. D. Representative 40x image inset from panel
H. of DAPI (blue), IB4 (green) conjugate fluorescence and CGRP (red) immunofluorescence, indicating a lack
of overlap between IB4, CGRP and DAPI signal in a control animal. E. Representative image demonstrating
regions of interest (ROI) used for calculation of intensity ratios. For TRPV1, SP, and CGRP, intensity values
from an oval ROI targeting a section of lamina 1 (L1) was divided by intensity values from an oval ROI in the
deeper lamina L1 control (L1con). For IB4 immunofluorescence, a circle targeting a section of lamina 2 (L2)
was divided by L2 control (L2con). This provides a ratio of the target area of interest divided by an internal
control. F. Representative 20x image demonstrating TRPV1 (red) and IB4 (green) immunofluorescence in a
section from a control rat. G. Representative 20x image demonstrating immunofluorescence for SP (red)
and IB4 (green) in a spinal cord section from a control treated rat. H. Representative 20x image
demonstrating immunofluorescence for CGRP (red) and IB4 (green) in a spinal cord section from a control
treated rat. I. Representative image demonstrating immunofluorescence of TRPV1 (red) and reduction of
IB4 (green) immunofluorescence. J. Representative image demonstrating lack of TRPV1 (red)
immunofluorescence following treatment with capsaicin with IB4 (green) immunofluorescence remaining.
K. Representative image demonstrating lack of SP (red) immunofluorescence following treatment with
capsaicin with IB4 (green) immunofluorescence remaining. L. Representative image demonstrating absence
of CGRP (red) immunofluorescence in capsaicin treated rats with IB4 (green) immunofluorescence
remaining. M. Intensity ratios demonstrate that there is a significant reduction in IB4-binding fibers within
the spinal cord of IB4-SAP treated rats compared to controls. No significant difference was observed in
capsaicin treated rats compared to controls. All dashed lines represent ratio value (100) at which there is
equivalent mean grey values for L1/L1con or L2/L2con. All graphs represent mean +/- SEM, *p<0.05 vs
control; **p<0.01 vs control. N. Intensity ratios demonstrate that there is a significant reduction in TRPV1
immunofluorescence in capsaicin treated rats compared to controls. No difference in TRPV1 intensity ratios
were observed in IB4-SAP treated rats. O. Intensity ratios demonstrate a significant reduction in SP
immunofluorescence compared to control, no difference in SP immunofluorescence is observed in IB4-SAP
treated rats compared to controls. P. Intensity ratios demonstrate a significant reduction in CGRP
immunofluorescence in capsaicin treated rats compared to controls with no significant change in CGRP
immunofluorescence in the IB4-SAP treated rats. Scale bar indicates 100 mm.
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demonstrated	 similar	 tactile	 hypersensitivity	 compared	 to	 the	 vehicle	 control	 (Fig.	 2.5A,	
***p<0.001).	 In	 contrast,	 rats	 treated	 with	 spinal	 IB4-SAP	 demonstrated	 tactile	 withdrawal	
thresholds	 that	 were	 significantly	 higher	 than	 the	 vehicle	 treated	 rats	 (Fig.	 2.5A,	 #p<0.05	 vs	
vehicle),	and	not	significantly	different	from	pre-tumor	baselines	(Fig.	2.5A,	p>0.05	vs	BL)	
The	effects	of	capsaicin-induced	elimination	of	TRPV1+	fibers	or	IB4-SAP	ablation	of	IB4	
binding	 fibers	 on	 movement-evoked	 BTP	 was	 determined	 using	 a	 single-trial	 conditioning	
protocol	following	spinal	injection	of	capsaicin,	IB4-SAP	or	the	appropriate	vehicle	as	outlined	by	
the	 flow-chart	 (Fig.	2.5B).	Movement	 failed	 to	 induce	CPA	 in	sham-treated	 rats	 irrespective	of	
spinal	 treatment	 with	 capsaicin	 or	 IB4-SAP	 (Fig.	 2.5B,	 p>0.05	 vs	 0).	 Cancer-treated	 rats	 that	
received	spinal	administration	of	the	appropriate	intrathecal	vehicle	demonstrated	movement-
induced	CPA	as	demonstrated	by	a	significantly	 lower	difference	score	compared	to	the	sham-
treated	 rats	 (Fig.	 2.5B,	 *p<0.05	 vs	 sham).	 Tumor-bearing	 rats	 that	 received	 spinal	 capsaicin	
demonstrated	 movement-induced	 CPA	 represented	 by	 a	 significantly	 lower	 difference	 score	
compared	to	sham-treated	rats	(Fig.	2.5B,	**p<0.01	vs	sham).	Notably,	the	difference	scores	of	
the	 spinal	 vehicle	 and	 spinal	 capsaicin	 treated	 tumor-bearing	 rats	 did	 not	 differ	 (p>0.05,	
Bonferroni	 t-test).	Cancer-bearing	 rats	 that	 received	 spinal	 IB4-SAP	 failed	 to	 show	movement-
induced	CPA,	demonstrated	by	difference	scores	that	did	not	differ	from	sham	control	rats	(Fig.	
2.5B,	p>0.05).		
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Figure 2.5. Tactile Hypersensitivity and Movement-induced Breakthrough Pain is Dependent on IB4
Positive Fibers. A. Spinal administration of IB4-SAP attenuated tumor-induced tactile hypersensitivity.
Vehicle treated tumor-bearing rats demonstrated tactile hypersensitivity with paw withdrawal thresholds
significantly lower than pre-cancer implantation baselines, ***p<0.01 vs. BL. Ablation of IB4-binding fibers
by spinal administration of IB4-SAP attenuated tumor-induced tactile hypersensitivity with paw withdrawal
thresholds significantly higher compared to SAP control rats, #p<0.05 vs. SAP. Spinal ablation of TRPV1
expressing terminals in the spinal dorsal horn by spinal administration of capsaicin failed to eliminate
tumor-induced tactile hypersensitivity with paw withdrawal thresholds significantly lower than pre-cancer
baselines, ***p<0.01 vs. BL. B. Group comparison of difference scores demonstrates that movement
induced CPA in vehicle treated rats compared to sham controls, *p<0.05 vs sham. Ablation of IB4-binding
fibers blocked movement-induced CPA. In contrast, ablation of TRPV1 expressing terminals in the spinal
dorsal horn failed to block movement-induced CPA **p<0.01 vs. shams. Graphs show mean  SEM, n
(sham)= 10 capsaicin, 10 IB4-SAP; n (cancer) = 9 SAP, 8 capsaicin vehicle, 11 IB4-SAP, 10 capsaicin.
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2.4.6.	 Ablation	 of	 IB4	 or	 TRPV1-expressing	 Fibers	 Did	 Not	 Alter	 Tumor-induced	 Bone	
Remodeling.	
Radiograph	 images	 show	 representative	 bone	 remodeling	 illustrating	 the	 rating	 scale	
that	was	used	to	determine	tumor-induced	bone	remodeling	D13	post-surgery	(Fig.	2.6A).	Rats	
treated	 with	 spinal	 capsaicin	 or	 with	 IB4-SAP	 did	 not	 demonstrate	 altered	 bone	 remodeling	
compared	to	their	respective	vehicle	controls	(Fig.	2.6B).		
	
	
2.5.	Discussion	
We	have	developed	and	characterized	a	novel	measure	of	movement-evoked	BTP	in	the	
setting	of	morphine-controlled	ongoing	pain	 in	a	 rat	model	of	 cancer-induced	bone	pain.	 This	
measure	 uses	 the	 motivational	 aspects	 of	 pain	 averseness	 to	 capture	 a	 movement-triggered	
transient	 increase	 in	 the	 apparent	 intensity	 of	 cancer-induced	 bone	 pain.	When	 this	 event	 is	
paired	 with	 a	 distinctive	 context,	 rats	 show	 avoidance	 of	 the	 chamber	 in	 a	 subsequent	 trial	
producing	 conditioned	 place	 aversion	 (CPA).	 This	 approach	 is	 consistent	 with	 clinical	
observations	in	which	patients	with	bone	metastases	report	transient	increases	in	pain	intensity	
67	
	
that	 can	 be	 triggered	 by	 voluntary	 (e.g.	 switching	 positions)	 or	 involuntary	 (e.g.	 cough)	
movement.	 Notably,	 this	 is	 relatively	 common	 in	 patients	 with	 skeletal	 metastases	 and	 can	
diminish	 daily	 activity	 of	 these	 patients	 due	 to	 their	 desire	 to	 avoid	 triggering	 BTP,	 greatly	
diminishing	these	patients’	quality	of	life	(Mercadante	2015).		
	
2.5.1.	Reverse	Translation	of	BT	Pain	
Hind	 limb	 movement	 prior	 to	 placement	 into	 the	 pairing	 chamber	 produced	 CPA	
selectively	 in	 tumor	 bearing	 rats	 indicating	 that	 the	 movement-triggered	 increase	 in	 pain	 is	
aversive	 and	 provides	 learning	 that	 motivates	 animals	 to	 avoid	 that	 chamber.	 Movement-
induced	 CPA	 is	 observed	 in	 rats	 undergoing	morphine	 treatment	 previously	 demonstrated	 to	
control	 tumor-induced	ongoing	pain	 (Remeniuk,	Sukhtankar	et	al.	2015).	Notably,	 the	defining	
feature	of	BTP	is	that	it	occurs	in	patients	on	opioid	medication	that	is	controlling	the	persistent	
background	 pain	 (Portenoy	 and	 Hagen	 1989,	 Portenoy	 and	 Hagen	 1990,	 Mercadante	 2015).	
Moderate-to-severe	cancer	pain	is	often	treated	with	extended	release	opioids	that	engage	the	
mu-opioid	 receptor	 (MOR)	 (Paice	 and	 Ferrell	 2011,	 Mercadante	 2015).	 Therefore,	 our	
observations	show	reverse	translation	from	the	clinic	to	the	rat	model	of	cancer-induced	bone	
pain.	Opioids	predominately	act	 to	modulate	affective	dimensions	of	pain	by	actions	at	opioid	
receptors	within	 the	brain	 (Fields	2004,	Navratilova,	Atcherley	et	 al.	 2015).	Additionally,	MOR	
agonists	may	act	at	 receptors	 localized	on	primary	afferent	nociceptors	and	 in	 the	spinal	 cord	
(Fields	2004,	Ossipov,	Dussor	et	al.	2010).	The	clinical	observations	and	our	data	 indicate	 that	
movement	 likely	 engages	 additional	 nociceptive	 drive	 that	 is	 insensitive	 to	 MOR	 agonists	 at	
doses	that	control	ongoing	pain.	
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2.5.2.	Potential	Role	of	Peripheral	and	Central	Sensitization	
Nociceptors	 are	 likely	 to	be	 sensitized	as	 a	 consequence	of	 tumor	or	 immune-derived	
factors	within	the	intramedullary	space	(Mantyh	2013,	Falk	and	Dickenson	2014,	Mantyh	2014).	
In	 addition,	 the	 ongoing	 pain	 from	 the	 tumor	 bearing	 bone	 can	 produce	 spinal	 sensitization	
(Urch,	Donovan-Rodriguez	et	al.	2003,	Yanagisawa,	Furue	et	al.	2010,	Falk,	Bannister	et	al.	2014,	
Mantyh	2014).	We	propose	that	both	peripheral	and	central	sensitization	amplifies	nociceptive	
input	 from	 movement-evoked	 stimulation	 of	 the	 tumor-bearing	 limb	 resulting	 in	 a	 transient	
increase	 in	 pain	 intensity	 that	 occurs	 in	 the	 setting	 of	 opioids	 controlling	 the	 persistent	
background	 ongoing	 pain.	 Preclinical	 studies	 demonstrated	 that	 spinal	 cord	 neurons	 show	
enhanced	responses	to	evoked	stimuli	and	wide	dynamic	range	neurons	display	an	 increase	 in	
receptive	 field,	 hallmarks	 of	 spinal	 sensitization	 (Urch,	 Donovan-Rodriguez	 et	 al.	 2003,	 Falk,	
Bannister	et	al.	2014).	These	changes	are	observed	 in	 the	 setting	of	morphine	and	have	been	
proposed	to	underlie	opioid	resistant	allodynia	and	BTP	(Urch,	Donovan-Rodriguez	et	al.	2005).	
Such	 signaling	 likely	 increases	 the	 intensity	 of	 pain	 experienced,	 thereby	 also	 increasing	 the	
affective/motivational	 component	 of	 the	 tumor-induced	 pain	 (Fields	 1999).	 The	 transient	
increase	 in	 pain	 and	 related	 unpleasantness	 surpasses	 the	 ability	 of	 the	 onboard	 dose	 of	
morphine	to	control	the	pain	resulting	in	the	requirement	for	additional	rapid	onset	opioids	as	
seen	in	the	clinical	setting,	i.e.,	BTP.	
	
2.5.3.	Mechanistic	Difference	Between	Initiation	and	Maintenance	of	BTP	
Sensory	input	from	the	tumor-bearing	bone	is	required	for	initiation	of	BTP.	Saphenous	
nerve	block	administered	10	min	prior	to	movement	of	the	tumor-bearing	hind	limb	prevented	
movement-induced	BTP	and	 induced	CPP.	This	observation	 indicates	that	the	peripheral	nerve	
block	 not	 only	 prevented	 the	 movement-triggered	 BT	 pain,	 but	 also	 blocked	 tumor-induced	
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ongoing	 pain.	 Therefore,	 the	 rats	 experience	 pain	 relief	 in	 the	 lidocaine/movement	 paired	
chamber.	Thus,	pain	relief	is	the	motivating	factor	that	results	in	the	increased	time	spent	in	the	
chamber	 paired	 with	 nerve	 block	 and	 movement.	 This	 replicated	 our	 previous	 findings	 that	
peripheral	 nerve	 block	 produces	 relief	 from	 tumor-induced	 ongoing	 bone	 pain	 (Remeniuk,	
Sukhtankar	et	al.	 2015).	 In	 contrast,	blockade	of	 sensory	 input	 following	hind	 limb	movement	
failed	 to	 block	 CPA.	 These	 observations	 suggest	 that	 once	 established,	 blocking	 sensory	 input	
from	 the	 tumor-bearing	 bone	 is	 no	 longer	 sufficient	 to	 reverse	 movement-induced	 BTP.	 We	
speculate	 that	 one	 possible	 explanation	 is	 the	 engagement	 of	 reverberating	 circuits	 that	
maintain	 activity	 within	 the	 spinal	 cord,	 or	 between	 the	 spinal	 cord	 and	 central	 nuclei,	
independently	 from	 peripheral	 input.	 Such	 altered	 processing	 could	 account	 for	 prolonged	
withdrawal	responses	to	noxious	pinprick	as	reported	following	chronic	constriction	injury	of	the	
sciatic	 nerve	 (Bennett	 and	 Xie	 1988).	 A	 reverberating	 circuit	 between	 spinal	 cord	 dorsal	 horn	
and	 the	 dorsal	 reticular	 nucleus	 within	 the	 caudal	 medulla	 has	 been	 proposed	 to	 promote	
enhanced	 response	 capacity	 of	 spinal	 neurons	 to	 noxious	 stimulation	 and	 implicated	 in	 acute	
pain	 responses	 to	 noxious	 heat	 and	 formalin	 (Lima	 and	 Almeida	 2002).	 Such	 reverberating	
circuitry	may	be	critical	in	maintaining	BTP	and	deserves	further	study.		
	
2.5.4.	Separate	Roles	of	TRPV1+	and	IB4-binding	Fibers	in	BT	Pain	
The	observation	that	saphenous	nerve	block	prevents	movement-induced	CPA	suggests	
that	 initiation	 of	 BTP	 is	 dependent	 on	 sensory	 input	 from	 the	 tumor-bearing	 bone.	 Our	 data	
indicate	 that	 IB4	 binding	 fibers	 mediate	 movement-induced	 breakthrough	 cancer	 pain	 and	
referred	 tactile	 hypersensitivity,	 whereas	 TRPV1+	 fibers	 do	 not.	 These	 observations	 are	
consistent	with	 studies	 demonstrating	 that	 functional	 blockade	 of	 TRPV1+	 fibers	 fails	 to	 alter	
responses	 to	 noxious	mechanical	 stimulation	 and	 tactile	 hypersensitivity	 (Ossipov,	 Bian	 et	 al.	
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1999,	Cavanaugh,	Lee	et	al.	2009,	Scherrer,	 Imamachi	et	al.	2009,	Okun,	DeFelice	et	al.	2011).	
Our	 findings	are	also	consistent	with	studies	demonstrating	 that	ablation	of	 IB4	binding	 fibers	
blocks	 tactile	 hypersensitivity	 in	 preclinical	 models	 of	 inflammation,	 neuropathic	 pain	 and	
cancer-induced	orofacial	 pain	 (Stucky	 and	 Lewin	1999,	Vulchanova,	Olson	et	 al.	 2001,	 Joseph,	
Chen	 et	 al.	 2008,	 Cavanaugh,	 Lee	 et	 al.	 2009,	 Ye,	 Dang	 et	 al.	 2012).	 Given	 these	 data,	 we	
propose	 that	 movement	 recruits	 TRPV1	 negative	 nociceptive	 fibers	 resulting	 in	 an	 increased	
pain	 signal	 that	 initiates	 an	episode	of	BTP	 that	 is	 not	 adequately	 prevented	by	peripheral	 or	
central	actions	of	opioids	used	to	control	background	persistent	ongoing	pain.		
Following	 capsaicin,	 we	 saw	 reduced	 CGRP	 and	 complete	 elimination	 of	 SP	
immunofluorescence	 and	 TRPV1+	 fiber	 terminals	 in	 the	 spinal	 dorsal	 horn,	 observations	
consistent	 with	 previous	 studies	 (Yaksh,	 Farb	 et	 al.	 1979,	 Cavanaugh,	 Lee	 et	 al.	 2009).	 IB4-
Saporin	 eliminated	 IB4	 immunofluorescence	 indicating	 elimination	 of	 input	 from	 IB4	 binding	
sensory	 afferent	 fibers.	 The	 absence	 of	 sensory	 input	 by	 these	 nerve	 terminals	within	 the	 L3	
segment	 of	 the	 lumbar	 spinal	 cord	 likely	 eliminates	 much	 of	 the	 sensory	 input	 from	 the	
saphenous	 nerve,	 previously	 demonstrated	 to	 be	 the	 primary	 innervation	 for	 the	 rat	 tibia	
(Ivanusic	 2009,	 Kaan,	 Yip	 et	 al.	 2010).	 Previous	 studies	 have	 suggested	 a	 lack	 of	 IB4	 binding	
fibers	 in	 mouse	 models	 of	 cancer-induced	 bone	 pain	 (Jimenez-Andrade,	 Mantyh	 et	 al.	 2010,	
Castaneda-Corral,	 Jimenez-Andrade	 et	 al.	 2011).	 In	 contrast,	 retrograde	 labeling	 techniques	
indicate	that	IB4	binding	fibers	do	innervate	the	intramedullary	space	and	the	periosteum	of	the	
rat	tibia	(Ivanusic	2009,	Kaan,	Yip	et	al.	2010).	It	 is	unclear	whether	the	discrepancies	between	
these	 reports	 are	 due	 to	 methodological	 differences	 or	 species	 differences.	 Irrespective	 of	
whether	 IB4	 binding	 fibers	 innervate	 the	 bone,	 it	 is	 likely	 that	 sensory	 input	 from	 tissue	
surrounding	the	bone	may	also	contribute	to	the	initiation	of	movement-evoked	BTP.		
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Spinal	 capsaicin	was	 demonstrated	 to	 reduce	 SP	 content	within	 sensory	 fibers	 within	
seven	 days	 (Yaksh,	 Farb	 et	 al.	 1979).	 Such	 observations	 indicate	 that	 the	 capsaicin-induced	
blockade	of	sensory	input	by	TRPV1+	fibers	in	our	studies	occurred	prior	to	tumor	cell	injection	
and	subsequent	growth	of	tumor	cells	within	the	tibia,	thereby	eliminating	ongoing	input	from	
TRPV1+	nociceptive	fibers	throughout	the	experiment.	Our	data	demonstrate	that	elimination	of	
signaling	by	TRPV1+	fibers	is	not	sufficient	to	block	movement-induced	CPA	or	referred	pain	as	
measured	 by	 tactile	 hypersensitivity	 in	 the	 ipsilateral	 hind	 paw.	 This	 is	 consistent	 with	 other	
observations	 that	 long-term	 desensitization	 of	 TRPV1	 expressing	 fibers	 by	 systemic	
administration	of	 the	ultra-potent	 capsaicin	analogue	 resiniferotoxin	 (RTX)	blocks	 thermal	and	
ongoing	 pain,	 but	 fails	 to	 block	 development	 of	 tactile	 hypersensitivity	 in	 other	 chronic	 pain	
models	 (Ossipov,	 Bian	 et	 al.	 1999,	 King,	 Qu	 et	 al.	 2011,	 Okun,	 DeFelice	 et	 al.	 2011).	 Our	
observations	of	hind	paw	tactile	hypersensitivity,	a	measure	of	 referred	pain,	and	 initiation	of	
BTP	by	a	normally	non-noxious	stimulus	suggest	that	the	tumor	bearing	rats	developed	central	
sensitization	 in	 the	 absence	 of	 input	 from	 TRPV1	 expressing	 fibers.	 Previous	 studies	 have	
demonstrated	that	development	of	central	sensitization	is	dependent	on	input	from	nociceptive	
afferents,	presumably	C-fibers	(Gracely,	Lynch	et	al.	1992,	Sang,	Gracely	et	al.	1996).	It	 is	 likely	
that	 sustained	 input	 from	 non-TRPV1	 nociceptive	 fibers	 is	 sufficient	 to	 develop	 central	
sensitization	that	mediates	hypersensitivity	to	non-noxious	mechanical	stimulation.		
Further	research	is	warranted	to	examine	subpopulations	of	sensory	fibers	in	relation	to	
bone	pain.	As	noted	above,	 single	 cell	 RNA	 sequencing	 studies	have	demonstrated	 that	 there	
are	many	potential	subcategories	of	sensory	fibers,	with	as	many	as	11	types	of	sensory	neurons	
in	the	mouse	DRG	(Usoskin,	Furlan	et	al.	2015).	Moreover,	some	studies	have	indicated	overlap	
of	 CGRP	 in	 IB4	 binding	 neurons	 in	 species	 and	 site-specific	 patterns	 (Aoki,	Ohtori	 et	 al.	 2005,	
Hwang,	Oh	et	al.	2005,	Price	and	Flores	2007).	Future	studies	using	techniques	such	as	single	cell	
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capture	 and	 RNAseq	 of	 DRG	 cells	 that	 have	 been	 retrogradely	 labeled	 from	 the	 bone,	
periosteum	and	perhaps	the	surrounding	tissue	are	necessary	to	clarify	potential	subpopulations	
of	IB4	binding	neurons	that	may	mediate	BT	pain.	Additionally,	studies	examining	corresponding	
protein	expression	and	the	relative	functional	contribution	of	observed	subpopulations	of	fibers	
innervating	the	bone	are	necessary.		
Our	 data	 indicate	 distinctive	mechanisms	underlying	 tumor-induced	ongoing	 and	BTP.	
As	 with	 all	 preclinical	 studies,	 future	 studies	 are	 required	 to	 show	 reproducibility	 of	 these	
findings	 across	 different	 strains	 and	 species.	 This	 highlights	 the	 need	 to	 determine	 whether	
therapeutic	 strategies	 currently	 under	 development	 block	 both	 ongoing	 and	 BTP.	 Notably,	
advances	in	non-opioid	therapies	for	ongoing	pain	are	urgently	needed	to	diminish	reliance	on	
opioids	 irrespective	 of	 whether	 they	 effectively	 block	 BTP.	 Alternatively,	 novel	 compounds	
targeting	 IB4	binding	nociceptors	may	 improve	pain	management	for	cancer	pain	patients	and	
other	patient	populations	suffering	from	BTP	that	is	inadequately	treated	by	currently	available	
medications.	
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CHAPTER	3	
UTILIZING	OPTOGENETICS	TO	INVESTIGATE	THE	ROLE	OF	PERIPHERAL	NEURONS	INVOLVED	IN	
CANCER-INDUCED	BONE	PAIN	IN	THE	MOUSE	
	
3.1.	Introduction	
3.1.1.	Background	of	Fiber	Types	in	Cancer-induced	Bone	Pain	
	 Previous	 work	 by	 Patrick	 Mantyh	 and	 colleagues	 demonstrated	 a	 critical	 role	 for	
peptidergic	 nociceptors	 (i.e.	 CGRP,	 SP,	 TRPV1	 expressing)	 in	 the	 role	 of	 CIBP.	 As	 mentioned	
previously,	 both	 through	 the	use	of	 IHC	and	a	 transgenic	 reporter	mouse,	work	by	 this	 group	
had	demonstrated	 the	 presence	of	 CGRP+	 fibers	 in	 naïve	 bone,	 and	pathological	 sprouting	 of	
these	fibers	following	cancer	cell	 implantation	and	growth	(Mach,	Rogers	et	al.	2002,	Jimenez-
Andrade,	Mantyh	et	al.	2010).	Work	by	this	group	also	demonstrated	that	sequestration	of	NGF	
by	 a	 primary	 antibody	 results	 in	 diminishment	 of	 pathological	 sprouting	 of	 these	 fibers	 and	
evoked	pain	behaviors	(Jimenez-Andrade,	Bloom	et	al.	2010).	These	findings	coincide	well	with	
observations	 in	 the	mouse	 demonstrating	 a	 lack	 of	 non-peptidergic	 nociceptors	 (IB4-binding,	
P2X3	and/or	MrgD	expressing)	in	the	innervation	of	the	bone	and	periosteum,	leading	much	of	
the	CIBP	field	to	believe	they	play	little	role	in	communicating	pain	in	preclinical	models	of	CIBP	
in	 the	 mouse	 (Jimenez-Andrade,	 Mantyh	 et	 al.	 2010).	 Pharmacological	 work	 using	 a	 primary	
antibody	 to	 NGF	 and	 an	 antibody	 that	 targets	 the	 cation	 channel	 P2X3	 to	 investigate	 a	
comparative	role	for	peptidergic	vs	non-peptidergic	nociceptors	was	also	investigated	(Guedon,	
Longo	et	al.	2016).	
The	role	for	each	antibody,	being	to	either	sequester	NGF	as	previously	described	in	Pat	
Mantyh’s	work,	or	presumably	block	 the	 ion	passage	pore	 in	 the	P2X3	channel,	allowing	 for	a	
side	by	 side	 comparison	 in	behavioral	 changes	 that	 these	 two	agents	may	have.	 This	was	 the	
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first	attempt	to	assess	the	role	of	these	fibers	side	by	side	in	a	behavioral	paradigm	in	CIBP.	This	
publication	 demonstrated	 a	 role	 for	 blocking	 the	 P2X3	 channel	 in	 alleviating	 tactile	
hypersensitivity	 that	 develops	 after	 tumor	 growth	 consistent	 with	 the	 belief	 that	 non-
peptidergic	 nociceptors	 convey	 mechanical	 nociceptive	 input	 (Cavanaugh,	 Lee	 et	 al.	 2009).	
While	sequestration	of	NGF	ameliorated	tactile	hypersensitivity	and	measures	of	“skeletal	pain”	
quantified	 by	 weight	 bearing	 away	 from	 the	 cancer	 afflicted	 limb,	 rearing,	 and	 nocifensive	
behaviors	 typical	 of	 CIBP	 in	 preclinical	 models	 (Guedon,	 Longo	 et	 al.	 2016).	 This	 latter	
observation	 is	 likely	due	 to	 the	blunting	of	pathological	 sprouting	of	TrkA+	 (and	CGRP+)	 fibers	
within	the	bone	and	the	role	this	plays	in	CIBP,	as	work	has	demonstrated	this	treatment	does	
not	blunt	tumor	growth	or	bone	destruction.	
While	 interesting,	 the	most	provocative	piece	of	data	shared	 in	 this	body	of	work	was	
the	ability	 for	 the	NGF	antibody	to	 reverse	off-set	weight	bearing,	and	the	 failure	of	 the	P2X3	
antibody	to	do	so.	One	interpretation	of	this	as	the	authors	concluded,	is	that	blockade	of	P2X3	
fails	 to	 alleviate	 pain	 from	 the	 bone,	 however,	 while	 convincingly	 reliable,	 it	 is	 still	 debated	
whether	weight	bearing	is	effective	in	assessing	ongoing/evoked	pain	from	a	pathological	 joint	
or	bone.	Additionally,	 this	work	did	not	directly	 assess	 the	2	populations	of	 fibers	 themselves	
e.g.	 peptidergic	 vs	 non-peptidergic.	 Rather,	 this	 work	 investigated	 the	 function	 of	 the	 P2X3	
channel	 specifically,	which	 is	 primarily	 expressed	on	 non-peptiderigc	 fibers,	 and	 added	 to	 the	
body	 of	 work	 supporting	 the	 efficacy	 of	 NGF	 sequestration	 in	 reducing	 CIBP.	 This	 leaves	 the	
question	 of	whether	 or	 not	 the	 non-peptidergic	 fibers	 themselves	 play	 a	 role	 in	measures	 of	
CIBP,	as	blockade	of	one	receptor	population	on	a	neuron	does	not	necessarily	silence	the	entire	
neuron’s	function.	Our	work	(Havelin	et	al.	2017)	in	the	rat	implicates	a	role	for	fibers	that	bind	
IB4	(i.e.	non-peptidergic)	in	evoked	BTP.		
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However,	 there	 is	 the	 possibility	 that	 these	 observations	 are	 a	 result	 of	 a	 species	
difference.	 Differences	 in	 the	 populations	 of	 fibers	 has	 previously	 been	 described	 between	
species	and	anatomical	 location	(DRG	versus	TG)	by	Price	et	al	2009,	and	differing	 innervation	
patterns	reported	by	Ivanusic	2009,	and	Kaan	et	al.	2010	in	the	rat	vs	Pat	Mantyh’s	work	in	the	
mouse	(Price	and	Flores	2007,	Ivanusic	2009,	Kaan,	Yip	et	al.	2010).	Classically	peptidergic	fibers	
have	 been	 implicated	 in	 driving	 thermal	 nociception	 and	 spontaneous	 pain	 while	 non-
peptidergic	fibers	have	been	implicated	in	mechanical	pain	in	both	mouse	(Cavanaugh,	Lee	et	al.	
2009,	 Scherrer,	 Imamachi	 et	 al.	 2009)	 and	 rat	 studies	 (Ossipov,	 Bian	 et	 al.	 1999,	 Vulchanova,	
Olson	et	 al.	 2001,	King,	Qu	et	 al.	 2011,	Havelin,	 Imbert	et	 al.	 2017).	 Therefore,	we	wanted	 to	
examine	 whether	 the	 differential	 role	 of	 peptidergic	 and	 non-peptidergic	 fibers	 in	 the	 rat	
translates	 to	 the	 mouse.	 The	 potential	 for	 analgesic	 targets	 that	 may	 exist	 on	 the	 non-
peptidergic	population	of	fibers	that	inhibit	the	fiber	rather	than	a	single	channel	(i.e.	the	P2X3	
channel)	would	be	 a	worthwhile	 discovery.	 Further,	 lack	 of	 evaluation	of	 peptidergic	 fibers	 in	
alleviating	 ongoing	 or	 breakthrough	 pain	 in	models	 of	 cancer-induced	 bone	 pain	 sparked	 our	
interest	 in	 investigating	 the	 potentially	 differing	 roles	 these	 fiber	 populations	 may	 play	 in	
treating	cancer-induced	bone	pain.			
	
3.1.2.	Justification	of	Targeting	Subpopulations	of	Sensory	Neurons	
Nav1.8	 Expressing	 Fiber	 Population.	 Nav1.8	 is	 a	 voltage	 gated	 sodium	 channel	 that	
allows	 the	 conductance	 of	 sodium	 in	 a	 tetrodotoxin-resistant	 manner	 and	 is	 expressed	 on	
peripheral	neurons	 (Shields,	Ahn	et	 al.	 2012).	Nav1.8	has	been	used	as	a	 selective	marker	 for	
nociceptive	 neurons	 for	 at	 least	 10-15	 years,	 and	 has	 been	 implicated	 to	 be	 critical	 to	
nociception	 in	 a	 number	 of	 publications	 (Akopian,	 Souslova	 et	 al.	 1999,	 Nassar,	 Stirling	 et	 al.	
2004).	 Interesting	 clinical	 correlates	 have	 been	 demonstrated,	 in	 which	 gain	 of	 function	
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mutations	in	human	Nav1.8	correlate	with	some	patients	that	experience	“painful	neuropathy”	
(Han,	Huang	 et	 al.	 2016).	 The	 generation	 of	 the	Nav1.8-cre	mouse	by	 John	Woods	 group	has	
allowed	 for	 the	 extensive	 use	 of	 the	 cre-lox	 system	 to	 target	 these	 nociceptive	 neurons	 for	
nearly	 2	 decades	 (Nassar,	 Stirling	 et	 al.	 2004).	 While	 the	 original	 publication	 determined	 a	
critical	 role	 of	 the	 Nav1.7	 channel	 in	 nociception	 normally	 expressed	 on	 Nav1.8	 expressing	
fibers,	 subsequent	 work	 has	 highlighted	 the	 role	 of	 the	 fibers	 that	 express	 Nav1.8.	While	 its	
utilization	as	a	marker	by	crossing	the	cre	mouse	with	a	reporter	line	(cre-dependent	reporter)	
for	 purely	 nociceptive	 neurons	 has	 its	 limitations	 as	 demonstrated	 by	 Shields	 et	 al.	 2012,	
functional	 evaluation	 and	 involvement	 of	 Nav1.8	 fibers	 in	 nociception	 implies	 their	 direct	
involvement	 in	 transducing	 nociceptive	 stimuli	 (Daou,	 Tuttle	 et	 al.	 2013,	 Uhelski,	 Bruce	 et	 al.	
2017).	 Interestingly,	while	 in	models	of	 neuropathic	 injury	 some	 reports	demonstrate	 a	down	
regulation	of	Nav1.8	channels	(Laedermann,	Pertin	et	al.	2014)	there	are	alternative	reports	that	
suggest	 in	models	of	CIBP	Nav1.8	expression	actually	 increases	 (Liu,	Yang	et	al.	2014).	Beyond	
this,	 due	 to	 the	 well-characterized	 role	 of	 Nav1.8	 fibers	 in	 transducing	 nociceptive	 input	 in	
preclinical	models	of	pain	(Bonin,	Wang	et	al.	2016,	Daou,	Beaudry	et	al.	2016,	Uhelski,	Bruce	et	
al.	 2017),	 we	 hypothesized	 that	 transiently	 optogenetically	 silencing	 this	 population	 of	 fibers	
would	block	ongoing	pain	in	our	model	of	CIBP.		
MrgD	 Expressing	 Fiber	 Population.	 Our	 interest	 in	 MrgD	 expressing	 fibers	 lies	 not	
necessarily	 in	 the	 function	 of	 the	 receptor,	 but	 the	 function	 of	 the	 cells	 that	 express	 MrgD.	
Although	the	effects	of	activating	or	inhibiting	MrgD	are	not	ignored	in	the	grand	scheme	of	our	
work.	The	GPCR	MrgD	was	first	reported	by	Dong	et	al.	2001	(Dong,	Han	et	al.	2001)	along	with	
a	 number	 of	 other	GPCRs	 in	 the	Mrg	 family.	 Unique	 expression	 patterns	 of	 the	 protein	were	
reported	 in	 sensory	 neurons	within	 the	DRG	 and	 TG	 in	 neonatal	 and	 adult	mice,	with	 special	
attention	being	given	to	a	seeming	overlap	of	MrgD	expression	in	nociceptors	(Dong,	Han	et	al.	
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2001).	Critical	to	its	use	as	a	cre-line,	the	authors	demonstrated	that	between	development	and	
adulthood	 in	the	mice,	expression	patterns	of	MrgD	became	more	restricted	(Dong,	Han	et	al.	
2001).	 Analysis	 of	 expression	 between	 preclinical	 species	was	 performed	 by	 Zylka	 et	 al	 2003,	
who	 reported	 many	 of	 the	 same	 findings,	 including	 MrgD	 expression	 overlap	 with	 the	 IB4-
binding	population	of	sensory	neurons	in	the	mouse,	as	well	as	overlap	of	expression	with	the	
GDNF-receptor	c-RET	(Zylka,	Dong	et	al.	2003).	Interestingly	while	in	the	mouse	the	Mrg	family	
of	GPCRs	can	be	subdivided	 into	 the	MrgA,	MrgB,	MrgC	and	MrgD	 families,	 the	 rat	and	gerbil	
have	 a	 much	 less	 diverse	 repertoire	 of	 this	 family	 of	 GCPRs	 (Zylka,	 Dong	 et	 al.	 2003).	While	
humans	 do	 have	 an	 MrgD	 ortholog,	 potentially	 allowing	 rapid	 translational	 pharmacological	
work	 from	 preclinical	 models,	 humans	 have	 a	 set	 of	 “MrgX”	 genes	 that	 do	 not	 have	 “clear”	
orthologs	 to	 rodents	but	 closely	 resemble	 the	MrgA	 subfamily	of	Mrg	GPCRs,	highlighting	 the	
potential	for	translational	work	between	species	(Zhang,	Taylor	et	al.	2005).	
The	 generation	 of	 a	 transgenic	 fluorescent	 reporter	 mouse	 by	 Zylka	 et	 al.	 2005,	
expanded	 on	 the	 previous	 work	 utilizing	 RNA	 specific	 in-situ	 hybridization.	 Namely	 that	
expression	of	MrgD	appeared	to	be	restricted	to	non-peptidergic	sensory	neurons,	with	distinct	
lack	of	co-expression	with	markers	for	peptidergic	sensory	neurons	such	as	CGRP	and	TRPV1,	an	
observation	 that	may	not	directly	 translate	 to	primates	 let	alone	humans	 (Zhang,	Taylor	et	al.	
2005,	Zylka,	Rice	et	al.	2005).	Work	by	this	group	demonstrated	that	MrgD	innervation	is	unique	
to	a	specific	layer	within	the	skin,	the	stratum	granulosum,	as	well	as	the	stratinum	gelatinosa	of	
the	 spinal	 cord	 (lamina	 II)	within	 the	 spinal	 cord	 (Zylka,	 Rice	 et	 al.	 2005).	 The	 authors	 of	 this	
paper	demonstrated	that	protein	expression	of	MrgD	coincided	well	with	the	RNA	transcription	
previously	reported	(Dong,	Han	et	al.	2001).	Wang	and	Zylka	2009,	demonstrated	that	synaptic	
terminals	from	MrgD	afferent	fibers	were	capable	of	generating	excitatory	postsynaptic	currents	
in	a	number	of	types	of	lamina	II	spinal	cord	neurons	in	a	monosynaptic	fashion	(Wang	and	Zylka	
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2009).	 In	 line	with	 this	 work,	 Braz	 et	 al.	 2005	 investigated	where	 this	 population	 of	 neurons	
project	into	higher	orders	of	the	CNS.	Finding	that	projections	from	DRG	cells	selectively	labeled	
by	Nav1.8	induced	expression	of	wheat	germ	agglutinin,	project	to	interneurons	in	lamina	II	of	
the	 spinal	 cord	 dorsal	 horn.	 Beyond	 this,	 projections	 from	 these	 interneurons	 continue	 on	 to	
lamina	 V,	 and	 the	 amygdala,	 hypothalamus	 and	 other	 regions	 of	 the	 CNS,	 reportedly	 unique	
from	 the	 projections	 from	 the	 peptidergic	 class	 of	 peripheral	 nociceptors	 (Braz,	 Nassar	 et	 al.	
2005).	
	 While	much	 is	 still	 unknown	 about	 implications	 of	 activating	 the	MrgD	 receptor	 itself	
(other	 than	 inducing	 itch),	 some	 work	 has	 uncovered	 ligands	 capable	 of	 activating	 this	
population	of	neurons	in-vitro	and	ex-vivo	(Liu,	Sikand	et	al.	2012).		Beta-alanine	a	small	amino	
acid,	 appears	 to	 be	 the	 endogenous	 ligand	 able	 to	 activate	 the	 MrgD	 receptor,	 as	 reports	
suggest	it	has	nearly	a	10	fold	lower	EC50	to	GABA,	its	closest	competitor	(Shinohara,	Harada	et	
al.	2004).	This	work	additionally	indicated	that	activation	of	MrgD	may	result	in	the	intracellular	
activation	of	Gq	and	Gi	classes	of	G-proteins,	on	small	diameter	and	nociceptive	cells,	 lending	
authors	to	believe	the	possibility	 that	activation	of	MrgD	plays	a	role	 in	regulating	nociceptive	
signals	 in	 the	 periphery,	 differential	 to	 that	 of	 GABA	 (Shinohara,	 Harada	 et	 al.	 2004).	 More	
diffuse	 investigation	 of	 MrgD	 expressing	 neurons	 has	 revealed	 that	 they	 have	 many	 of	 the	
electrophysiological	 hallmarks	 of	 nociceptors	 as	 well.	 Dussor	 et	 al.	 2008	 revealed	 that	 these	
neurons	 respond	 to	 extracellular	ATP	 and	 can	 generate	 “long-duration	 action	potentials”	 that	
are	TTX-resistant,	and	that	these	cells	possessed	calcium	currents	that	were	inhibited	the	MOR	
agonist	DAMGO,	an	effect	blocked	by	naloxone.	These	findings	led	the	authors	to	the	conclusion	
that	MrgD	expressing	 fibers	 likely	 respond	 to	keratinocyte	 release	of	ATP	 (Dussor,	 Zylka	et	 al.	
2008).	 Due	 to	 structural	 and	 anatomical	 descriptions	 of	 these	 fibers	 compared	 to	 peptidergic	
(CGRP	expressing),	they	may	play	a	unique	role	in	transducing	nociceptive	stimuli	from	the	skin	
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(Dussor,	Zylka	et	al.	2008).	An	interesting	body	of	work	from	Rau	et	al.	also	demonstrated	that	
knocking	out	MrgD	in	mice	resulted	in	decreased	sensitivity	to	heat,	mechanical	sensitivity,	cold,	
and	 demonstrated	 in-vitro	 that	 activation	 of	 MrgD	 via	 beta-alanine	 results	 in	 the	 hyper	
excitability	of	the	neuron	(Rau,	McIlwrath	et	al.	2009).	
	 While	 investigation	 of	 the	 cellular	 mechanisms	 of	 the	 MrgD	 receptor	 and	 MrgD	
expressing	fibers	has	garnered	interesting	findings	and	implications	to	the	pain	field,	little	work	
has	been	published	as	to	the	role	of	the	intact	fiber	in	behavioral	models.	This	may	be	a	result	of	
the	challenges	of	effectively	targeting	these	cells	 in	a	whole	 living	animal,	or	a	repercussion	of	
the	approaches	used	to	target	these	cells	in-vivo.	MrgD,	has	a	proposed	>90%	overlap	in	identity	
with	 IB4-binding	 neurons	 which	 was	 classically	 used	 to	 characterize	 non-peptidergic	 fibers	
(Cavanaugh,	Lee	et	al.	2009).	This	population	of	neurons,	much	like	the	IB4-binding	neurons,	has	
been	shown	to	be	critical	in	the	transduction	of	mechanical	nociception,	while	not	directly	being	
involved	in	the	transduction	of	thermal	nociceptive	input	from	the	periphery	(Cavanaugh,	Lee	et	
al.	 2009).	 This	 may	 imply	 a	 unique	 function	 for	 these	 neurons	 (Cavanaugh,	 Lee	 et	 al.	 2009).	
Another	 convincing	 piece	 of	 work	 targeting	 these	 cells	 in	 whole	 animals	 was	 a	 side	 by	 side	
comparison	performed	by	Beaudry	et	al.	2017,	where	authors	demonstrated	 that	optogenetic	
activation	of	TRPV1	expressing	neurons	resulted	in	noxious	behavior	and	an	aversive	state,	but	
activation	of	MrgD	afferents	was	not	aversive	to	the	animals	(Beaudry,	Daou	et	al.	2017).		
	
Preclinical	 evidence	 in	 the	 mouse	 suggests	 that	 MOR	 and	 DOR	 may	 be	 differentially	
expressed	on	nociceptive	fiber	subtypes	and	play	differing	roles	in	alleviating	modalities	of	pain	
in	the	mouse	(Scherrer,	 Imamachi	et	al.	2009).	Given	the	observations	by	Scherrer’s	group,	we	
tested	 the	 hypothesis	 that	 the	 administration	 of	 the	 peptidergic	MOR	 agonist	 DAMGO	would	
alleviate	ongoing	pain	 in	a	model	of	CIBP	 in	 the	mouse,	whereas	 the	peptidergic	DOR	agonist	
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Deltorphin	II	would	fail	to	do	so.	The	basis	for	this	hypothesis	relies	on	previous	implications	of	
the	 role	 of	 peptidergic,	 presumably	 MOR	 expressing	 nociceptive	 fibers,	 in	 the	 periphery	
transducing	 pain	 from	 the	 cancer-afflicted	 limb	 (Jimenez-Andrade,	 Mantyh	 et	 al.	 2010)	 and	
clinical	 observations	 that	MOR	 agonists	 can	 block	 persistent	 cancer-induced	 bone	 pain	 (Paice	
and	Ferrell	2011,	Mercadante	and	Bruera	2016).		
It	was	our	belief	that	due	to	MOR	agonists	inability	to	treat	breakthrough	pain,	and	the	
potential	 for	 differential	 expression	 of	 MOR	 and	 DOR	 on	 nociceptive	 fibers	 we	 would	 see	 a	
distinct	 difference	 in	MOR	and	DOR	agonists	 to	 ameliorate	ongoing	 versus	breakthrough	pain	
(Havelin,	Imbert	et	al.	2017).	Here	we	report	our	utilization	of	both	classic	and	novel	approaches	
to	investigate	and	demonstrate	the	differential	effects	on	pain	behaviors	these	fiber	populations	
have	in	cancer-induced	bone	pain.		Due	to	the	lack	of	published	work	able	to	directly	assess	the	
role	of	non-peptidergic	fibers,	and	our	success	in	implicating	a	role	for	non-peptiderigc	fibers	in	
a	 model	 of	 BTP	 in	 the	 rat,	 we	 chose	 to	 use	 a	 pharmacological	 and	 optogenetic	 approach	 to	
selectively	 and	 transiently	 silence	 targeted	 populations	 of	 nociceptive	 fibers.	 This	 approach	
would	allow	us	 to	address	 some	of	 the	short-comings	of	our	work	 in	 the	 rat,	 centered	mainly	
around	limitations	associated	with	ablating	neurons	and	the	responsive	neural	adaptations	that	
may	arise	after.		
Working	with	our	 collaborators	 at	 the	Canadian	Neurophotonic	Center	 in	Quebec,	we	
were	able	to	selectively	silence	the	fibers	 in	the	Nav1.8-cre	and	 inducible	MrgpdCreERT2	 (MrgD-
cre)	line	of	mice,	by	selectively	expressing	the	light	sensitive	ArchT	pump	in	these	fibers.	Initial	
work	utilized	a	selectively	cre-activated	Flex	viral	vector	to	activate	and	induce	expression	of	the	
ArchT	cassette,	while	subsequent	work	utilized	the	ArchT	transgenic	mouse	from	Jackson	labs.	
By	delivering	light	to	the	lumbar	section	of	the	spinal	cord	using	methods	published	by	Bonin	et	
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al.	 2016,	 we	 have	 successfully	modified	 nociceptive	 behavioral	 responses	 both	 in	 a	model	 of	
CIBP	and	AITC-induced	nociception.	
We	 attempted	 to	 adapt	 our	 measure	 of	 hind	 limb	 movement-induced	 breakthrough	
pain	 that	 we	 previously	 characterized	 in	 the	 rat	 (Havelin,	 Imbert	 et	 al.	 2017)	 to	 the	 mouse.		
However,	this	proved	more	difficult	than	simply	repeating	the	approach	utilized	 in	the	rat	and	
instead	characterized	novel	behavioral	measures	in	response	to	hind	limb	movement.		
	
3.1.3.	Brief	Overview	of	Utility	of	Optogenetics	in	the	Study	of	Pain	
	 The	relatively	recent	integration	of	light	sensitive	ion	channels	and	pumps	into	the	field	
of	 neuroscience	 research	 has	 undoubtedly	 been	 one	 of	 the	 largest	 advances	 in	 decades.	 The	
ability	to	selectively	activate	or	inhibit	a	neuron	with	spatial	and	temporal	precision	will	play	an	
immense	role	in	furthering	our	understanding	of	how	the	nervous	system	functions	both	under	
“normal”	circumstances	and	pathological	ones.	Additionally,	the	inability	to	resolve	spatial	and	
temporal	challenges	with	tools	that	have	been	widely	used	has	limited	the	progress	of	the	pain	
field	in	locating	anatomical	and	molecular	changes	in	circuitry	due	to	pathological	pain.	Perhaps	
one	day	this	technology	can	also	be	used	to	treat	pathologies	in	the	clinic.	To	better	understand	
where	these	tools	came	from	and	likely	where	they	will	go	in	the	near	future,	it	may	help	to	give	
some	 background	 into	 their	 function	 and	 history.	 Several	 excellent	 reviews	 already	 exist	
encompassing	 the	 promising	 adventure	 and	 tale	 of	 optogenetics	 and	 its	 utilization	 in	 pain	
research	(Copits,	Pullen	et	al.	2016,	Xie,	Wang	et	al.	2018).	Rather,	I	will	have	a	brief	explanation	
highlighting	some	key	features	that	contribute	to	our	utilization	of	this	tool	in	studying	CIBP.		
	 The	 first	 critical	 piece	 of	 optogenetics	was	 the	 discovery	 of	microbial	 opsins,	 proteins	
isolated	from	various	single	celled	organisms	that	respond	with	varying	efficiencies	to	different	
wavelengths	of	light	(Copits,	Pullen	et	al.	2016).	As	a	result	of	their	native	function,	ion	transport	
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across	 a	membrane	 in	 response	 to	 light,	 they	 have	 lent	 themselves	 to	 a	 very	 suitable	 use	 in	
neuroscience	 research.	 Depending	 on	 the	 opsin,	 activation	 can	 result	 in	 a	 net	 increase	 in	
positive	charge	within	a	neuron,	causing	it	to	depolarize	and	become	activated.	Two	opsins	used	
for	this	are	channel	rhodopsin	and	the	improved	version	channel	rhodopsin	2	(Daou,	Tuttle	et	al.	
2013,	Daou,	Beaudry	et	al.	2016,	Browne,	Latremoliere	et	al.	2017).	These	2	opsins	respond	to	
blue	light	and	once	activated	allow	cations	to	flow	into	the	cell	causing	a	wave	of	depolarization.	
With	 application	 of	 the	 correct	 parameters,	 it	 has	 been	 reported	 that	 this	 can	 be	 used	 to	
generate	 single	 action	 potentials,	 which	 when	 translated	 to	 an	 in-vivo	 prep,	 are	 capable	 of	
generating	 nocifensive	 behavioral	 responses	 in	 animal	 that	 express	 ChR2	 under	 the	 TRPV1	
promoter	(Browne,	Latremoliere	et	al.	2017).		
	While	 one	major	 use	 of	 opsins	 results	 in	 the	 depolarization	 of	 neurons,	 activation	 of	
another	 major	 classes	 of	 opsins	 results	 in	 a	 net	 negative	 charge	 in	 the	 neuron,	 resulting	 in	
inhibition	of	 the	neuron.	Two	hyperpolarizing	opsins	exist	and	are	widely	used,	 the	 first	being	
halorhodospin	which	is	activated	by	yellow	light	and	allows	for	chloride	ions	to	flow	through	the	
cellular	membrane.	The	other	major	opsins	being	archaerhodopsin	(Arch)	and	archt-rhodospins	
(ArchT)	which	are	activated	by	orange	to	green	light	and	actively	pump	protons	to	the	exterior	
of	 the	cellular	membrane.	Both	of	 these	opsins	net	 function	 result	 in	 the	hyperpolarization	of	
the	 interior	of	neurons,	 resulting	 in	 inhibition	of	 the	neuron	 (Xie,	Wang	et	 al.	 2018).	While	at	
surface	level	both	of	the	mechanisms	of	these	opsins	would	seem	to	work	to	the	same	extent,	
our	work	was	directed	towards	the	use	of	the	ArchT	opsin.	This	was	due	to	the	observation	that	
activation	 of	 halorhodospin	 can	 result	 in	 a	 net	 change	 in	 the	 chloride	 gradient	 within	 a	 cell,	
which	in	turn	allowed	for	the	unintentional	depolarization	of	a	cell	following	exposure	to	GABA	
(Raimondo,	 Kay	 et	 al.	 2012).	 This	 observation	 was	 not	 made	 in	 work	 with	 the	 Arch	 pump	
(Raimondo,	Kay	et	al.	2012).	While	Arch	has	been	implemented	and	used	successfully	to	inhibit	
84	
	
neuronal	activity	(Copits,	Pullen	et	al.	2016,	Daou,	Beaudry	et	al.	2016,	Xie,	Wang	et	al.	2018),	
our	work	utilized	 the	optimized	ArchT	proton	 cassette	described	by	Han	et	 al.	 2011.	Han	and	
colleagues	 describe	 the	 ArchT	 pump	 isolated	 from	 Halorubrum	 strain	 TP009	 in	 their	 work	
comparing	 to	 Arch	 isolated	 from	Halorubrum	 sodomense,	 as	 readily	 trafficked	 in	mammalian	
cells	and	a	more	 light	 sensitive	 tool	 capable	of	 inhibiting	neurons.	 	Work	by	our	 collaborators	
demonstrated	 a	 unique	 approach	 for	 delivery	 of	 the	 ArchT	 cassette	 and	 sight	 of	 neuronal	
inhibition	 that	 aided	 in	 the	 direction	 of	 our	work,	 and	 laid	 feasibility	 for	 our	 approach	 in	 the	
mouse	(Bonin,	Wang	et	al.	2016).	
The	next	challenge	of	using	optogenetic	intervention	in	an	in-vivo	setting	is	the	hurdle	of	
delivery	of	the	opsin	of	choice	as	well	as	light	to	activate	it.	Several	delivery	methods	of	an	opsin	
cassette	are	widely	used	currently	 for	 in-vivo,	each	with	their	own	advantages	and	challenges.	
The	first	utilized	here	in	this	work	and	widely	by	others	is	through	the	delivery	of	a	viral	vector.	
Injection	of	a	viral	vector	carrying	the	opsin	cassette	of	interest	can	either	be	injected	locally	to	
allow	 for	 specific	 anatomical	 distribution	 of	 the	 virus	 or	 systemically	 to	 allow	 for	widespread	
expression	 of	 the	 vector.	 The	 use	 of	 either	 approach	 depends	 on	 the	 ultimate	 goal	 of	 the	
research	 to	 be	 performed.	 If	 investigators	wish	 to	 target	 a	 unique	 location	 in	 the	 CNS	 (spinal	
cord	or	brain),	viral	vector	can	be	specifically	delivered	to	that	area	and	expression	of	the	light	
sensitive	opsin	will	be	 restricted	 to	cell	bodies	and	projections	of	 those	bodies.	This	approach	
can	also	be	used	to	selectively	deliver	an	opsin	to	a	 location	in	the	peripheral	nervous	system,	
i.e.	 a	 specific	portion	of	 the	hind	paw,	which	allows	 for	 selective	expression	only	 in	 cells	with	
terminal	 endings	 at	 that	 location.	 	 Alternatively,	 systemic	 injection	 of	 viral	 vector	 allows	 for	
widespread	and	diffuse	expression	of	the	virus,	which	as	in	our	case,	may	be	more	optimal	when	
targeting	a	diffuse	region	of	neurons,	i.e.	the	lumbar	region	of	the	spinal	cord.	The	inclusion	of	
Cre-sensitive	 components	 in	 viral	 cassette	 construction	 (loxp	 sites	 for	 flip-excision	 or	 stop-
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cassette	removal)	allows	for	activation	of	viral	vectors	within	Cre	expressing	cell	populations	of	
an	investigators	choice.	The	alternative	to	viral	delivery	of	an	opsin	is	the	use	transgenic	animals	
that	either	 selectively	express	an	opsin	under	a	 specific	promoter,	or	a	 transgenic	animal	 that	
expresses	an	opsin	in	a	Cre	sensitive	manner.	Depending	on	the	construct	of	the	cassette,	viral	
delivery	of	an	opsin	can	also	be	used	to	target	projections	of	a	specific	anatomical	location,	i.e.	
cassettes	 that	 jump	 a	 single	 synapse	 can	 allow	 for	 selective	 activation	 of	 opsins	 in	 the	
projections	 of	 a	 brain	 region	 (Gradinaru,	 Zhang	 et	 al.	 2010).	While	 use	 of	 transgenic	 animals	
imbue	 a	 less	 complicated	 technical	 approach,	 investigators	 must	 rely	 on	 breeding	 their	 own	
animals	and	ensuring	genetic	reliability	of	said	colony.	
Challenges	of	using	 a	 viral	method	 to	deliver	 an	opsin	 include	 variables	 that	 can	alter	
concentration	of	viral	vector	delivery,	 this	may	result	 in	differential	delivery	and	expression	of	
opsins	 in	 tissue	which	may	 give	 rise	 to	 unavoidable	 variability	 in	 experiments.	 This	 is	 true	 of	
either	localized	or	systemic	injections.	Depending	on	the	timing	of	delivery	of	the	viral	vector	it	
is	 possible	 to	 inadvertently	 induce	 long	 term	 changes	 to	 the	 immune	 system	 that	 may	
complicate	or	confound	results	in	the	future.	Additionally,	systemic	injection	of	viral	vectors	may	
result	in	stark	differences	in	opsin	protein	expression	between	individual	animals,	a	complicated	
variable	 to	 account	 for.	 These	 however	 can	 also	 be	 strengths	 of	 the	 approach	 of	 viral	 vector	
delivery.	Viral	delivery	of	an	opsin	can	allow	for	transfection	and	expression	of	an	opsin	beyond	
the	normal	levels	of	a	transgenic	animal,	allowing	for	activation	of	opsins	beyond	what	may	be	
possible	using	a	transgenic	animal.	This	of	course	may	result	in	its	own	confounds	to	the	work	at	
hand.	 Viral	 delivery,	 localized	 or	 systemic,	 can	 allow	 for	 timed	 delivery	 of	 cre	 sensitive	 opsin	
cassettes	 that	 bypass	 expansion	 of	 genetic	 activation	 during	 development,	 i.e.	 TRPV1,	 which	
would	 be	 unavoidable	 in	 a	 non-inducible	 mouse	 cre	 line	 (Daou,	 Beaudry	 et	 al.	 2016).	
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Unavoidable	 activation	 of	 cre	 during	 a	 transgenic	 animal’s	 development	 may	 result	 in	 opsin	
expression	in	undesired	populations	of	cells	in	adult	animals.		
The	 last	 hurdle	 to	 consider	 when	 using	 optogenetics	 in	 an	 in-vivo	 approach	 is	 the	
delivery	of	light	to	the	opsin	at	sufficient	magnitude	to	active	the	opsin.	This	depends	heavily	on	
the	 tissue	 of	 interest,	 e.g.	 a	 specific	 brain	 region,	 specific	 location	 in	 the	 spinal	 cord,	 specific	
location	 within	 the	 peripheral	 nervous	 system.	 The	 easiest	 form	 of	 light	 delivery	 is	 simply	
exposure	of	 tissue	through	 lighting	within	the	test	area,	or	directly	applying	 light	 to	 the	tissue	
with	a	 laser	 (Daou,	 Tuttle	et	 al.	 2013).	 This	 form	of	 light	delivery	 lends	 itself	 to	 investigations	
targeting	fibers	in	the	skin	or	perhaps	the	eye,	essentially	tissue	with	exposed	fibers	to	ambient	
light.	Delivery	of	 light	 to	regions	of	 the	brain	require	skilled	 implantation	of	cannulas	or	 fibers	
that	illuminate	the	region	of	interest	without	confounding	“normal”	behavior	of	the	animals.	A	
similar	approach	has	now	been	developed	to	target	regions	of	the	spinal	cord,	with	the	goal	of	
both	 targeting	 afferent	 terminals	 prior	 to	 entering	 the	 spinal	 cord	 and	 regions	 of	 the	 deeper	
spinal	cord	(Bonin,	Wang	et	al.	2016).	Illuminating	light	cuffs	to	deliver	light	to	the	sciatic	nerve	
have	also	been	used	(Towne,	Pertin	et	al.	2009,	Xie,	Wang	et	al.	2018).	The	use	of	many	of	these	
approaches	has	progressed	and	will	 continue	 to	progress	as	options	 for	wireless	 light	delivery	
continue	to	 improve.	One	of	 the	major	challenges	originally	 facing	wireless	delivery	of	 light	 to	
tissues	was	delivering	light	of	sufficient	power	to	activate	opsins	in	desired	tissues,	a	hurdle	that	
appears	to	be	progressively	nearer	to	being	jumped	(Copits,	Pullen	et	al.	2016).	
Many	 studies	 have	 used	 optogenetics	 to	 investigate	 mechanisms	 driving	 nociception	
and	 pain,	 whether	 targeting	 the	 central	 nervous	 system	 or	 the	 peripheral	 nervous	 system	
(Copits,	Pullen	et	al.	2016,	Xie,	Wang	et	al.	2018).	Of	interest	to	the	work	completed	here,	where	
our	goal	 is	 to	use	optogenetics	 to	 investigate	 the	Nav1.8	and	MrgD	expressing	populations	of	
sensory	fibers,	I	will	report	findings	from	a	few	papers	that	performed	relevant	work.	Not	only	
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to	justify	our	approach	to	targeting	these	populations	of	peripheral	neurons	but	the	feasibility	of	
our	optogenetic	paradigm.	Optogenetic	investigation	of	sensory	neurons	expressing	ChR2	under	
the	Nav1.8	promoter	(cre-lox	system)	has	demonstrated	that	many	of	the	C-fibers	that	express	
Nav1.8	 respond	 to	 nociceptive	 modalities	 such	 as	 mechanical	 and	 thermal	 stimuli	 and	 these	
fibers	can	be	successfully	activated	by	blue	 light	 (Uhelski,	Bruce	et	al.	2017).	Daou	et	al.	2013	
has	 demonstrated	 by	 using	 blue	 light	 in	mice	 that	 activation	 of	 Nav1.8	 fibers	 results	 in	 both	
behavioral	 and	 immunohistochemical	 hallmarks	 of	 nociceptor	 activation.	 Namely	 by	 acutely	
inducing	nocifensive	behaviors	following	blue	light	stimulation	of	the	hind	paw,	condition	placed	
aversion	 to	 activation	 of	 Nav1.8	 fibers	 blocked	 by	morphine,	 and	 c-fos	 staining	 in	 superficial	
lamina	 of	 the	 spinal	 cord	 dorsal	 horn	 (Daou,	 Tuttle	 et	 al.	 2013).	 Authors	 of	 this	 paper	 also	
demonstrated	 that	 prolonged	 activation	 of	 Nav1.8	 fibers	 using	 blue	 light	 resulted	 in	 central	
sensitization	of	animals.	Daou	et	al.	2016	demonstrated	that	through	Arch-induced	inhibition	of	
Nav1.8	 fibers,	 nociceptive	 stimuli	 and	 inflammation	 induced	 tactile	hypersensitivity	 could	 also	
be	 blocked	 (Daou,	 Beaudry	 et	 al.	 2016).	 Bonin	 et	 al.	 2016	 demonstrated	 light	 delivery	 of	 an	
epidural	fiber	meant	to	target	afferent	terminals	in	the	spinal	cord	dorsal	horn	could	also	allow	
for	 optogenetic	 activation	 or	 inhibition	 of	 Nav1.8	 fibers,	 and	 their	 associated	 behavioral	
responses.	Due	to	the	overlap	between	this	epidural	optogenetic	surgery	and	our	own	in	the	rat	
(Havelin	et	 al.	 2017),	 and	 the	ability	 to	overcome	potential	 adaptive/compensatory	 responses	
with	that	can	occur	in	ablative	approaches,	we	chose	to	use	this	surgical	approach	to	investigate	
the	role	of	these	fibers	in	CIBP.	
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3.2.	Materials	and	Methods	
3.2.1.	LLC	Cell	Line	Maintenance		
	 The	 C57BL/6	mouse	 cell	 line,	 Lewis	 Lung	 Carcinoma	 (LLC)	 cells	 were	 purchased	 from	
American	 Type	 Culture	 Collection	 (ATCC,	 CRL	 1642,	 Manassas,	 VA)	 and	 were	 maintained	 in	
DMEM	media	 with	 L-glutamine	 (CellGro,	Manassas,	 VA)	 with	 10%	 fetal	 bovine	 serum	 (ATCC,	
Manassas,	VA)	and	1%	penicillin/streptomycin	at	37°C	in	a	5%	CO2	atmosphere.	Prior	to	surgical	
implantation,	 cells	 were	 washed	 with	 phosphate-buffered	 saline	 and	 lifted	 from	 cell	 culture	
plates	with	0.05%	trypsin-EDTA	(CellGro,	Manassas,	VA).	Cells	were	spun	at	0.7	RCF	for	no	more	
than	 5	minutes	 and	 re-suspended	 at	 a	 concentration	 of	 1	 x	 108	 cells/	 µL	 in	 the	 same	DMEM	
media	used	to	culture	the	cells	using	a	BioRad	TC10	Automated	Cell	Counter	(BioRad,	Hercules,	
CA).		
	
3.2.2.	Animal	Care	and	Treatment	
Female	and	male	C57BL/6	mice	(Charles	River,	Willington,	MA)	aged	8-12	weeks,	were	chosen	
based	 on	 their	 histocompatibility	 with	 the	 LLC	 cell	 line.	Mice	 were	maintained	 on	 a	 12-hour	
light/dark	 cycle	with	 food	 and	water	 available	ad	 libitum.	 All	 experiments	were	 performed	 in	
accordance	 with	 the	 policies	 and	 recommendations	 of	 the	 International	 Association	 for	 the	
Study	 of	 Pain,	 National	 Institutes	 of	 Health,	 and	 the	 Institutional	 Animal	 Care	 and	 Use	
Committee	of	the	University	of	New	England.		
	
3.2.3.	Transgenic	Mouse	Lines	and	Crosses	
	 Transgenic	 reporter	mice	were	purchased	and	maintained	as	homozygous	 lines	 in	 the	
animal	facilities	at	the	University	of	New	England.	Mice	were	paired	in	harem	breeding	with	one	
male	 and	 two	 females.	 Both	 Nav1.8	 and	MrgD	 cre	 lines	 of	 mice	 were	 also	 maintained	 on	 a	
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homozygous	 background.	Mice	 heterozygous	 for	 both	 genes	 were	 generated	 by	 crossing	 the	
male	homozygous	cre	mice	with	homozygous	floxxed-stop	transgenic	female	mice.	For	example,	
male	Nav1.8	 cre	would	be	crossed	with	 female	 tdtomato	 reporter	mice.	Mice	were	paired	no	
earlier	than	6	weeks	of	age	and	allowed	to	continue	to	breed	until	they	were	roughly	8	months	
of	 age	 or	 until	 they	 stopped	 producing	 litters.	 Pups	 were	 weaned	 at	 postnatal	 day	 21	 and	
females	and	males	were	housed	separately.	Mice	that	underwent	optic	fiber	implantation	were	
not	 used	 for	 experiments	 until	 they	 were	 roughly	 12	 weeks	 old	 to	 allow	 ease	 of	 surgical	
placement	of	optical	fibers	as	described	later.	
Nav1.8-cre.	The	Nav1.8-cre	mouse	line	was	generously	transferred	to	us	by	Dr.	Ian	Meng	
from	the	University	of	New	England,	the	original	origins	of	this	mouse	reported	to	be	from	John	
Woods	group	(Nassar,	Stirling	et	al.	2004).		
MrgD-Cre-ERT2.	 The	 MrgDcreERT2	 mouse	 line	 was	 generously	 transferred	 to	 us	 by	
Wengqin	Luo	from	the	University	of	Pennsylvania.	Characterization	of	this	specific	mouse	line	is	
reported	by	 (Olson,	Abdus-Saboor	et	al.	2017).	This	mouse	 is	also	now	commercially	available	
through	Jackson	Labs,	Bar	Harbor,	ME,	at	the	time	of	this	dissertation	stock	number	01286.	
Floxxed	 stop	 tdtomato	 Ai14.	 Experiments	 utilizing	 the	 fluorescent	 tdtomato	 reporter	
uses	 the	 Ai14	 mouse	 purchased	 from	 Jackson	 Labs,	 Bar	 Harbor,	 ME,	 at	 the	 time	 of	 this	
dissertation	 stock	 number	 007914.	 The	 Ai14	 mouse	 utilizes	 a	 floxxed-STOP	 cassette	 that	
requires	 cre	 activation	 for	 the	 functional	 expression	 of	 the	 red	 fluorescent	 protein	 variant	
“tdtomato”.			
Floxxed	 stop	ArchT	 JAX	Ai40D.	Experiments	utilizing	 the	ArchT-eGFP	 transgenic	mouse	
use	 the	 Ai40D	 mouse	 from	 Jackson	 Labs,	 Bar	 Harbor,	 ME,	 stock	 number	 021188.	 The	 Ai40	
mouse	utilizes	a	floxxed-STOP	cassette	that	requires	cre-activation	to	express	the	light	sensitive	
ArchT-eGFP	fusion	protein.	ArchT	 is	a	 functionally	enhanced	version	of	 the	orange-yellow	light	
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sensitive	Arch	protein	which	silences	neurons	by	actively	pumping	protons	into	the	extracellular	
space	 following	 exposure	 to	 orange	 light	 (Han,	 Chow	 et	 al.	 2011).	 ArchT	 was	 chosen	 as	 it	 is	
reported	to	be	more	light	sensitive	than	its	predecessor,	demonstrates	adequate	expression	on	
axons,	a	critical	component	to	our	targeted	area	for	light	delivery,	and	has	a	much	faster	time	of	
recovery	 from	 light-induced	 inactivity	 compared	 to	 other	 neuron	 inactivating	 light	 sensitive	
channels	such	as	halorhodopsin	(Han,	Chow	et	al.	2011).	Functionally,	pumping	protons	into	the	
extracellular	space	results	in	hyperpolarization	of	the	transmembrane	electrochemical	potential,	
which	has	demonstrated	efficacy	in	silencing	neurons.	
	
3.2.4.	Genotyping	of	Mouse	Lines	
Genotyping	of	samples	was	completed	by	the	COBRE	Behavioral	core	at	the	University	
of	 New	 England.	 Tissue	 is	 collected	 from	 each	 mouse	 at	 approximately	 Day	 21	 of	 age	
simultaneous	with	weaning,	using	surgical	scissors	to	remove	a	2mm	snip	of	tail.	Tail	snips	were	
placed	 in	 a	 1.5mL	 conical	 bottom	 tube	 and	 lysed	 by	 adding	 50mM	 NaOH	 to	 the	 tube.	 Each	
sample	was	heated	to	95oC	for	35	minutes,	followed	by	the	addition	of	50mM	HCL	and	1M	Tris	
HCL	 buffer.	 Each	 sample	 was	 then	 spun	 down	 and	 stored	 at	 4oC	 until	 processing.	 Animal	
genotypes	 were	 confirmed	 using	 three	 separate	 protocol	methods	 once	 sample	 preparations	
were	completed.	Nav1.8	cre	and	ArchT	mutant	reactions	were	prepared	using	Promega	GoTaq	
Flexi	 PCR	buffer,	while	ArchT	wild	 type	and	MrgD-cre	 reactions	were	prepared	with	Econotaq	
Plus	2x	Buffer.	1	µL	of	DNA	sample	was	added	per	reaction,	into	master	mix	of	the	appropriate	
buffer.	 The	 conditions	 for	 each	 protocol	 varied	 by	 annealing	 temperature	 and	 the	 number	 of	
cycles	run	to	produce	the	desired	product.		
Nav1.8	cre/cre	and	Nav1.8	Wild	Type	must	be	processed	as	2	separate	reactions,	due	to	
final	 product	 band	 sizes	 being	 approximately	 the	 same	 (~538	 bp).	 Primers	 and	 conditions	 for	
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performing	 Nav1.8	 Cre	 and	 wild	 type	 are	 as	 follows,	 Nav1.8	 cre	 common	 forward	 –	
GGAATGGGATGGAGCTTCTTA,	Nav1.8	cre	mutant	reverse	–	CCAATGTTGCTGGATAGTTTTTACTGC,	
Nav1.8	cre	wild	type	reverse	–	TTACCCGGTGTGTGCTGTAGAAAG.	MrgD	cre	were	performed	as	a	
single	 reaction,	with	 final	product	sizes	being	550	bp	 for	 the	mutant	allele	and	200	bp	 for	 the	
wild	 type	 allele.	 Primers	 are	 as	 follows:	 MrgD	 cre	 mutant	 forward	 –	 GGATCCGCCGCATAACC,	
MrgD	 cre	 wild	 type	 forward	 –	 ATACTTTTTGCCGACTTGAACTTG,	 MrgD	 cre	 common	 reverse	 –	
TTGGGCTGCTAAGAGTGG.	ArchT	mutant	conditions:	ArchT	mutant	and	ArchT	wild	type	must	be	
processed	as	2	separate	reactions,	due	to	final	product	band	sizes	for	both	being	approximately	
the	 same	 (~300	 bp).	Mutant	 reactions	 performed	with	 Promega	GoTaq	 Flexi	 buffer	 using	 the	
following	primers:	ArchT	mutant	forward	–		ATTGCAGCCATTGTCTGAG,	ArchT	common	reverse	–	
CCGAAAATCTGTGGGAAGTC.	 ArchT	 wild	 type	 conditions:	 ArchT	 wild	 type	 processed	 with	
EconoTaq	2x	Buffer	and	performed	under	the	following	conditions	and	primers:	ArchT	wild	type	
forward	 –	 AAGGGAGCTGCAGTGGAGTA,	 ArchT	 common	 reverse	 –	 CCGAAAATCTGTGGGAAGTC.	
All	DNA	products	were	loaded	on	a	1.5%	agarose	gel	for	electrophoresis.	Voltage	was	typically	
set	for	130V,	for	a	duration	of	30	minutes	to	separate	bands.	Gels	were	then	imaged	under	UV	
light	for	analysis.	
	
3.2.5	Surgical	Procedures	and	Manipulations	
Viral	 Information	and	Transduction	Protocol.	Virus	used	 for	 viral	 transfection	of	ArchT	
was	 purchased	 from	 the	 Canadian	 Neurophotonics	 Center,	 QC,	 Canada.	 Viral	 cassette	
information	 supplied	 by	 the	 Canadian	 Neurophotonics	 Center	 reported	 the	 vector	 used	 is	
AAV2/8-CAG-Flex-ArchT-eGFP.	 The	 AAV2/8	 serotype	 is	 a	 combination	 of	 AAV2	 and	 AAV8	
serotypes.	The	CAG	promoter	 is	comprised	of	the	cytomegalovirus	enhancer	element,	the	first	
exon	and	intron	of	the	chicken	beta-actin	gene	as	a	promoter,	and	the	rabbit	beta-globin	splice	
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acceptor	gene	which	has	previously	been	shown	 to	 induce	high	expression	when	used	 in	AAV	
vector	delivery	in	vivo	(Nitta,	Kawamoto	et	al.	2005).	“Flex”	is	an	acronym	for	“flip-excision”,	a	
function	of	 the	endonuclease	protein	Cre.	When	 loxp	sites	are	oriented	appropriately,	vectors	
are	excised,	inverted	and	re-inserted	into	the	genome.	In	this	case	this	vector	is	provided	in	the	
anti-sense	direction,	upon	exposure	to	Cre,	the	vector	is	excised	and	flipped	to	a	sense	direction	
resulting	 in	successful	expression	of	the	ArchT-eGFP	pump	and	fluorescent	reporter.	Virus	was	
prepared	and	purchased	 from	Canadian	Neurophotonics	Center,	QC,	CA.	Titer	varied	minutely	
between	lots	received.	Virus	was	prepared	in	the	absence	of	helper	virus,	purified	from	culture	
medium	on	iodixanol	gradient	and	resuspended	in	PBS	320	millimolar	sodium	chloride	and	5%	
sorbitol	and	0.001%	pluronic	acid.		
Mice	received	injections	of	20	microliters	of	undiluted	virus	suspension	at	postnatal	day	
5.	 To	 reduce	 stress	 and	 potential	 for	 cannibalization	 of	 pups,	 the	 mother	 was	 removed	 and	
lightly	 anesthetized	with	 isoflurane	~1-2%	prior	 to	handling	pups.	After	 removing	 the	mother,	
gloves	were	rubbed	in	the	bedding	of	the	cage	of	pups	in	an	attempt	to	reduce	scent	from	the	
investigator	and	add	scent	from	the	home	cage	to	the	gloves	of	the	investigator.	Pups	were	then	
individually	 picked	 up	 and	 injected	 with	 20	 microliters	 of	 virus	 suspension	 from	 a	 modified	
Hamilton	syringe	that	allowed	minimal	waste	of	virus.	A	blunted	30-gauge	needle	was	attached	
to	 the	 luer	 tip	 of	 a	 100	microliter	 syringe,	 this	 needle	 tip	was	 then	 attached	 to	 PE10	 tubing,	
which	was	then	attached	to	the	end	another	30	gauge	needle	tip	that	was	gripped	with	a	pair	of	
inter-locking	 hemostats.	 After	 injection	 pups	 were	 then	 returned	 to	 their	 home	 cage	 and	
covered	with	bedding	prior	to	the	return	of	the	mother.	Pups	were	observed	for	~2	hours	prior	
to	being	returned	to	the	animal	facility.		
Cancer	 Implantation	 in	Mice.	 Surgical	 implantation	 of	 the	 LLC	 cell	 line	was	 consistent	
with	those	previously	described	(Schwei,	Honore	et	al.	1999,	Isono,	Suzuki	et	al.	2011).	Briefly,	
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mice	that	were	2-3	months	old	were	anesthetized	with	isoflurane	2-3%.	Animals	had	their	right	
hind	 limb	 area	 shaved	 and	wiped	with	 70%	 ethanol	 followed	 by	 iodine.	 A	 small	 incision	was	
made	laterally	above	the	femur	to	expose	underlying	tissue.	Going	along	the	iliotibial	band	using	
a	pair	of	curved	forceps,	muscle	was	separated	with	blunt	dissection	to	allow	the	pair	of	forceps	
to	hook	over	the	femur	and	roll/displace	the	quadriceps	over	the	femur	exposing	the	distal	end	
of	 the	 femur,	 taking	 care	 to	 avoid	 ripping	 or	 damaging	 tissue.	 A	 small	 hole	 was	 then	 drilled	
between	the	2	condyles	using	a	dental	drill	with	a	0.6-millimeter	bit.	A	small	cannula	was	then	
inserted	 into	 the	 bone	 marrow	 and	 attached	 to	 a	 50	 microliter	 Hamilton	 syringe	 and	 2	
microliters	of	cell	suspension	(1	x	108	cells/mL)	was	injected	delivering	2	x	105	cells	or	cell	 free	
media.	 After	 injection	was	 complete	 the	 cannula	was	 removed	 and	 the	 hole	was	 then	 sealed	
with	 bone	 wax	 and	 bone	 cement.	 The	 muscles	 displaced	 previously	 in	 the	 procedure	 were	
returned	to	their	original	position	and	the	incision	in	the	skin	closed	with	suture.	Mice	were	then	
returned	to	their	home	cages	and	monitored	for	1-2	hours	prior	to	being	returned	to	the	animal	
facility.	Mice	were	monitored	for	weight	loss	and	any	animals	that	lost	greater	than	20%	of	their	
original	body	weight	at	any	given	time	were	removed	from	the	study	(no	animals	removed	due	
to	weight	loss	prior	to	end	of	experiments).	
Epidural	 Fiber	 Optic	 Manufacturing,	 Utilization	 of	 Laser	 diode	 system,	 and	 Quality	
Assurance.	Optic	 fibers	were	used	and	purchased	as	described	 in	Bonin	et	al	2016,	 from	Doric	
lenses	 (QC,	 Canada).	 Fibers	 were	 custom	 made	 with	 a	 diffusive	 tip,	 product	 information,	
MMF_POF_240/250-0.6_8	cm	DFL.	Fibers	were	fixed	in	place	within	a	ceramic	ferrule	with	blue	
epoxy	(Fiber	Instrument	Sales,	 Inc.)	 	and	allowed	to	dry	overnight.	Fibers	were	then	cut	with	a	
ruby	dualscribe	S90R	(THORLABS,	Newton,	NJ)	to	measure	4.8cm	in	length,	to	allow	placement	
directly	above	the	lumbar	enlargement.	After	roughly	cutting	with	the	dualscribe	implants,	were	
held	 within	 a	 polishing	 disc	 D50-FC	 (THORLABS,	 Newton,	 NJ)	 and	 progressively	 polished	 in	 a	
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figure	 8	 motion	 to	 ensure	 even	 polishing	 of	 the	 end	 of	 the	 fiber	 optic.	 Polishing	 paper	
increments	used	were	as	 follows:	M15	silicon	carbide	15	micrometers	 (Fiber	 Instrument	Sales,	
Inc.,	 Oriskany,	 NY),	 diamond	 lapping	 6	 micrometer	 (THORLABS,	 Newton,	 NJ),	 3M	 aluminum	
oxide	3	micrometers	 (Fiber	 Instrument	Sales,	 Inc.,	Oriskany,	NY).	 Implants	were	then	sealed	 in	
dental	cement	molded	to	rubber	caps	to	imitate	the	shape	of	a	mouse	skull	and	allowed	to	dry	
overnight.	Fibers	were	then	tested	for	transmittance	to	ensure	adequate	transmission	of	light	to	
the	end	of	the	fiber	and	ensure	the	manufacturing	process	did	not	compromise	the	integrity	of	
the	 fiber.	Testing	of	 representative	group	of	 fibers	 is	displayed	 in	Figure	3.1,	 fibers	with	<30%	
transmittance	at	the	measured	power	output	of	the	laser	were	not	used.		
After	mice	received	surgical	implantation	of	the	fiber,	animals	were	attached	in	line	with	
the	following	fiber	optics	 for	transmittance	of	 light	 from	the	 laser	source	to	the	diffusive	fiber	
optic.	 Light	 sources	 used	 in	 experiments	 were	 generated	 from	 a	 fiber-coupled	 laser	 diode	
module	–	450	and	520	nm,	 LDFLS_450/080_520/060	 (Doric	 Lenses,	QC,	Canada).	 Laser	diodes	
were	connected	to	a	patch	cord	MFP_100/125/LWMJ-0.22_0cm_FC-FCA,	core	100	micrometers,	
NA0.22,	jacket	2400	micrometers	(Doric	Lenses,	QC,	Canada).	This	cord	was	attached	to	a	fiber	
optic	 rotary	 joint,	 FRJ_1x1_FC-FC	 and	 fiberoptic	 rotary	 joint	 holder,	 holder	 FRJ_small	 rotary	
(Doric	 Lenses,	 QC,	 Canada).	 The	 rotary	 was	 then	 connected	 to	 an	 optical	 fiber	 patchcord,	
MFP_200/240/900-0.22_1.5m_FC-ZF2.5,	 core	 200um,	 NA	 0.22,	 jacket	 900	micrometers	 (Doric	
Lenses,	QC,	Canada).		This	was	then	attached	to	a	bronze	split	jacket	used	to	connect	the	laser	
source	 and	 patch	 cords	 to	 the	 fiber	 optic	 implant	 attached	 to	 the	 mice.	 Depending	 on	 the	
behavioral	test,	lasers	were	either	manually	activated	by	hand,	setting	the	laser	diode	system	to	
“constant	wave”,	 or	 controlled	 by	 signals	 from	ANYMAZE	 software	 (Stoelting,	Wood	Dale,	 IL)	
with	TTL	signals.	
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Epidural	 Fiber	 Implant	 Surgery.	 Implanting	 the	 fiber	 optic	 cable	 to	 target	 the	 lumbar	
enlargement	 of	 the	 spinal	 cord	 was	 performed	 as	 previously	 described	 (Bonin,	 Wang	 et	 al.	
2016).	Animals	were	anesthetized	with	2-3%	isoflurane	with	oxygen	flow	of	1	liter/minute.	The	
neck	and	top	of	 the	head	of	 the	mouse	was	shaved	using	small	hair	clippers	and	then	treated	
with	70%	ethanol	wipe	and	 iodine.	A	small	 incision,	~3cm,	was	made	cutting	 rostral	 to	caudal	
from	 roughly	 the	 middle	 of	 the	 skull	 (immediately	 rostral	 to	 lambdoid	 suture)	 down	 to	 the	
middle	of	the	neck.	The	skull	was	then	rubbed	with	a	cotton	tip	applicator	that	had	been	soaked	
in	3%	hydrogen	peroxide	to	remove	residual	tissue	on	the	skull.	This	aided	in	ensuring	a	dry	skull	
surface	for	later	in	the	surgery.		A	set	of	microscissors	were	used	to	cut	underlying	neck	muscle	
along	the	midline	of	 the	animal	 taking	care	to	not	sheer	 tissue	 lateral	 to	 the	midline.	After	an	
incision	 of	 roughly	 2	 cm	was	made	 a	 cotton	 tip	 applicator	was	 inserted	 into	 the	 incision	 and	
vigorously	rubbed	and	spun	to	bluntly	force	tissue	away	from	the	skull	and	to	increase	workable	
space	within	 the	 incision.	 Following	 this,	 tissue	 spreaders	were	 inserted	 into	 the	 incision	 and	
used	to	open	the	incision	to	a	workable	area.	Using	fine	tipped	forceps,	a	small	hole	was	made	
in	 the	 layer	 of	 tissue	 lying	 over	 the	 duramater	 just	 rostral	 to	 the	 C1	 vertebra,	 taking	 care	 to	
avoid	puncturing	the	dura	which	was	made	obvious	by	the	release	of	cerebrospinal	fluid	(CSF)	if	
the	dura	mater	was	punctured.		
Occasionally	this	did	happen	and	animals	were	recorded	and	noted	as	such.	After	blunt	
dissecting	a	small	useable	hole,	the	end	of	the	fiber	optic	implant	with	the	diffusive	tip	was	held	
with	ceramic	 tip	 forceps,	7	MZ	Ceramic	Tip	Tweezer	 (Electron	Microscopy	Series,	Hatfield,	PA)	
and	carefully	placed	into	the	hole.	After	the	fiber	optic	 implant	was	successfully	 inserted	using	
the	ceramic	tip	forceps,	the	implant	was	carefully	and	slowly	threaded	down	the	length	of	the	
vertebral	column	and	spinal	cord	to	 the	 lumbar	enlargement.	Noting	 two	points	of	 resistance,	
initially	 as	 the	 implant	passes	 the	arch	 in	 the	 cervical	 region	of	 the	mouse’s	 vertebral	 column	
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and	again	nearing	the	lumbar	enlargement.	These	hurdles	were	overcome	by	manipulating	the	
mouse	 and	 gently	 applying	 force	 to	 the	 fiber	 to	 encourage	 it	 to	 terminate	 where	 necessary.	
Using	 Loctite	 brand	 superglue	 (blue	 cap)	 the	 dental	 cement	 cap	was	 fixed	 to	 the	 skull	 of	 the	
mouse.	The	 incision	was	then	closed	using	suture	and	the	animals	were	placed	 into	cages	and	
individually	housed.	Animals	were	monitored	for	paralysis	or	complications	from	the	surgery	for	
2-3	 hours	 and	 then	 returned	 to	 the	 animal	 facility.	 Animals	 that	 were	 paralyzed	 were	
euthanized.	Prior	to	testing	animals	were	attached	to	a	laser	diode	light	source	to	determine	if	
the	 implants	 were	 successfully	 (hit)	 or	 incorrectly	 placed	 (miss).	 Roughly	 <20%	 of	 animals	
received	 incorrectly	 implanted	 fibers	 or	 required	 euthanasia	 due	 to	 complications	 of	 the	
surgery,	representative	images	can	be	found	in	Figure	3.1.		
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Animals	 were	 allowed	 5-7	 days	 to	 recover	 prior	 to	 verification	 of	 implant	 as	 well	 as	
experimental	procedures.	At	least	one	day	prior	to	behavioral	testing	animals	were	attached	to	
the	 laser	 and	 allowed	 30	 minutes	 to	 acclimate	 to	 being	 attached	 to	 the	 fiber.	 This	 was	
performed	 prior	 to	 verification	 of	 proper	 placement	 of	 the	 implants.	 Proper	 placement	 was	
determined	by	verifiable	light	transmitted	through	the	back	of	the	animal	in	the	lumbar	region	
of	 the	 spinal	 cord,	 see	 Figure	 3.1	 for	 correct	 vs	 incorrect	 implant	 of	 fiber.	 Animals	 with	
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incorrectly	implanted	fibers	were	used	as	offsite	controls	as	the	animals	did	not	appear	to	find	
the	misplaced	fiber	aversive,	painful	or	stressful.	
Estimates	made	 by	 Bonin	 et	 al.	 2016	 place	 light	 penetration	 to	 a	 rough	maximum	 of	
100-200	micrometers	through	spinal	cord	myelin,	indicating	that	light	penetration	is	limited	and	
likely	not	possible	to	deep	lamina	of	the	spinal	cord.	Cells	beyond	the	reach	of	this	light	are	also	
protected	which	allows	for	specific	illumination	of	cells	shallow	into	the	spinal	cord	dorsal	horn. 
 
3.2.6.	Behavioral	Assays	and	Observations 
	 Quantification	 of	 flinching,	 guarding,	 limb	 use	 behaviors.	 Quantification	 of	 altered	
behavior	due	to	the	development	of	CIBP	was	assessed	as	previously	described	(Honore,	Rogers	
et	 al.	 2000).	Mice	were	 allowed	 to	 acclimate	 to	 a	 small	 pan	empty	of	 bedding	 for	 at	 least	 15	
minutes	prior	to	observation	of	behavior.	Mice	were	then	observed	for	2	minutes	and	the	total	
number	 of	 flinching	 bouts	 and	 time	 spent	 guarding	 was	 assessed.	 Some	 mice	 were	 also	
observed	 via	 video	 camera	 set	 to	 record	 from	 underneath	 them	 in	 clear	 box,	 and	 total	 time	
spent	 guarding	 the	 cancer-afflicted	hind	 limb	was	measured.	 Limb	use	behavior	was	 assessed	
over	a	2-minute	time	frame	and	rated	by	the	following	scale.	4,	normal	limb	use,	3,	limping	with	
less	use	of	the	cancer	afflicted	limb,	2,	limping	and	guarding	of	the	impaired	limb,	1,	partial	non-
use	of	the	hind	limb,	and	0,	complete	lack	of	use	(dragging)	of	the	hind	limb.		
Von-frey	assessment	of	 tactile	hypersensitivity.	Development	of	 tactile	hypersensitivity	
following	 implantation	 of	 LLC	 cells	 in	 to	 the	 femur	 of	 mice	 was	 assessed	 using	 the	 up-down	
method	as	previously	described	 (Chaplan,	Bach	et	al.	 1994,	Honore,	Rogers	et	al.	 2000).	Mice	
were	 allowed	 to	 acclimate	 to	 small	 elevated	 chambers	with	mesh	 flooring	 for	 30-60	minutes	
prior	to	testing.	Testing	was	conducted	using	the	calibrated	von	frey	filaments:	2.44,	2.83,	3.22,	
3.61,	4.08,	4.31,	4.56,	and	beginning	with	filament	3.61.	A	maximal	threshold	obtained	from	lack	
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of	a	response	from	the	4.56	filament	was	recorded	as	4	grams,	and	a	minimal	response	with	a	
positive	response	from	the	2.44	filament	was	recorded	as	0.04	grams.		
	Quantification	of	rearing	behaviors.	Similar	to	previously	described	(Guedon,	Longo	et	
al.	 2016),	 mice	 were	 placed	 into	 a	 clear	 bottom	 plastic	 bin	 and	 recorded	 for	 either	 5	 or	 30	
minutes	as	described	 in	each	experimental	paradigm.	Total	number	of	times	mice	placed	their	
full	weight	on	their	hind	limbs	was	totaled,	this	simultaneously	occurred	when	animals	removed	
all	weight	from	their	forepaws.		
Mustard	oil	(AITC)	induced	nocifensive	behaviors	in	animals	with	virally	delivered	ArchT.	
Previous	 reports	 have	 demonstrated	 the	 efficacy	 of	 AITC	 to	 induce	 robust,	 but	 short	 lived	
nocifensive	 behaviors	 mediated	 by	 activation	 of	 the	 TRPA1	 channel	 (Eid,	 Crown	 et	 al.	 2008,	
Okun,	Liu	et	al.	2012).	Due	to	the	overlap	of	TRPA1	RNA	expression	with	Nav1.8	and	MrgD	RNA	
expression	(Figure	3.2),	we	chose	to	use	this	robust	behavior	to	assess	whether	our	optogenetic	
approach	could	activate	ArchT	in	Nav1.8	or	MrgD	fibers	and	block	nocifensive	behaviors,	prior	to	
use	 in	our	CIBP	model.	Wildtype	animals	that	did	not	have	fiber	 implants	were	restrained	and	
received	either	an	injection	of	20	microliters	of	30%	DMSO,	or	1%	AITC	dissolved	in	30%	DMSO	
into	the	plantar	surface	of	their	hind	paw.	Mice	with	fiber	optic	implants	were	first	handled	and	
restrained	 (scruffed)	 and	 attached	 to	 the	brass	 collar	 to	 connect	 the	 laser	 source	 to	 the	 fiber	
implant	attached	to	the	mouse’s	head.	Mice	were	then	allowed	a	15	to	30	minute	habituation	
period	in	their	home	cages	before	proceeding	with	testing.	Most	animals	immediately	returned	
to	normal	mouse	behavior	within	their	home	cages,	 i.e.	grooming,	sifting	through	bedding	and	
locomotion	behavior.	Immediately	prior	to	injection	of	AITC,	lasers	were	activated	at	200mA	on	
continuous	 wave	 for	 constant	 delivery	 of	 light	 to	 the	 animal	 during	 injection	 and	 the	 5	 min	
observation	period.	These	mice	then	received	either	an	injection	of	20uL	of	30%	DMSO,	or	1%	
AITC	dissolved	in	30%	DMSO	into	the	plantar	surface	of	their	hind	paw.	Following	injections	of	
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either	vehicle	or	AITC	animals	were	immediately	placed	into	a	plastic	chamber	with	a	camera	set	
up	beneath	to	record	time	spent	licking	and	flinching	bouts	for	5	minutes.		
	
Locomotor	 assay	 chamber	 assessment	 of	 behaviors.	 Work	 previously	 published	 by	
Majuta	 et	 al.	 assessed	 the	 effects	 CIBP	 on	 distance	 travelled	 in	 animals	 with	 cancer	 cells	
implanted	 into	 their	 femurs.	 Animals	 with	 cancer	 were	 shown	 to	 have	 reduced	 movement	
simultaneous	with	disease	progression	(Majuta,	Guedon	et	al.	2017).	Behaviors	were	analyzed	
as	previously	reported	(Lowery,	Raymond	et	al.	2011).	Animals	were	placed	into	a	10	by	10	inch	
plastic	 chamber	 (Coulbourn	 Instruments,	 Allentown,	 PA)	 and	 data	was	 acquired	 and	 reported	
using	 TruScan	 software	 (Coulbourn	 Instruments,	 Allentown,	 PA).	 Animal	 movements	 were	
Taken	 from	Usoskin et	al.	2016
Figure	3.2.	Potential	Overlap	in	the	Mrgprd	(MrgD)	and	Trpa1	(TRPA1)	Expressing	Cells	in	the	
DRG.	Single	Cell	 RNAseq	demonstrating	subpopulations	of	sensory	 fibers.	Colored	 table	 taken	
from	 Usoskin	 et	 al.	 2015.	 Data	 mined	 from	 Linnarsson	 Lab	 website,	
(http://linnarssonlab.org/drg/).	Figure	adapted	with	color	scheme	by	Joshua	Havelin	for	ease	of	
visualization. 
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tracked	by	a	set	of	infrared	beams	at	the	floor	level,	as	well	as	a	set	of	infrared	beams	2	inches	
above	 to	 detect	 rearing	 behaviors.	 Total	 distance	 traveled,	 time	 spent	 in	 the	 center	 of	 the	
chamber,	at	the	edges	of	the	chamber	and	number	of	center	entries	was	recorded.	Breaking	the	
vertical	 infrared	beams	allowed	 for	 quantification	of	 time	 spent	 rearing	 and	number	of	 rears.	
Distance	traveled	 is	reported	 in	centimeters.	Data	was	collected	and	summed	across	1-minute	
bins.	 Representative	 time	 course	 data	 is	 displayed	 as	 sum	 values	 across	 5-minute	 bins	
throughout	 the	 30-minute	 experiment,	 and	 area	 under	 the	 curve	 was	 calculated	 using	 the	
trapezoidal	Riemann	sum	between	bins.		
Conditioned	 place	 preference	 to	 pain	 relief	 or	 aversion	 to	 hindpaw	 movement.	 	 A	
number	of	previous	publications	have	demonstrated	the	efficacy	of	conditioning	animals	to	pain	
relief	(King,	Vera-Portocarrero	et	al.	2009,	Remeniuk,	Sukhtankar	et	al.	2015,	Havelin,	Imbert	et	
al.	2017).	
Using	a	 conditioned	place	preference	 (CPP)	paradigm	animals	undergo	a	3-day	 testing	
procedure.	 The	 basic	 single	 trial	 CPP	 protocol	 occurs	 within	 a	 three-chambered	 box	 as	
previously	described	 (Havelin,	 Imbert	 et	 al.	 2017).	 The	 three	 chambers	 are	distinct	 from	each	
other	 in	 texture	 of	 flooring,	 visual	 cues	 (shades	 of	 construction	 paper,	 and	 black	 and	 white	
stripes),	and	scent	(pink	lemonade	vs	vanilla	chap	stick),	a	representative	image	can	be	found	in	
Figure	 3.3.	 On	 day	 1	 of	 testing	 animals	 are	 allowed	 to	 freely	 explore	 the	 box	 for	 15	minutes	
while	their	movements	and	time	spent	in	each	chamber	are	tracked	and	quantified	by	ANYMAZE	
software	 (Stoelting,	 Wood	 Dale,	 IL).	 Time	 spent	 in	 each	 of	 the	 unique	 pairing	 chambers	 is	
counter	 balanced	 to	 ensure	 no	 unintentional	 bias	 is	 introduced	 into	 the	 experiment.	 The	
following	day	animals	are	placed	into	the	AM	chamber	with	exposure	to	a	control	stimulus	for	
30-minutes.	 In	 the	 case	 of	 evaluating	 a	 drug	 this	 chamber	 would	 be	 paired	with	 vehicle	 (i.e.	
saline),	or	hooked	up	to	the	lasers	without	having	the	laser	turned	on,	or	undergo	handling	with	
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explicit	 attention	 to	 cause	 no	 movement	 of	 the	 hind	 paw.	 Animals	 are	 then	 removed	 and	
returned	to	their	home	cages	for	4	hours.	Following	the	intermission	period,	animals	are	placed	
into	the	PM	chamber	with	the	experimental	stimulus	for	30-minutes.	In	the	case	of	evaluating	a	
drug,	this	chamber	would	be	paired	with	drug	(i.e.	the	MOR	agonist	DAMGO),	or	hooked	up	to	
the	lasers	with	the	laser	turned	on,	or	a	2-minute	period	of	movement	of	the	hind	paw.	Animals	
are	 then	 removed	 and	 returned	 to	 the	 animal	 facility.	 The	 following	 day	 animals	 are	 again	
allowed	to	 freely	explore	 the	CPP	chambers	 for	15	minutes	and	their	 time	 in	each	chamber	 is	
quantified	 by	 ANYMAZE	 software.	 Results	 are	 reported	 as	 time	 spent	 in	 each	 chamber	 pre-
conditioning	 and	 post-conditioning,	 an	 increase	 time	 spent	 in	 either	 chamber	 pre	 vs	 post	
considered	CPP	to	that	chamber,	whereas	a	decrease	is	CPA.	In	addition,	“different	scores”	are	
calculated	 by	 subtracting	 time	 spent	 in	 the	 afternoon	 chamber	 pre-conditioning	 from	 post-
conditioning,	a	positive	number	indicates	CPP	to	the	pairing	where	as	a	negative	value	indicates	
CPA,	this	measurement	is	used	to	compare	whether	treatment	effects	differed	between	groups.		
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Pharmacological	 intervention	 for	 CPP.	Mice	 were	 briefly	 anesthetized	 with	 isoflurane	
~2%	and	their	tails	were	warmed	in	42	C°	water.	Mice	were	then	quickly	injected	i.v.	with	either	
normal	saline	for	AM	conditioning	or	during	PM	conditioning	DAMGO	or	Deltorphin	II	to	deliver	
a	 dose	 of	 3	mg/kg.	 Solutions	were	 injected	 at	 10mL/kg,	 eg.	 a	 20-gram	 (0.02kg)	mouse	would	
receive	0.2	mL	of	injection.	Mice	were	then	allowed	to	wake	from	light	anesthesia	before	being	
placed	into	their	respective	pairing	chambers.	
Laser	 activation	 paradigm	 for	 CPP.	Mice	 were	 handled	 and	 restrained	 (scruffed)	 and	
attached	 to	 the	 brass	 collar	 to	 connect	 the	 laser	 source	 to	 the	 fiber	 implant	 attached	 to	 the	
mouse’s	 head.	Mice	 were	 then	 allowed	 a	 15	 to	 30	minute	 habituation	 period	 in	 their	 home	
cages	 before	 proceeding	 with	 conditioning.	 Most	 animals	 immediately	 returned	 to	 normal	
mouse	behavior	within	their	home	cages,	i.e.	grooming,	sifting	through	bedding	and	locomotion	
behavior.	Animals	were	then	placed	into	their	respective	conditioning	chambers	and	ANYMAZE	
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software	was	activated.	 In	the	AM	conditioning	phase	the	 lasers	remained	off	and	animals	did	
not	 receive	 any	 light	 to	 their	 spinal	 cord	 dorsal	 horn.	 During	 the	 PM	 conditioning	 phase	
ANYMAZE	 software	 was	 set	 to	 deliver	 a	 continuous	 200	 mA	 pulse	 of	 green	 light	 (520nm	
wavelength)	to	the	mouse	for	2	minutes,	then	the	laser	would	turn	off	for	1	minute,	and	then	
the	laser	would	turn	on	at	200	mA	output.	This	cycle	continues	for	the	entirety	of	the	30-minute	
conditioning	 phase.	 After	 each	 session	 the	 animals	 were	 then	 removed	 and	 restrained	 and	
detached	from	the	brass	collar	and	laser	source	and	returned	to	their	home	cages.	
Total	distance	travelled	as	assessed	by	ANYMAZE	software.	Animals	were	placed	into	a	
clear	 bottom	 plastic	 bin	 and	 recorded	 for	 varying	 amounts	 of	 time	 while	 being	 tracked	 by	
calibrated	ANYMAZE	software.	Total	distance	traveled	is	reported	in	meters	with	this	analysis.	
Radiographic	 analysis	 of	 cancer-induced	 bone	 remodeling	 for	 inclusion/exclusion	 of	
animals	in	behavioral	studies.	X-ray	radiographs	were	taken	at	the	completion	of	all	behavioral	
studies	(except	when	the	x-ray	machine	was	not	functioning).	A	qualitative	scoring	system	was	
used	 to	 score	 the	 level	 of	 bone	 remodeling	 induced	 by	 tumor	 growth	 similar	 to	 previously	
described	 (Edwards,	 Havelin	 et	 al.	 2018).	 Digital	 radiographs	 were	 taken	 using	 a	
MINXRAYHF100/30	X-ray	source	(MinXray,	 Inc	Northbrook,	 IL),	at	an	exposure	setting	of	40kV,	
1.5	 mAs	 and	 0.05	 seconds	 captured	 on	 a	 Wireless	 Digital	 Flat	 Panel	 Detector	 (Model	
Mars1417V-TSI,	 iRay	Technology	Co.	Shanghai,	China)	and	analyzed	with	Opal	Software	(20/20	
Imaging,	Konica	Minolta	Healthcare	Wayne,	NJ)	at	the	completion	of	all	behavioral	testing.	Bone	
loss	was	 rated	by	 a	 blinded	experimenter	 according	 to	 a	 3-point	 scale.	 0	 	 =	 being	 a	 “normal”	
bone,	 consistent	 with	 the	 contralateral	 leg,	 1	 =	 osteolytic	 or	 osteoblastic	 bone	 remodeling	
compared	 to	 the	 contralateral	 bone,	 and	 a	 2	 =	 unicortical	 or	 bicortical	 bone	 fracture.	
Representative	 images	 can	be	 found	 in	 Figure	 3.4.	Animals	with	 radiograph	measurements	 of	
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“0”	 that	had	undergone	cancer	cell	 implantation	were	 removed	 from	the	study	due	 to	 lack	of	
apparent	cancer-induced	bone	remodeling.	
	
3.2.7.	 Tissue	 Collection	 and	 Immunohistochemical	 Staining	 for	 Verification	 of	MrgD-cre-ER2	
mouse	line	
	 Verification	of	MrgD-Cre	line	of	mice	and	induction	protocol	was	determined	by	IHC	in	
DRG	and	spinal	cord	 tissue	using	 the	 following	protocols.	Mice	were	deeply	anesthetized	with	
Beuthanasia-D	(Henry	Schein	Animal	Health)	and	underwent	intracardiac	perfusion	through	the	
left	ventricle	with	50mL	of	ice	cold	PBS	followed	by	50mL	of	ice	cold	4%	PFA	containing	PBS,	pH	
7.4.	The	L2–L4	spinal	cord	segments	were	 immediately	dissected	out	and	post	fixed	 in	4%	PFA	
overnight.	 L2-L4	 DRG	 were	 also	 immediately	 dissected	 and	 post	 fixed	 in	 4%	 PFA	 overnight.	
Tissue	was	then	moved	into	a	30%	sucrose	solution	at	4°C	for	12–24	h	for	cryoprotection.	Spinal	
cords	and	DRG	were	embedded	in	optimal	cutting	temperature	(OCT)	medium	(VWR)	and	frozen	
in	 a	 70%	ethanol	 bath	 at	 -80°C.	 Spinal	 cord	 sections	were	 cut	 on	 a	 cryostat	 (Leica)	 at	 30	um,	
whereas	 DRG	 sections	 were	 cut	 at	 12	 um,	 collected	 onto	 positively	 charged	 slides	 (Azer	
Scientific),	and	allowed	to	dry	before	storage	at	-20°C.	
Staining	protocols	used	to	visualize	CGRP	and	IB4	were	performed	by	the	UNE	Histology	
Core.	 Sections	were	 rinsed	3	 times	 for	10	minutes	with	PBS	 containing	0.1%	 triton	 (PBSTx)	 to	
remove	 OCT,	 then	 non-specific	 binding	 proteins	 were	 blocked	 by	 30	min	 incubation	with	 5%	
normal	 donkey	 serum	 (EMD	Millipore,	 Billerica,	 MA)	 in	 0.1%	 PBS-Tx	 for	 15-60	 minutes.	 This	
blocking	 solution	was	also	 the	antibody	diluent.	 Primary	antibodies	 and	Alexa	647-conjugated	
IB4	were	incubated	overnight	at	4°C	as	follows:	IB4-AF647	1:750	(1.3ug/mL,	Invitrogen	I32450);	
rabbit	 anti-CGRP	 1:2000	 (ImmunoStar	 Cat#	 24112	 RRID:AB_572217).	 Sections	 were	 rinsed	 3	
times	with	PBS-Tx	and	incubated	in	the	dark	for	1	hour	at	room	temperature	with	appropriate	
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cross-adsorbed	 secondary	 antibodies:	 Donkey	 anti-rabbit	 Alexa	 Fluor	 647	 1:1000	 (2	 ug/mL,	
ab150063,	 Abcam,	 Cambridge,	 MA).	 Sections	 were	 rinsed	 with	 PBS-Tx	 3	 times	 and	 mounted	
with	DAPI-containing	Fluoroshield	(ab104139,	Abcam).	Representative	images	were	taken	using	
a	wide	 field	epifluorescence	Leica	DM2500	microscope,	using	either	5x	or	10x	objective,	using	
suitable	 filters	 for	 DAPI,	 GFP,	 tdtomato,	 and	 Alexa	 Fluor	 647.	 Tissue	 was	 imaged	 using	 Leica	
Application	 software	 with	 a	 Leica	 DFC365	 FX	 16-bit	 CCD	 camera,	 gain	 and	 exposure	 settings	
varied	between	channels	and	tissue	samples.	
	
3.2.8.	Statistical	Analysis	and	Graphing	
	 Data	was	transformed	from	raw	data	gathered	either	via	ANYMAZE,	Truscan,	or	by	hand	
to	grouped	data	using	Microsoft	Excel.	Data	was	 then	graphed	and	statistically	analyzed	using	
Graphpad	Prism	software.	Results	from	quantification	of	flinching,	guarding,	limb	use	behaviors	
were	analyzed	with	a	2-way	ANOVA	and	a	Tukey	post	hoc	to	compare	between	groups	at	each	
time	point.	Results	from	Von-frey	assessment	of	tactile	hypersensitivity	were	analyzed	with	a	2-
way	ANOVA	and	a	Tukey	post	hoc	to	compare	between	groups	at	each	time	point.	Results	from	
quantification	of	rearing	behaviors	were	analyzed	with	a	2-way	ANOVA	and	a	Sidak	post	hoc	to	
compare	between	 groups	 at	 each	 time	point,	 and	 a	 Tukey	post-hoc	 to	 compare	within	 group	
differences.	Data	 from	mustard	oil	 (AITC)	 induced	nocifensive	behaviors	 in	animals	with	virally	
delivered	ArchT	were	not	 statistically	 analyzed	due	 to	 the	 small	 n	 size	of	 the	groups.	 	 Results	
from	LMA	chamber	analysis	of	cancer-induced	change	in	behaviors	were	analyzed	with	a	2-way	
ANOVA	 and	 a	 Tukey	 post	 hoc	 to	 compare	 between	 groups.	 Pre-conditioning	 versus	 post-
conditioning	time	spent	in	chamber	in	experiments	testing	conditioned	place	preference	to	pain	
relief	or	 aversion	 to	hind	paw	movement	were	analyzed	using	a	within	 subject	2-way	ANOVA	
with	 Sidak’s	 post	 hoc	 test	 comparing	 pre	 vs	 post	 conditioning	 values	 within	 each	 group.	
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Difference	scores	between	groups	were	analyzed	with	either	an	unpaired	student	T-test,	or	a	1-
way	 ANOVA	 with	 Uncorrected	 Fisher’s	 Least	 Squared	 Difference	 post	 hoc.	 Groups	 were	
considered	 statistically	 significantly	 different	 when	 p	 values	 less	 than	 0.05.	 Outliers	 were	
calculated	using	Graphpad	Prism	Grubb’s	Outlier	test,	exclusion	criteria	set	at	alpha	<	0.05.	
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3.3.	Results	
3.3.1.	Classical	Cancer-Induced	Measures	of	Pain.		
Consistent	with	previous	 reports,	both	male	and	 female	mice	 that	underwent	 LLC	 cell	
injection	 into	 the	 femur	 underwent	 dramatic	 bone	 remodeling	 and	 loss	 (Figure	 3.4)	 that	was	
accompanied	by	the	development	of	tactile	hypersensitivity,	decreased	limb	use	and	presented	
with	 increased	 flinching	 bouts	 (Figure	 3.5).	 Female	 and	male	 cancer	 bearing	 animals	 showed	
elevated	 flinching	at	Day	12	post	cancer	cell	 implantation	 into	 the	 femur	compared	 to	 female	
sham	animals	(p<	0.0001,	n	size	=	12	female	cancer,	11	female	sham,	21	male	cancer).		Female	
and	male	cancer	treated	animals	displayed	decreased	 levels	of	 limb	use	at	Day	12	post	cancer	
cell	 implantation	compared	 to	 female	sham	animals	 (p<	0.0001,	n	size	=	12	 female	cancer,	11	
female	 sham,	 21	 male	 cancer).	 	 Female	 and	 male	 cancer	 animals	 demonstrated	 decreased	
tactile	 withdrawal	 thresholds	 compared	 to	 female	 shams	 at	 Days	 7	 and	 12	 post	 cancer	 cell	
implantation	 (p<	 0.0001,	 n	 size	 =	 12	 female	 cancer,	 11	 female	 sham,	 21	 male	 cancer).	 In	 a	
separate	set	of	experiments	animals	were	observed	 for	changes	 in	 time	spent	guarding	of	 the	
cancer-afflicted	hind	limb	and	rearing	activity	displayed	in	Figure	3.6.	
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	A	 separate	 cohort,	 female	 mice	 were	 observed	 for	 guarding	 and	 rearing	 behaviors.		
Consistent	with	previous	reports	at	Days	11	and	12	post	cancer	cell	implantation	female	animals	
112	
	
that	 received	 cancer	 cell	 implantation	 into	 the	 femur	 spent	 more	 time	 guarding	 the	 cancer	
afflicted	hind	 limb	compared	to	female	sham	controls	 (p<	0.05	and	p<0.001,	n	size	=	6	 female	
cancer,	 6	 female	 sham).	 Female	 cancer	 animals	 showed	 a	 decreased	 in	 rearing	 compared	 to	
female	shams	at	Days	11	and	12	post	cancer	cell	implant	(p	<	0.05	and	p	<	0.0001),	and	cancer	
treated	animals	showed	a	decrease	compared	to	their	own	baseline	values	11	and	12	days	post	
cancer	cell	implant	(p	<	0.001,	p	<	0.0001),	sham	treated	animals	showed	a	significant	decrease	
from	their	baseline	values	at	day	12,	likely	due	to	repetitive	exposure	to	observation	chambers	
(p	<	0.05,	n	size	=	8	female	cancer,	8	female	sham).	Combined	these	results	indicate	that	in	our	
hands	this	surgical	intervention	produces	CIBP	results	similar	to	other	groups	(Guedon,	Longo	et	
al.	2016).	
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3.3.2.	DAMGO	Induced	Pain	Relief,	and	Failure	or	Deltorphin	II	to	Relieve	Ongoing	Pain.						
		 Administration	of	the	peptidergic	MOR	agonist	DAMGO	at	a	dose	of	3	mg/kg	in	cancer	
bearing	but	not	sham	treated	animals	 resulted	 in	an	 increase	 in	 time	spent	 in	 the	drug	paired	
chamber	 post-conditioning,	 indicating	 a	 relief	 of	 ongoing	 pain	 in	 the	 cancer	 bearing	 animals	
(Figure	 3.7A	 **p	 <	 0.01,	 n	 size	 =	 10	 sham,	 12	 cancer	 animals).	 A	 nearly	 significant	 difference	
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between	 groups	 when	 comparing	 “different	 scores”	 was	 detected	 indicating	 a	 difference	
between	 groups	 in	 response	 to	 being	 treated	 with	 3	mg/kg	 DAMGO	 (Figure	 3.7B,	 one	 tailed	
unpaired	 t-test,	 p	 =	 0.058,	 n	 size	 =	 10	 sham,	 12	 cancer	 animals).	 Neither	 sham	 nor	 cancer	
treated	 animals	 demonstrated	 an	 increase	 in	 time	 spent	 in	 the	 3	mg/kg	 Deltorphin	 II	 paired	
chamber	post-conditioning,	 indicating	at	 this	dose	Deltorphin	 II	 fails	 to	alleviate	ongoing	pain,	
and	no	difference	was	detected	between	groups	when	comparing	“different	scores”	 in	Figures	
3.7C	and	3.7D	(no	significance,	n	=	12	sham,	12	cancer	animals).		
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3.3.3.	Evaluation	of	Tdtomato	Expression	in	MrgDCreER2	Mouse	Line.		
Visual	 inspection	of	 immunohistochemical	 staining	 for	CGRP	and	 IB4	 labeling	of	 spinal	
cord	 slices	 and	 cells	within	 L4	DRG	 revealed	no	notable	 overlap	 of	 CGRP	 and	MrgD-tdtomato	
signal	in	either	tissue	as	seen	in	Figures	3.8G	and	Figure	3.8H.	Whereas	IB4	labeling	with	the	IB4-
AF647	conjugate	and	MrgD-tdtomato	positive	signals	showed	significant	overlap	 in	both	spinal	
cord	slices	and	cell	bodies	of	L4	DRG	(Figure	3.8C	and	Figure	3.8D).	This	labeling	shows	that	the	
tamoxifen	protocol	used	was	successful	 in	activation	of	cre	 in	MrgD	and	 IB4-binding	cells,	but	
not	CGRP	positive	 cells.	 Images	displayed	 in	 Figure	 3.8	 have	been	pseudo	 colored	 for	 ease	of	
consistency	within	this	dissertation.	Figure	3.8	panels,	A,	C,	D,	E,	G,	and	H	tdtomato	is	displayed	
in	green,	panel	B,	C	and	D	IB4-AF647	signal	is	blue,	panel	F,	G	and	H	CGRP	signal	from	Secondary	
AF647	 is	 red.	
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3.3.4.	Evaluation	of	Delivery	and	Activation	of	Undiluted	AAV2/8	ArchT	Viral	Vector	in	MrgD-
tdtomato	Positive	Cells.		
Delivery	 of	 the	 viral	 vector	 containing	 the	 ArchT-eGFP	 cassette	 at	 postnatal	 day	 5	
resulted	 in	 robust	 expression	 of	 ArchT-eGFP	 in	MrgD-tdtomato	 positive	 spinal	 cord	 slices	 and	
cells	within	the	L4	DRG.	Figure	3.9	displays	a	representative	 image	of	 lumbar	spinal	cord	slices	
and	L4	DRG	where	MrgD-tdomato	signal	overlaps	robustly	with	virally	delivered	ArchT-eGFP.	In	
this	 image	 greater	 than	 ~70%	 of	 the	 cells	 expressing	 tdtomato	 also	 express	 ArchT-eGFP,	 and	
signal	 in	 the	 spinal	 cord	 dorsal	 horn	 show	 robust	 overlap.	 These	 results	 were	 a	 large	
improvement	from	previous	attempts	to	administer	a	1:10	dilution	of	the	stock	viral	vector	(data	
not	shown).	In	Figure	3.9	tdtomato	is	displayed	in	red,	ArchT-eGFP	fusion	protein	is	visualized	in	
green.	
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3.3.5.	Fiber	Optic	Implant	Quality	Assurance	and	Surgical	Implant	Challenges.		
Following	hand	polishing	of	each	individual	fiber	optic	 implant,	fibers	were	individually	
tested	 for	 adequate	 light	 transmission	 compared	 to	 raw	output	 from	 the	 laser	patch	 cord.	As	
seen	 in	 Figure	 3.1,	 similar	 output	 efficiencies,	 roughly	 50-80%,	 were	measured	 at	 2	 separate	
power	outputs	 from	the	 laser	source	 (30mA	and	60mA)	 indicating	no	change	 in	 light	emission	
efficiency	 between	 the	 two	 laser	 power	 settings.	 Relative	 distribution	 of	 power	 efficiency	
between	fibers	indicated	consistent	results	from	production	of	implants.	Measured	efficiencies	
were	 also	 consistent	 with	 reports	 from	 collaborators	 at	 Laval	 University	 from	 Dr.	 Yves	
DeKonick’s	 lab,	where	 I	was	 trained.	Of	note,	 later	batches	of	 fiber	production,	 such	as	 those	
reported	 in	 Figure	 3.12,	 had	 reduced	 transmission	 efficiency,	 we	 believe	 as	 a	 result	 of	
production	 differences	 in	 lots	 of	 fiber	 optics.	 A	 representative	 image	 of	 challenges	 resulting	
from	 implanting	 the	 fiber	 optic	 using	 previously	 described	 surgical	 procedures	 is	 displayed	 in	
Figure	 3.1.	 After	 adequate	 practice	 it	 was	 estimated	 that	 <	 ~20%	 of	 surgeries	 resulted	 in	
incorrectly	 placed	 fiber	 implants,	 whereas	 paralysis	 of	 animals	 following	 surgery	 occurred	
independent	of	this.	
	
	 	
3.3.6.	Successful	Optogenetic	Blockade	of	AITC	 Induced	Nocifensive	Behaviors	 in	Nav1.8	and	
MrgD	Expressing	Fibers.		
Injection	 of	 a	 1%	 AITC	 solution	 into	 the	 hind	 paw	 of	mice	 induced	 robust	 licking	 and	
flinching	 behaviors	 in	 wildtype	 mice	 with	 no	 fiber	 optic	 implant,	 as	 well	 as	 animals	 with	
incorrectly	 implanted	fiber	optic	 implants	expressing	virally	delivered	ArchT	in	Nav1.8	or	MrgD	
expressing	 cells	 displayed	 in	 Figure	 3.10.	 Animals	 expressing	 virally	 delivered	 ArchT	 in	 either	
Nav1.8	 or	MrgD	 expressing	 cells	 with	 correctly	 placed	 fiber	 optic	 implants	 displayed	 a	 nearly	
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complete	 blockade	 of	 nocifensive	 behaviors.	 Although	 not	 statistically	 analyzed	 this	 data	
demonstrates	 that	 not	 only	 did	 our	 optogenetic	 approach	 to	 silence	 nociceptive	 fibers	 at	 the	
level	 of	 the	 spinal	 cord	 dorsal	 horn	 prove	 effective,	 but	 silencing	 either	 Nav1.8	 or	 MrgD	
expressing	fibers	is	sufficient	to	block	AITC	induced	nociceptive	behaviors	(n	=	6	wildtype	vehicle	
treated	animals	with	no	fiber,	8	wildtype	1%		AITC	treated	animals	with	no	fiber,	2	Nav1.8	virally	
delivered	ArchT	animals	with	incorrectly	implanted	fiber	optics,	2	Nav1.8	virally	delivered	ArchT	
animals	 with	 correctly	 implanted	 fiber	 optics,	 3	 MrgD	 virally	 delivered	 ArchT	 animals	 with	
incorrectly	 implanted	 fiber	 optics,	 3	 MrgD	 virally	 delivered	 ArchT	 animals	 with	 correctly	
implanted	fiber	optics).	
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3.3.7.	ArchT	Expression	in	Animals	from	Nav1.8	and	MrgD	cre	Mouse	Lines	Crossed	with	Ai40D	
ArchT	Transgenic	Animals.	
Representative	images	of	spinal	cord	dorsal	horn	near	the	lumbar	section	of	the	spinal	
cord	 in	Nav1.8	and	MrgD	animals	crossed	with	the	transgenic	ArchT	mice	revealed	differential	
expression	 patterns	 of	 ArchT-eGFP	 displayed	 in	 Figure	 3.11.	 Microscopic	 evaluation	 of	 tissue	
taken	from	either	Nav1.8-ArchT	or	MrgD-ArchT	animals	demonstrated	robust	eGFP	expression	
in	 expected	 lamina	 of	 the	 spinal	 cord	 dorsal	 horn	 and	 robust	 expression	 of	 eGFP	 in	 L4	 DRG.	
Incomplete	activation	of	Cre	in	an	MrgD-ArchT	animal	resulted	in	tissue	found	in	representative	
images	 in	 panels	G	 and	H.	 This	was	 relatively	 uncommon	 in	 animals	 and	 if	 detected,	 animals	
were	removed	from	behavioral	studies.	DRG	tissue	was	not	used	for	ArchT-eGFP	verification	as	
MrgD	positive	cells	are	likely	not	homogenously	distributed	throughout	the	DRG	and	attempting	
to	use	IHC	or	staining	methods	to	verify	percent	activation	of	IB4	to	MrgD	cells	would	have	been	
labor	 intensive	 and	 ultimately	 inconclusive	 as	 no	 arbitrary	 percentage	 of	 cells	 required	 to	 be	
activated	was	 established.	 Additionally,	 as	 light	was	 being	 delivered	 to	 the	 spinal	 cord	 dorsal	
horn,	 spinal	 cord	 tissue	 was	 more	 relevant	 to	 verify	 ArchT-eGFP	 expression.	 ArchT-eGFP	 is	
displayed	in	green.	
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3.3.8.	 ArchT	 Induced	 Silencing	 of	 Nav1.8	 fibers	 Relieves	 Cancer-induced	 Ongoing	 Pain,	 and	
ArchT	Induced	Silencing	of	MrgD	Fibers	in	Animals	with	Cancer	Induces	CPP.	
Activation	of	ArchT	in	Nav1.8-ArchT	animals	with	cancer	resulted	in	an	increase	in	time	
spent	 in	the	 laser	paired	chamber	post-conditioning,	whereas	no	 increase	 in	time	spent	 in	the	
laser	paired	chamber	was	observed	 in	Nav1.8-ArchT	 sham	 treated	animals	displayed	 in	Figure	
3.12A	 (p	 <	 0.01,	 n	 =	 7	 Nav1.8-ArchT	 sham	 treated	 animals,	 9	 Nav1.8-ArchT	 cancer	 treated	
animals).	MrgD-ArchT	animals	that	underwent	cancer	implantation	spent	an	increase	in	time	in	
the	 laser	 paired	 chamber	 post-conditioning,	 indicating	 a	 preference	 to	 the	 chamber	 ArchT	
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induced	 silencing	 of	 MrgD-fibers	 occurred	 in	 (p	 <	 0.01,	 n	 =	 11	 MrgD-ArchT	 cancer	 treated	
animals).	 Analysis	 of	 “different	 scores”	 between	 the	 3	 groups	 of	 animals	 demonstrated	 a	
significant	 difference	 between	 Nav1.8-ArchT	 sham	 treated	 animals	 and	 Nav1.8-ArchT	 cancer	
treated	 and	MrgD-ArchT	 cancer	 treated	 animals,	 Figure	 3.12B	 (p	 <	 0.05,	 n	 =	 7	 Nav1.8-ArchT	
sham	 treated	 animals,	 9	Nav1.8-ArchT	 cancer	 treated	 animals,	 11	MrgD-ArchT	 cancer	 treated	
animals).	 This	 indicates	 cancer	 treated	 animals	 that	 express	 ArchT	 either	 on	 Nav1.8	 or	MrgD	
fibers	 showed	 a	 significant	 preference	 compared	 to	 Nav1.8-ArchT	 sham	 animals.	 A	 lack	 of	
additional	 animals	 restricted	 our	 ability	 to	 add	 and	 compare	 a	 group	 of	 sham	 treated	MrgD-
ArchT	 animals.	 We	 conclude	 that	 silencing	 Nav1.8	 expressing	 fibers	 induce	 CPP	 indicating	
blockade	of	ongoing	pain,	and	the	same	is	likely	true	as	a	result	of	silencing	MrgD	fibers.	Once	
MrgD-Cre-ArchT	 mice	 are	 regenerated,	 we	 will	 rerun	 a	 replication	 that	 includes	 shams	 to	 1)	
provide	a	replication	of	this	novel	and	exciting	finding	and	2)	include	the	appropriate	MrgD-Cre-
ArchT	sham	group	for	publication	purposes.		
	 Comparing	 the	 “difference	 score”	 in	 Nav1.8-ArchT	 animals	 that	 underwent	 sham	
surgery	or	cancer	surgery	and	MrgD-ArchT	cancer	treated	animals	with	the	measured	fiber	optic	
implant	 efficiency	 does	 not	 reveal	 a	 convincing	 linear	 correlation	 between	 an	 animals	
preference	and	 the	amount	of	 light	exposure	 to	 their	 spinal	cord	dorsal	horn	Figure	3.12C	 (R2	
values	 =	 0.11	 in	 Nav1.8-ArchT	 sham	 treated	 animals,	 0.25	 in	 Nav1.8-ArchT	 cancer	 treated	
animals,	 and	 0.06	 in	MrgD-ArchT	 cancer	 treated	 animals).	 This	 indicates	 that	 there	 is	 likely	 a	
threshold	 for	 light-induced	 ArchT	 activation	 required	 to	 silence	 fibers	 resulting	 in	 CPP	 (on-off	
scenario),	rather	than	a	 linear	relation	between	ArchT	activation	and	pain	relief.	We	note	that	
CPP	may	not	 have	 sufficient	 resolution	 to	 detect	 potential	 subtle	 changes	 in	 intensity	 of	 pain	
relief.	
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3.3.9.	 Failure	 to	 Induce	 CPA	 to	 Hind	 Paw	 Movement	 in	 Cancer	 Treated	 Animals,	 and	
Alternative	Behavioral	Measures	Affected	by	Hind	Paw	Movement.		
Movement	of	the	hind	limb	for	2-minutes	failed	to	induce	conditioned	place	aversion	in	
either	sham	or	cancer	treated	mice,	a	finding	that	differs	from	our	published	observations	in	the	
rat	 (Havelin,	 Imbert	 et	 al.	 2017).	 Conditioned	 place	 aversion	 to	 hind	 paw	movement	 failed	 in	
both	male	and	female	mice	that	underwent	cancer	cell	 implantation	in	the	femur	Figure	3.13A	
and	Figure	3.13B	(n	=	13	sham	treated	male	mice,	20	cancer	treated	male	mice,	12	sham	treated	
female	mice,	12	cancer	 treated	 female	mice).	 In	an	effort	 to	measure	alternative	behaviors	 to	
conditioned	 place	 aversion,	 animals	 underwent	 a	 2-minute	 hind	 limb	 movement	 paradigm	
Figure 3.12. ArchT Induced Silencing of Nav1.8 Fibers Causes Relief of Ongoing Pain and ArchT Induced
Silencing of MrgD Fibers in Cancer Animals Results in CPP. In Nav1.8-ArchT animals with cancer activation
of ArchT paired with the PM chamber results in conditioned place preference, but fails to do so in sham
treated Nav1.8-ArchT animals, indicating relief of ongoing pain from the bone. MrgD-ArchT animals with
cancer also demonstrate a conditioned place preference for the PM chamber paired with ArchT activation,
however no sham animals were run limiting the interpretation of these results. A) Both Nav1.8-ArchT and
MrgD-ArchT animals with cancer demonstrated an increase in time spent with the laser paired PM
chamber, ** p < 0.01 pre vs post conditioning. A1) Scatter plots demonstrating individual animals change in
behavior following conditioning paradigm. B) Comparison of “different scores” reveals that both Nav1.8-
ArchT and MrgD-ArchT animals with cancer but not Nav1.8-ArchT sham treated animals developed a
change in time spent in the PM chamber. C) Linear regression analysis of “different score” compared to
measured power output of fiber optic implant reveals no correlation between power output and preference
or aversion to the PM/laser paired conditioning chamber
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followed	 by	measurement	 of	 distance	 traveled	 and	 rearing	 behaviors,	 2	measures	 previously	
demonstrated	 to	 decrease	 in	 animals	 with	 cancer-afflicted	 hind	 limbs	 (Majuta,	 Guedon	 et	 al.	
2017).	 Consistent	 with	 previous	 findings,	 animals	 with	 cancer	 travelled	 and	 reared	 less	 than	
their	 sham	 counter	 parts	 Figure	 3.14	 (p	 <	 0.01	 and	 p	 <	 0.01	 respectively).	 No	 statistically	
significant	 difference	 in	 distance	 travelled	 or	 rearing	 behavior	 was	 observed	 between	 sham	
animals	who	did	not	receive	2-minute	hind	limb	movement	and	those	that	did	(p	>	0.05	and	p	>	
0.05).	Animals	with	cancer	that	received	movement	of	their	cancer-afflicted	hind	limb	travelled	
less	distance	compared	to	cancer	animals	that	did	not	receive	hind	limb	movement,	however	no	
statistical	 difference	 between	 groups	was	 found	 in	 rearing	 behavior	 (p	 <	 0.05).	 These	 results	
indicate	 that	 hind	 limb	 movement	 in	 cancer	 treated	 animals	 but	 not	 sham	 treated	 animals	
causes	a	decrease	in	movement	over	the	45-minute	observation	period	(n	=	5	sham	treated	no	
movement	 animals,	 6	 sham	 treated	 hind	 limb	 movement	 animals,	 5	 cancer	 treated	 no	
movement	animals,	6	cancer	treated	hind	limb	movement	animals).	
	 Other	 behaviors	 that	 were	 monitored	 were	 time	 spent	 and	 distance	 travelled	 in	 the	
margin	 and	 center	 of	 the	 LMA	 chambers,	 as	 well	 as	 number	 of	 center	 entries	 (Figure	 3.15).	
Animals	with	cancer	spent	 less	 time	 in	 the	margin,	while	hind	 limb	movement	 in	animals	with	
cancer	decreased	the	distance	travelled	in	the	margin	Figures	3.15A1	and	Figure	3.15A	(p<	0.05,	
n	=	5	sham	no-movement,	6	sham	movement,	6	cancer	no-movement,	5	cancer	movement	and	
p<	 0.05,	 n	 =	 5	 sham	 no-movement,	 5	 sham	 movement,	 6	 cancer	 no-movement,	 5	 cancer	
movement	respectively).	Tumor	bearing	animals	travelled	less,	spent	less	time	and	entered	the	
center	 of	 the	 LMA	 chambers	 less	 than	 sham	 controls	 Figures	 3.15B,	 3.15B1	 and	 Figure	 3.15C	
respectively	(p	<	0.01;	n	=	6	sham	no-movement,	6	sham	movement,	6	cancer	no-movement,	5	
cancer	 movement;	 p	 <	 0.05	 n	 =	 5	 sham	 no-movement,	 5	 sham	 movement,	 6	 cancer	 no-
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movement,	5	cancer	movement;	and	p	<	0.05	n	=	5	sham	no-movement,	5	sham	movement,	6	
cancer	no-movement,	6	cancer	movement,	respectively).	
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3.4.	Discussion	
	 We	have	developed	a	novel	approach	to	measuring	ongoing	cancer-induced	bone	pain	
and	 demonstrated	 that	 Nav1.8	 and	 MrgD	 expressing	 sensory	 fibers	 play	 a	 critical	 role	 in	
transducing	pain	 in	 this	model	of	CIBP	 in	 the	mouse.	Further,	we	have	expanded	the	utility	of	
previously	published	methods	to	investigate	the	role	of	afferent	fibers	in	transducing	pain	with	
intervention	to	block	pain	signals	at	the	level	of	the	spinal	cord	dorsal	horn	(Bonin,	Wang	et	al.	
2016).	Moreover,	we	 adapted	 new	measures	 of	movement-induced	 pain	 that	may	 serve	 as	 a	
foundation	for	further	development	of	a	measure	of	BTP	in	the	mouse	by	monitoring	previously	
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described	behavioral	changes	that	arise	as	a	result	of	CIBP	(Guedon,	Longo	et	al.	2016,	Majuta,	
Guedon	 et	 al.	 2017).	We	 demonstrate	 that	 hind	 limb	movement	 induced	 changes	 in	 several	
behaviors,	 distance	 traveled,	 rearing	 and	 movement	 in	 the	 margin	 and	 center	 of	 an	 LMA	
chamber,	that	may	prove	useful	in	developing	a	model	of	breakthrough	pain	in	the	mouse.	
	
3.4.1.	Classical	Measures	of	CIBP.	
Time	 course	 data	 displayed	 in	 Figures	 3.5	 and	 3.6	 demonstrate	 that	 in	 our	 hands	we	
have	 replicated	previous	 reports	within	 the	CIBP	 literature.	 In	both	 female	 and	male	C57BL/6	
mice	 as	 tumor	 growth	 progresses	 within	 the	 femur,	 mice	 develop	 classical	 tactile	
hypersensitivity,	 decreased	 limb	 use	 and	 an	 increase	 in	 flinching	 behaviors,	 consistent	 with	
previous	 reports	 (Jimenez-Andrade,	 Bloom	 et	 al.	 2010,	 Guedon,	 Longo	 et	 al.	 2016,	 Majuta,	
Guedon	 et	 al.	 2017).	 Female	mice	 also	 demonstrated	 classical	 increase	 in	 hind	 limb	 guarding	
behavior	 and	 decrease	 in	 rearing,	 consistent	with	work	 by	 others	 (Honore,	 Luger	 et	 al.	 2000,	
Guedon,	Longo	et	al.	2016,	Majuta,	Guedon	et	al.	2017).	While	these	measures	have	been	used	
consistently	over	the	past	20	years	in	animal	models	of	CIBP,	we	wanted	to	expand	and	utilize	
novel	 measures	 of	 pain	 that	 rely	 on	 the	 affective	 components	 of	 pain,	 and	 the	 ability	 to	
condition	 animals	 to	 pain	 relief	 in	 a	 paradigm	of	 conditioned	place	preference	 in	mice	where	
previous	 work	 has	 focused	 on	 the	 rat	 (King,	 Vera-Portocarrero	 et	 al.	 2009,	 Remeniuk,	
Sukhtankar	 et	 al.	 2015,	 Havelin,	 Imbert	 et	 al.	 2017,	 Remeniuk,	 King	 et	 al.	 2018).	 Additionally	
transferring	focus	to	the	mouse	would	allow	us	access	to	use	novel	tools	such	as	optogenetics	to	
investigate	the	role	of	ongoing	afferent	activity	in	CIBP.	
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3.4.2.	Efficacy	of	the	MOR	agonist	DAMGO	to	Alleviate	Ongoing	CIBP.		
Previous	work	 by	 Scherrer	 et	 al.	 2009	 has	 demonstrated	 distinct	 overlap	 of	 the	MOR	
with	 peptidergic	 nociceptive	 afferents	 and	 the	DOR	with	 non-peptidergic	 afferents.	 This	work	
also	 demonstrated	 a	 unique	 delineation	 of	 pain	 modalities	 between	 the	 two	 nociceptive	
populations,	 namely	 that	 peptidergic	 fibers	 respond	 to	MOR	 agonists	 and	 transduce	 thermal	
nociception	and	that	non-peptidergic	fibers	respond	to	DOR	agonists	and	transduce	mechanical	
nociception	 (Scherrer,	 Imamachi	 et	 al.	 2009).	 These	 findings	 interest	 our	 group	 as	 we	 have	
previously	published	evidence	that	IB4-binding	nociceptors	(i.e.	the	non-peptidergic	population)	
but	 not	 TRPV1	 expressing	 (i.e.	 the	 peptidergic	 population)	 fibers	 plays	 a	 critical	 role	 in	 the	
transduction	of	hind	 limb	movement	 induced	BTP,	a	 traditionally	mechanical	pain	experience.	
However,	 our	 previous	 work	 did	 not	 investigate	 the	 role	 of	 these	 two	 fiber	 populations	 in	
ongoing	pain	from	the	cancer-afflicted	hind	limb.	The	observations	that	these	fiber	populations	
and	 receptors	 have	overlap	 gave	us	 the	opportunity	 to	 attempt	 to	 evaluate	 the	 role	 of	 these	
fiber	types	in	ongoing	pain	in	the	mouse.	Previously	our	group	has	demonstrated	the	ability	for	
systemic	morphine	to	alleviate	ongoing	pain	in	a	model	of	CIBP	in	the	rat	that	mimics	findings	in	
the	clinic	(Remeniuk,	Sukhtankar	et	al.	2015).	Our	attempts	to	use	systemic	morphine	delivery	
via	morphine	pellets	in	mice	led	to	too	many	complications	to	accurately	test	antinociception	in	
mice	 (data	 not	 shown).	 Unlike	 work	 in	 the	 rat	 where	 analgesia	 without	 hyperlocomotion	 or	
sedation	 at	 24	 hrs	 post	 pellet	 implantation	was	 observed,	 implantation	 of	 a	 single	morphine	
pellet	 (25	mg,	s.c.)	 resulted	 in	hyperlocomotion	that	persisted	through	the	24-hour	time-point	
which	interfered	with	our	ability	to	accurately	measure	behaviors	(data	not	shown).	Therefore,	
we	moved	to	a	strategy	implementing	peptidergic	opioid	agonists.	
We	 tested	 the	 hypothesis	 that	 the	 peptidergic	 MOR	 agonist	 DAMGO	 but	 not	 the	
peptidergic	DOR	agonist	Deltorphin	 II	 could	alleviate	ongoing	pain	 in	 the	mouse.	The	basis	 for	
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this	 hypothesis	 following	 previous	 work	 by	 Patrick	 Mantyh	 demonstrating	 the	 peptidergic	
population	 of	 fibers	 plays	 a	 critical	 role	 in	 transducing	 ongoing	 pain	 from	 the	 cancer-afflicted	
limb,	and	the	non-peptidergic	fiber	did	not	(Jimenez-Andrade,	Bloom	et	al.	2010).	In	addition	to	
this,	work	 in	 that	 rat	 ablating	 TRPV1	 expressing	 (peptidergic	 population)	 fibers	 demonstrated	
these	 fibers	 play	 a	 critical	 role	 in	 transducing	ongoing	pain	 (King,	Qu	et	 al.	 2011).	Our	 results	
demonstrate	 that	 systemic	 injection	 and	 activation	 of	 the	 MOR	 with	 DAMGO	 does	 alleviate	
ongoing	 pain,	 consistent	 with	 our	 hypothesis	 and	 with	 previous	 findings	 and	 clinical	
observations	that	MOR	agonists	manage	cancer-induced	ongoing	pain	(Remeniuk,	Sukhtankar	et	
al.	2015,	Guedon,	Longo	et	al.	2016,	Havelin,	Imbert	et	al.	2017).	However,	at	a	dose	of	3	mg/kg	
Deltorphin	 II	 failed	 to	 induce	 conditioned	place	 preference	 in	mice,	 again	 consistent	with	 our	
hypothesis	and	previous	work	(Scherrer,	Imamachi	et	al.	2009,	King,	Qu	et	al.	2011).	It	is	possible	
that	 this	 dose	 of	 Deltorphin	 II	 was	 too	 low	 to	 effectively	 block	 ongoing	 pain,	 this	 dose	 was	
chosen	 based	 on	 preliminary	 results	 from	 colleagues	 to	 reverse	 other	 pain	 behaviors.	 These	
findings	indirectly	demonstrate	a	role	for	peptidergic	nociceptors	in	transducing	ongoing	pain	in	
preclinical	models	of	CIBP,	and	add	to	both	preclinical	and	clinical	evidence	that	MOR	agonists	
are	capable	of	alleviating	ongoing	CIBP.	
	
3.4.3.	Efficacy	of	Virally	Delivered	ArchT	to	Block	AITC	Induced	Nociceptive	Behaviors.		
In	 an	 attempt	 to	 verify	 the	 efficacy	 of	 our	 approach	 to	 target	 the	 Nav1.8	 and	MrgD	
populations	of	nociceptive	fibers	we	chose	to	use	an	acute	robust	model	of	nociception	using	an	
injection	 of	 1%	 AITC	 solution	 into	 the	 hind	 paw	 of	 mice.	 After	 verifying	 expression	 of	 virally	
delivered	 ArchT-eGFP	 in	 both	 the	 spinal	 cord	 dorsal	 horn	 and	 cell	 bodies	 of	 the	 dorsal	 root	
ganglion	we	 sought	 to	block	nociceptive	 input	 from	both	populations	of	 fibers.	AITC	activates	
the	 TRPA1	 channel,	 which	 is	 critically	 involved	MIA	 induced	 osteoarthritic	 pain	 blocked	 with	
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TRPA1	antagonists	(Eid,	Crown	et	al.	2008,	Okun,	Liu	et	al.	2012).	Given	their	role	in	transducing	
nociceptive	 stimuli	 we	 believed	 that	 inhibition	 of	 Nav1.8	 fibers	 would	 block	 the	 nocifensive	
response	typically	observed	by	activating	TRPA1.	Beyond	this,	mining	the	Usoskin	2016	database	
revealed	that	Nav1.8	and	MrgD	RNA	transcripts	are	present	at	relatively	high	levels	in	the	same	
cell	 types	 that	 express	 TRPA1,	 leading	 us	 to	 believe	 that	 inhibition	 of	MrgD	 expressing	 fibers	
may	also	block	AITC	induced	nocifensive	behaviors.		
Robust	 nocifensive	 responses	 in	wild	 type	mice	were	 indeed	 observed	 following	 hind	
paw	injection	of	1%	AITC,	consistent	with	previous	reports	(Eid,	Crown	et	al.	2008).	Much	to	our	
excitement,	 laser	 induced	 activation	 of	 ArchT	 on	 Nav1.8	 fibers	 nearly	 completely	 blocked	
nocifensive	behaviors	in	mice	with	correctly	implanted	fiber	optics	that	allowed	for	light	delivery	
to	 the	afferent	 terminals	within	 the	 spinal	 cord	dorsal	horn.	A	 similar	blockade	of	nocifensive	
behaviors	was	observed	by	inhibiting	MrgD	afferents	with	ArchT,	a	most	exciting	finding	indeed.	
Due	 to	 the	 overwhelming	 evidence	 that	 Nav1.8	 expressing	 fibers	 play	 a	 critical	 role	 in	
nociceptive	 transduction,	 a	 recent	 benefit	 of	 the	 development	 of	 optogenetic	 technology,	we	
were	not	surprised	to	see	a	blockade	of	these	behaviors	in	mice	(Daou,	Tuttle	et	al.	2013,	Bonin,	
Wang	 et	 al.	 2016,	 Daou,	 Beaudry	 et	 al.	 2016).	 However,	 previous	 to	 this	 work	 no	 published	
evidence	 has	 demonstrated	 a	 transient	 and	 direct	 role	 of	 the	 MrgD	 fibers	 in	 transducing	
nociceptive	stimuli.	Beyond	our	work	in	the	rat	implicating	IB4-binding	afferents	in	transducing	
BTP,	evidence	for	the	non-peptidergic	fibers	in	playing	a	role	for	transducing	nociceptive	stimuli	
comes	from	ablating	these	neurons	and	demonstrating	a	critical	role	in	transducing	mechanical	
stimuli	 and	 tactile	 hypersensitivity	 by	 Cavanuagh	 et	 al.	 2009.	 Indeed	 previous	 studies	
demonstrated	 that	 whereas	 optogenetic	 activation	 of	 TRPV1	 and	 Nav1.8	 expressing	 fibers	
results	in	robust	nociceptive	behaviors	and	conditioned	place	aversion,	activation	of	MrgD	fibers	
by	channel	rhodopsin	resulted	in	paw	lifting	but	failed	to	produce	an	aversive	role	(Daou,	Tuttle	
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et	 al.	 2013,	 Bonin,	Wang	 et	 al.	 2016,	 Daou,	 Beaudry	 et	 al.	 2016,	 Beaudry,	 Daou	 et	 al.	 2017,	
Uhelski,	Bruce	et	al.	2017).	Interestingly	as	reported	by	Beaudry	et	al.	2017,	activation	of	TRPV1	
fibers	by	channel	rhodopsin	resulted	in	paw	withdrawal	and	paw	licking,	but	not	lifting,	whereas	
activation	of	MrgD	fibers	resulted	in	withdrawal	and	lifting	but	not	licking.	Our	results	 indicate	
that	inhibition	of	MrgD	fibers	blocks	afferent	input	that	leads	to	licking	responses,	a	finding	that	
we	 intend	to	verify	by	 repeating	 this	 study	with	adequate	numbers	 for	statistical	analysis.	We	
note	 that	 these	 observations	may	 indicate	 that	whereas	 direct	 stimulation	 of	 these	 afferents	
does	not	induce	a	response	sufficient	to	induce	nociception	or	pain,	inactivation	of	these	fibers	
in	 a	 state	 of	 acute	 pain	 is	 sufficient	 to	 produce	 pain	 relief.	 Nevertheless	 we	 demonstrate	 a	
unique	role	for	MrgD	fibers	 in	transducing	AITC	induced	TRPA1	activated	nociception,	and	add	
evidence	 to	 the	 field	 that	 Nav1.8	 fibers	 transduce	 a	 variety	 of	 nociceptive	 input.	 While	
technically	cumbersome,	these	results	also	demonstrate	the	powerful	efficacy	this	approach	to	
selectively	silence	sensory	afferents	at	the	 level	of	 the	spinal	cord	dorsal	horn	can	have	 in	the	
pain	field.	
	
3.4.4.	The	Role	of	Subsets	of	Nociceptive	Fibers	in	Cancer-Induced	Ongoing	Pain.		
The	 stimulation	 paradigm	was	 chosen	based	on	 the	 possibility	 of	 repetitive	 activation	
induced	 exhaustion	 of	 the	ArchT	 proton	 pump.	 There	 are	 few	 reported	methods	 of	 relatively	
long	 term	 laser	 exposures	 within	 behavioral	 paradigms	 investigating	 pain,	 especially	 with	
regards	to	ArchT-induced	CPP.	Therefore,	we	estimated	a	recovery	period	for	the	ArchT	proton	
pump	of	60	seconds.	Thus	we	selected	a	2	minute	on,	1	minute	off	 laser	activation	paradigm,	
that	would	result	in	a	total	of	20	out	of	30	minutes	of	potential	inhibition	of	fibers.		
Expanding	 on	 the	 use	 of	 conditioned	 place	 preference	 to	 pain	 relief	 we	 sought	 to	
demonstrate	 the	 role	 of	 Nav1.8	 fibers	 in	 transducing	 CIBP	 by	 silencing	 them	 with	 the	 light	
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sensitive	proton	pump	ArchT.	We	have	demonstrated	 that	ArchT-induced	 inhibition	of	Nav1.8	
fibers	in	animals	treated	with	cancer	but	not	shams	results	in	CPP	to	pain	relief	with	our	ArchT	
activation	paradigm.	These	results	demonstrate	that	ongoing	pain	from	the	cancer-afflicted	limb	
is	 transduced	 by	 Nav1.8	 expressing	 fibers.	 This	 observation	 is	 consistent	 with	 other	 work	
demonstrating	 that	 these	 channels	 are	 expressed	 on	 a	 broad	 population	 of	 sensory	 fibers	
including	 peptidergic	 and	 non-peptidergic	 fibers	 (Figure	 3.16)	 which	 have	 previously	 been	
implicated	in	ongoing	pain	and	other	pain	behaviors	in	models	of	CIBP	(Jimenez-Andrade,	Bloom	
et	al.	2010,	Bloom,	Jimenez-Andrade	et	al.	2011,	King,	Qu	et	al.	2011).	While	work	by	Shields	et	
al.	 has	 demonstrated	 that	Nav1.8	 is	 likely	 not	 restricted	 to	 C-fibers,	 optogenetic	 activation	 of	
Nav1.8	 fibers	 has	 been	 demonstrated	 to	 convey	 nociceptive	 information	 (Daou,	 Tuttle	 et	 al.	
2013,	Daou,	Beaudry	et	al.	2016,	Uhelski,	Bruce	et	al.	2017).	We	also	believe	this	to	be	the	first	
reported	 evidence	 of	 optogenetically	 silenced	 Nav1.8	 fibers	 resulting	 in	 CPP	 to	 pain	 relief,	
demonstrating	 a	 paradigm	 of	 ArchT	 induced	 silencing	 of	 fibers	 that	 can	 be	 used	 in	 future	
experiments.	 These	 results	 also	 serve	 as	 a	 positive	 control	 for	 our	 work	 in	 silencing	 MrgD	
expressing	fibers	to	measure	their	role	in	cancer-induced	ongoing	pain.	
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Taken	from	Bonin	et	al.	2016
Figure 3.16. Demonstrable Overlap in RNAseq Data of Sensory Neurons. Single Cell
RNAseq demonstrating subpopulations of sensory fibers. Scn10A, Nav1.8 fibers; Calca,
CGRP; Mrgprd, MrgD; P2rx3, P2X3. Colored table taken from Usoskin et al. 2016. Data
mined from Linnarsson Lab website, (http://linnarssonlab.org/drg/). Figure adapted with
color scheme by Joshua Havelin for ease of visualization. Note Y-axis change between
graphs.
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Interestingly,	our	results	also	demonstrate	that	ArchT-induced	inhibition	of	MrgD	fibers	
in	 animals	 with	 ongoing	 pain	 from	 the	 femur	 causes	 CPP.	 Initially	 the	 construction	 of	 our	
experiment	was	based	on	the	hypothesis	that	we	would	not	see	conditioned	place	preference	in	
MrgD-ArchT	 sham	 let	 alone	 cancer	 treated	 animals,	 and	 thus	 we	 needed	 to	 compare	MrgD-
ArchT	cancer	animals	to	a	group	we	were	confident	that	would	have	a	positive	outcome	in	the	
study.	 This	 group	 was	 run	 side	 by	 side	 with	 the	 positive	 control	 group,	 Nav1.8-ArchT	 cancer	
treated	 animals.	 Nevertheless	 this	 group	 of	 animals	 showed	 robust	 conditioned	 place	
preference	to	the	PM	laser	paired	chamber.	Prior	to	this	a	lack	of	evidence	suggested	that	MrgD,	
non-peptidergic,	 fibers	 would	 not	 play	 a	 role	 in	 transducing	 ongoing	 CIBP	 (Jimenez-Andrade,	
Bloom	et	 al.	 2010,	Guedon,	 Longo	et	 al.	 2016).	 Several	 possible	 explanations	do	exist	 for	 this	
outcome.	The	first	namely	being	that	MrgD	fibers	do	in	fact	play	a	role	in	transducing	ongoing	
pain	from	the	cancer-afflicted	bone.	This	would	require	as	previously	mentioned	the	inclusion	of	
an	 MrgD-ArchT	 sham	 group	 to	 demonstrate	 that	 inhibition	 of	 MrgD	 fibers	 is	 not	 inherently	
rewarding	for	some	strange	reason.		
Alternatively,	 as	 there	 is	 evidence	 that	MrgD	 fibers	 play	 a	 critical	 role	 in	 transducing	
mechanical	 nociception	 (Cavanaugh,	 Lee	 et	 al.	 2009,	 Scherrer,	 Imamachi	 et	 al.	 2009),	 It	 is	
possible	that	inhibition	of	these	fibers	blocks	the	occurrence	of	tactile	hypersensitivity	that	the	
mice	 may	 be	 chronically	 experiencing	 while	 applying	 weight	 to	 the	 skin	 on	 their	 hind	 paws.	
Many	times	over	in	CIBP	models,	measurements	of	tactile	hypersensitivity	from	the	skin	of	the	
hind	paw	have	been	demonstrated	 (Honore,	 Luger	et	al.	2000,	 Jimenez-Andrade,	Bloom	et	al.	
2010,	Guedon,	Longo	et	al.	2016,	Edwards,	Havelin	et	al.	2018).	Inhibition	of	this	experience	may	
result	 in	a	rewarding	affective	experience	to	the	mice,	which	could	result	 in	conditioned	place	
preference	to	the	inhibition	of	MrgD	fibers.	However,	the	initial	paper	characterizing	CPP	to	pain	
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relief	 	 (King,	Vera-Portocarrero	et	 al.	 2009)	demonstrated	 relief	of	 tactile	hypersensitivity	was	
not	sufficient	to	induce	CPP,	making	the	likelihood	of	this	justification	small.	
Additionally,	 previous	 evidence	 by	 our	 group	 has	 implicated	 IB4-binding	 sensory	
neurons	 (“non-peptidergic”)	 in	 being	 critically	 involved	 in	 transducing	 BTP	 following	 manual	
manipulation	of	the	cancer-afflicted	hind	limb	in	rats	(Havelin,	 Imbert	et	al.	2017).	As	CIBP	is	a	
heterogeneous	 and	 complicated	 pain	 pathology,	 further	muddled	 by	 the	 fact	 that	movement	
may	 induce	 additional	 pain	 episodes	 as	 reported	 from	 the	 clinic,	 it	 is	 possible	 that	 transient	
inhibition	 of	MrgD	 fibers	may	 have	 blocked	 the	 induction	 of	 BTP	 episodes	 caused	 by	 normal	
movement	 of	 the	 mice	 throughout	 the	 PM	 conditioning	 phase.	 Which	 if	 in	 the	 mouse	 is	 as	
painful	 as	 reported	 by	 patients	 in	 the	 clinic,	 could	 likely	 induce	 a	 drastically	 rewarding	 effect	
when	removed	from	animals	with	cancer.	A	potential	method	to	examine	this	would	be	the	use	
of	 ambulatory	 movement	 on	 a	 rot-a-rod	 apparatus	 with	 a	 similar	 optogenetic	 stimulation	
paradigm	 to	 that	 used	 in	 our	 hands,	 or	wheel	 running	behaviors.	Work	by	 Pat	Mantyh	 in	 the	
past	 has	 used	 the	 rot-a-rod	 apparatus	 to	 investigate	 the	 effects	 of	 ambulatory	movement	 on	
CIBP	and	demonstrated	some	interventions	reverse	CIBP	 induced	deficits	 (Luger,	Honore	et	al.	
2001,	 Sabino,	Ghilardi	 et	 al.	 2002,	 Peters,	Ghilardi	 et	 al.	 2005).	However	 this	method	has	not	
been	established	or	 characterized	as	a	model	of	BTP	 in	 the	mouse.	Additionally	 the	measures	
proposed	later	in	this	body	of	work	could	be	used	(Figures	3.13	and	3.14).		
To	confirm	any	of	these	possibilities	would	take	additional	work	that	would	require	the	
introduction	 of	 additional	 pain	 measures,	 potentially	 some	 that	 currently	 don’t	 exist	 (i.e.	 a	
measure	of	BTP	in	the	mouse).	
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3.4.5.	 Inability	 to	 Establish	 CPA	 to	 Hind	 Paw	 Movement	 in	 the	 Mouse	 and	 Potential	
Alternative	Measures	of	Hind	Paw	Movement-Induced	Pain.		
The	failure	to	translate	hind	limb	movement	induced	conditioned	place	aversion	in	the	
mouse	was	surprising.	The	robustness	of	aversion	observed	in	the	rat	convincingly	conveys	that	
movement	 of	 the	 cancer-afflicted	 hind	 limb	 induces	 an	 unpleasant	 experience	 in	 animals	
(Havelin,	 Imbert	 et	 al.	 2017).	Moreover,	 previous	work	 published	 by	 Patrick	Mantyh	 has	 also	
demonstrated	 that	 movement	 of	 the	 cancer-afflicted	 hind	 limb	 induces	 exacerbation	 of	 pain	
measurements	 and	 neurochemical	 markers	 of	 nociception	 in	 the	 spinal	 cord	 in	 mice	 (Luger,	
Honore	et	al.	2001,	Sabino,	Luger	et	al.	2003,	Peters,	Ghilardi	et	al.	2005).	Experimenter	notes	
from	our	group	during	hind	limb	movement	of	the	cancer-afflicted	limb	also	demonstrate	that	
even	 in	 our	 hands	 mice	 appear	 to	 be	 in	 an	 exacerbated	 pain	 state,	 within	 increased	 limb	
guarding	 and	 decreased	 limb	 use	 immediately	 following	 limb	movement.	 These	 observations	
make	 it	 is	 unlikely	 that	 an	 inter-technician	 variance	 is	 causing	 some	 sort	 of	 non-painful	
experience	 during	 hind	 limb	 movement	 in	 our	 hands	 that	 did	 not	 occur	 in	 others.	 Another	
possibility	is	that	while	rats	and	mice	differ	in	some	ways	in	their	temperament,	the	experience	
may	be	more	stressful	or	anxiety	inducing	in	the	mouse	compared	to	the	rat	which	may	impart	a	
detriment	 to	 the	 mice’s	 ability	 to	 learn	 and	 “remember”	 to	 avoid	 the	 hind	 limb	 movement	
paired	chamber	on	test	day.	This	challenge	would	implicate	that	the	conditioned	place	aversion	
approach	would	not	be	 feasible	with	mice.	More	 likely	and	surmountable	would	be	 that	mice	
might	require	additional	exposure	to	the	hind	limb	movement	paired	chamber,	i.e.	multiple	days	
of	pairing,	however,	due	to	the	nature	of	the	pain	state	the	mice	are	in	and	that	in	order	to	test	
this	hypothesis	the	animals	would	need	to	be	put	in	what	may	be	excruciating	pain	more	than	
once	with	no	intervention	to	diminish	or	manage	this	pain,	ethical	considerations	may	need	to	
be	discussed	before	such	an	approach	could	be	used.	
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	 As	 a	 result	 of	 our	 inability	 to	 observe	 aversion	 to	 the	 hind	 limb	 movement	 paired	
chamber,	 we	 performed	 an	 experiment	 to	 observe	 several	 other	 behaviors	 that	 have	 been	
previously	described	to	be	altered	as	a	result	of	tumor	growth	within	the	femur,	and	orofacial	
cancer.	Rearing	behavior	and	total	distance	traveled	has	been	reported	as	potential	measures	of	
pain	that	decrease	in	animals	with	cancer,	and	orofacial	pain	has	been	demonstrated	to	induce	
measures	 of	 anxiety	 in	 rats	 (Gambeta,	 Kopruszinski	 et	 al.	 2016,	 Gambeta,	 Kopruszinski	 et	 al.	
2017,	 Majuta,	 Guedon	 et	 al.	 2017).	 These	 two	 behaviors	 have	 not,	 to	 our	 knowledge,	 been	
monitored	 following	 hind	 limb	 movement	 of	 the	 cancer-afflicted	 femur	 with	 the	 intent	 to	
examine	changes	that	may	present	as	a	result	of	movement	 induced	pain.	We	have	replicated	
the	finding	that	cancer	animals	rear	and	travel	less	than	sham	treated	controls,	as	was	reported	
by	 (Majuta,	Guedon	et	al.	2017).	 Interestingly,	a	2-minute	movement	of	 the	hind	 limb	did	not	
significantly	alter	either	rearing	or	distance	traveled	in	sham	treated	animals,	but	did	decrease	
both	behaviors	in	cancer	treated	animals.	A	significant	difference	was	observed	in	the	amount	of	
distance	traveled	over	the	course	of	45	minutes,	where	as	a	difference,	albeit	not	statistically,	
was	observed	in	rearing	episodes	over	the	45	minute	observation	period.	We	note	that	there	is	
likely	a	floor	effect	for	rearing	at	the	time-point	that	we	tested	the	behaviors.	Testing	for	these	
behaviors	 at	 earlier	 time-points	 may	 allow	 for	 a	 larger,	 and	 more	 measureable	 change	 in	
behavior.	
Our	 intent	was	 to	monitor	whether	ArchT	 induced	 inhibition	of	Nav1.8	or	MrgD	fibers	
could	block	 this	effect	 in	 cancer	bearing	animals.	Due	 to	 restrictions	within	our	animal	 colony	
and	larger	animal	attrition	than	anticipated	due	to	the	technically	difficult	procedure	of	epidural	
implantation	of	optic	 fibers	 for	 the	epigenetic	studies,	 this	work	has	not	been	completed.	The	
colony	of	MrgD-ArchT	mice	used	in	the	previous	studies	will	be	re-established	in	Dr.	King’s	lab	to	
complete	 this	work.	A	pharmacological	 intervention	 could	be	performed	 in	 a	 timelier	manner	
138	
	
than	experiments	 requiring	 transgenic	 animals,	however	morphine	administration	 in	mice	 can	
result	in	hyperlocomotion.	We	have	observed	this	and	this	is	well	reported	in	the	past	(Lowery,	
Raymond	et	al.	2011).	The	hyperlocomotion	in	cancer	treated	animals	inevitably	confounds	the	
use	of	“distance	travelled”	and	rearing	episodes	as	a	measure	of	hind	limb	movement	induced	
suppression	of	this	behavior	that	would	have	to	be	demonstrated	to	classify	this	as	a	measure	of	
BTP.	It	is	likely	that	other	paradigms	of	MOR	agonist	administration	could	be	used,	we	have	not	
at	 this	 time	 characterized	 this	 work.	 Also,	 without	 a	 current	 pharmacological	 agent	 that	
effectively	 blocks	 BTP,	 screening	 of	 compounds	 using	 this	 approach	 would	 have	 no	
pharmacological	positive	control	to	compare	to.		
	
3.5.	Conclusion	
	 In	 conclusion,	 we	 have	 implemented	 a	 novel	 approach	 to	 investigate	 CIBP	 utilizing	
cutting	edge	optogenetic	approaches,	both	though	viral	transfection	of	peripheral	neurons	and	
transgenic	 delivery	 of	 light	 sensitive	 proteins.	Work	 presented	 here	 also	 lends	 evidence	 to	 a	
novel	 role	 of	 MrgD	 expressing	 or	 non-peptidergic	 nociceptive	 fibers	 may	 play	 in	 transducing	
CIBP.	We	 have	 demonstrated	 and	 implicated	 Nav1.8	 expressing	 fibers	 in	 transducing	 cancer-
induced	ongoing	pain,	 and	utilized	a	novel	 approach	using	optogenetically	 silenced	peripheral	
neurons	 to	 induce	 conditioned	 place	 preference	 to	 pain	 relief	 in	 the	 mouse.	 Lastly,	 work	
presented	here	may	allow	for	the	development	of	a	measure	of	BTP	in	the	mouse.	
	
	
	
	 	
	
139	
	
CHAPTER	4	
DISCUSSION	OF	FINDINGS	
	
4.1.	Summary	of	Results	
	 In	this	body	of	work,	we	put	forth	new	and	exciting	data	that	suggests	a	unique	role	for	
subpopulations	of	sensory	neurons	in	mediating	CIBP.	While	this	work	is	not	exhaustive	down	to	
the	electrophysiological	level,	it	is	the	first	to	investigate	the	role	for	subpopulations	of	sensory	
neurons	using	a	paradigm	of	pain	relief	that	involves	the	affective	components	of	pain	relief	and	
pain	 induction,	 rather	 than	 reflexive	 and	 evoked	 measures	 of	 pain.	 Work	 by	 myself	 and	
colleagues	have	produced	a	model	of	BTP	that	can	be	evoked	by	manipulating	the	hind	limb	of	a	
cancer	bearing	 rat,	which	 results	 in	 the	production	of	an	aversive	 state	 that	 “breaks	 through”	
onboard	morphine,	which	 can	 be	 blocked	with	 a	 peripheral	 nerve	 block	 prior	 to	 induction	 of	
pain.	 Interestingly	peripheral	nerve	block	after	the	induction	of	pain	fails	to	block	this	aversive	
pain	 state.	 We	 further	 demonstrate	 that	 the	 establishment	 of	 this	 pain	 state	 relies	 on	 the	
involvement	 of	 IB4-binding	 fibers	 (non-peptidergic),	 but	 not	 TRPV1	 expressing	 fibers	
(peptidergic),	 an	 observation	 contrary	 to	 a	 number	 of	 previous	 theories	 of	 CIBP.	 Additionally,	
work	 reported	 here	 demonstrates	 that	 in	 the	 mouse,	 activation	 of	 the	MOR,	 believed	 to	 be	
targeting	peptidergic	 sensory	neurons,	alleviates	ongoing	CIBP,	whereas	activation	of	 the	DOR	
may	 not.	 Interestingly,	 optogenetic	 induced	 silencing	 of	 Nav1.8	 sensory	 fibers	 also	 relieves	
ongoing	 pain	 in	 our	 mouse	 model	 of	 CIBP,	 and	 silencing	 MrgD	 (non-peptidergic)	 expressing	
sensory	fibers	in	cancer	bearing	animals	induces	conditioned	place	preference.	This	culmination	
of	 work	 demonstrates	 and	 implicates	 a	 potentially	 unique	 role	 for	 the	 IB4-binding/MrgD-
expressing/non-peptidergic	populations	of	 sensory	neurons	 in	 conveying	CIBP,	 contrary	 to	 the	
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majority	of	published	work	demonstrating	evidence	for	a	lack	of	involvement	of	these	fibers	in	
preclinical	models	of	CIBP.	
	
4.2.	Major	Findings	
Classical	 measures	 of	 Cancer-Induced	 Bone	 Pain	 in	 the	 Rat	 and	Mouse.	 As	 previously	
demonstrated	by	others	 in	the	field,	we	demonstrate	that	 implantation	of	the	MATB3	cell	 line	
into	the	tibia	of	rats,	and	the	implantation	of	the	LLC	cell	 line	into	the	femur	of	mice	results	in	
dramatic	 bone	 degradation	 accompanied	 by	 behaviors	 associated	 with	 preclinical	 models	 of	
CIBP.	In	both	species	of	animals,	mechanical	tactile	thresholds	decreased	as	tumor	growth	and	
bone	destruction	progressed,	consistent	with	original	 findings	 in	both	species	 (Schwei,	Honore	
et	al.	1999,	Medhurst,	Walker	et	al.	2002).	Limb	use	in	both	species	also	decreased	over	time,	a	
finding	that	is	consistently	reported	and	coincides	with	decreased	motor	activity	by	the	animals,	
and	decreased	weight	bearing	to	the	affected	hind	limb,	and	hind	limbs	as	a	result	of	decreased	
rearing	(Medhurst,	Walker	et	al.	2002,	Remeniuk,	Sukhtankar	et	al.	2015,	Guedon,	Longo	et	al.	
2016,	 Majuta,	 Guedon	 et	 al.	 2017,	 Remeniuk,	 King	 et	 al.	 2018).	 These	 behaviors	 have	 been	
demonstrated	 to	 coincide	 and	 likely	 be	 driven	 by	 pathological	 sprouting	 of	 peptidergic	 and	
sympathetic	nerve	fibers	in	both	the	periosteum	and	marrow	space	within	the	bone.			
Several	papers	have	examined	the	effects	of	an	anti-NGF	primary	antibody	and	its	ability	
to	 blunt	 the	 pathological	 sprouting	 observed	 in	 the	mouse	model	 of	 CIBP	 (Jimenez-Andrade,	
Bloom	et	al.	2010,	Mantyh,	Jimenez-Andrade	et	al.	2010,	Bloom,	Jimenez-Andrade	et	al.	2011,	
McCaffrey,	Thompson	et	al.	2014,	Guedon,	Longo	et	al.	2016).	Interestingly	while	this	antibody	
does	effectively	block	pathological	 sprouting	of	peptidergic	and	sympathetic	 fibers,	along	with	
the	accompanying	measures	of	pain,	whether	or	not	it	blunts	bone	remodeling	may	depend	on	
the	cell	 line,	surgical	preparation,	and	immune	system	integrity	as	varying	reports	by	the	same	
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group	have	been	published	 (Bloom,	 Jimenez-Andrade	et	 al.	 2011,	McCaffrey,	 Thompson	et	 al.	
2014).	 These	 observations	 coincide	 with	 additional	 work	 by	 Patrick	 Mantyh	 and	 colleagues	
examining	 models	 of	 pathological	 bone	 fracture	 and	 the	 nerve	 sprouting	 that	 accompanies	
incomplete	or	pathological	healing	(Chartier,	Thompson	et	al.	2014).	Measures	of	spontaneous	
pain	as	well	as	measures	of	movement	in	this	model	of	bone	fracture	pain	are	also	attenuated	
by	anti-NFG	 therapy,	highlighting	 the	 role	NGF	plays	 in	pain	associated	with	pathological	pain	
from	the	bone	(Majuta,	Guedon	et	al.	2017,	Majuta,	Mitchell	et	al.	2018).		
While	not	as	extensively	analyzed	as	it	has	been	in	the	mouse,	it	appears	that	in	similar	
models	of	bone	and	 joint	pain,	anti-NGF	therapy	appears	to	be	effective	 in	the	rat,	dogs,	cats,	
and	 human	 (Xu,	 Nwosu	 et	 al.	 2016,	 Suzuki,	 Millecamps	 et	 al.	 2018,	 Enomoto,	 Mantyh	 et	 al.	
2019).	 Fuseya	 et	 al	 2016	 targeted	 TRPV1	 expressing	 neurons	 with	 qx-314	 in	 mice	 and	
demonstrated	 reversal	 of	 spontaneous	 flinches	 but	 not	 scores	 of	 limb	 use,	 highlighting	 a	
differential	role	of	peripheral	fiber	types	and	the	role	they	play	in	CIBP	(Fuseya,	Yamamoto	et	al.	
2016).	 Interestingly,	 in	 our	 hands	 capsaicin	 induced	 ablation	 of	 TRPV1	 expressing	 sensory	
neurons	 (peptidergic)	 failed	 to	 block	 the	 development	 of	 cancer-induced	 mechanical	 tactile	
hypersensitivity	in	the	rat	(Havelin,	Imbert	et	al.	2017).	This	observation	may	be	result	of	specie	
differences,	or	perhaps	anatomical	 location	of	 the	 cancer-afflicted	bone	 (femur	 in	 the	mouse,	
tibia	 in	 the	 rat).	 While	 other	 treatments	 that	 are	 effective	 at	 blocking	 cancer-induced	 bone	
remodeling	 such	 as	 Denosumab/OPG	 and	 bisphosphonates,	 also	 appear	 to	 block	 classical	
measures	 of	 CIBP,	 it	 is	 unclear	 as	 to	 their	 effects	 on	 whether	 blocking	 pathological	 bone	
remodeling	 simultaneously	 blocks	 pathological	 sprouting.	 However,	 therapies	 that	 diminish	
bone	 degradation	 in	 the	 clinic	 are	 also	 reported	 to	 slow	 development	 of	 pain	 (Steger	 and	
Bartsch	2011).	
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	 While	 approaches	 to	 selectively	 target	 the	 peptidergic	 population	 of	 sensory	 neurons	
appear	to	be	wholly	efficacious	in	blocking	the	development	of	classical	CIBP	behaviors,	agents	
targeting	 the	 non-peptidergic	 population	 seem	 to	 have	 more	 varying	 effects.	 In	 the	 mouse,	
targeting	 the	 P2X3	 receptor	 with	 a	 primary	 antibody	 only	 resulted	 in	 reversal	 of	 tactile	
hypersensitivity	 and	 not	 other	 measures	 of	 bone	 pain	 such	 as	 shifted	 weight	 bearing	 and	
decreased	 rearing,	 indicating	 potential	 differential	 mechanisms	 mediating	 tactile	
hypersensitivity	and	other	kinds	of	pain	such	as	ongoing	pain	(Guedon,	Longo	et	al.	2016).	While	
in	the	rat,	antagonism	of	the	P2X3	receptor	resulted	in	a	reversal	of	tactile	hypersensitivity	in	2	
separate	 studies,	 and	 offset	 weight	 bearing	 (Kaan,	 Yip	 et	 al.	 2010,	 Wu,	 Xu	 et	 al.	 2012),	 an	
observation	that	did	not	occur	 in	 the	mouse	 (Guedon,	Longo	et	al.	2016).	 In	our	hands,	spinal	
administration	 of	 IB4-saporin	 induced	 ablation	 of	 IB4-binding	 fibers	 (non-peptidergic)	 and	
resulted	 in	 blockade	 of	 tactile	 hypersensitivity	 in	 the	 rat	 (Havelin,	 Imbert	 et	 al.	 2017).	 The	
combination	 of	 these	 results	 undeniably	 suggests	 a	 critical	 role	 for	 non-peptidergic	 sensory	
fibers	in	the	development	and	transduction	of	mechanical	tactile	hypersensitivity.	To	the	best	of	
my	knowledge,	no	alternate	approaches	have	been	attempted	in	the	mouse	in	a	model	of	CIBP,	
although	work	investigating	the	effects	of	oral	cancer	pain	has	used	an	ablative	approach	similar	
to	our	rat	work	(Ye,	Bae	et	al.	2014).		
	 While	work	presented	here	aligns	with	 literature	within	the	 field,	and	adds	 interesting	
new	 pieces	 that	warrant	 further	 investigation,	 these	 classical	measures	 of	 pain,	 i.e.	 flinching,	
guarding,	 limb	use,	 referred	 tactile	hypersensitivity,	weight	bearing,	don’t	necessarily	examine	
our	 main	 questions	 regarding	 fiber	 types	 and	 their	 involvement	 in	 driving	 ongoing	 and	
movement	evoked	breakthrough	pain.	Paramount	to	the	justification	to	 investigate	alternative	
behavioral	paradigms	King	et	al.	2009	demonstrated	that	alleviation	of	tactile	hypersensitivity	in	
a	 model	 of	 neuropathic	 pain	 did	 not	 equate	 to	 alleviation	 of	 ongoing	 pain.	 That	 is	 to	 say,	
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alleviation	of	 tactile	hypersensitivity	does	not	mean	 that	 alleviation	of	ongoing	pain	has	been	
achieved,	 a	 clinical	 and	 preclinical	 observation	 (King,	 Vera-Portocarrero	 et	 al.	 2009).	
Observations	 such	 as	 this	 placed	 the	 focus	 and	 priority	 of	 our	work	 on	 examining	 behavioral	
paradigms	 of	 pain	 that	 include	 the	 affective	 motivation	 to	 seek	 out	 pain	 relief	 or	 avoid	 the	
induction	 or	 association	 of	 pain.	 Namely,	 by	 using	 conditioned	 place	 pairing	 paradigms	 that	
allow	an	animal	to	freely	seek	out	pain	relief,	or	avoid	painful	stimuli.	
Role	of	Subsets	of	Peripheral	Neurons	 in	Cancer-induced	Ongoing	Pain.	Building	on	our	
observations	 that	different	 fiber	 types	mediate	different	 aspects	of	 cancer-induced	bone	pain	
(Havelin,	 Imbert	 et	 al.	 2017),	 we	 examined	 the	 role	 of	 MrgD	 vs	 Nav1.8	 expressing	 fibers	 in	
mediating	ongoing	pain	in	the	mouse.		Our	investigation	into	the	role	that	subsets	of	fibers	play	
in	 cancer-induced	 ongoing	 pain	 revealed	 an	 unsurprising	 role	 for	 the	 Nav1.8	 expressing	
population	 of	 fibers	 and	 a	 potentially	 unique	 role	 for	MrgD	 expressing	 fibers.	 Previous	 work	
used	 CPP	 to	 pain	 relief	 in	 a	 model	 of	 CIBP	 in	 the	 rat,	 demonstrating	 novel	 findings	 for	
mechanisms	 critical	 to	 the	 transduction	 of	 ongoing	 pain.	Namely	 that	 ongoing	 pain	 in	 the	 rat	
requires	 input	 from	 peripheral	 neurons	 that	 innervate	 the	 tibia,	 which	 can	 be	 blocked	 by	
peripheral	nerve	block	with	4%	lidocaine,	and	that	the	same	paradigm	that	results	in	CPP	to	pain	
relief	 results	 in	 release	 of	 dopamine	 in	 the	 Nucleus	 Accumbens,	 a	 hallmark	 of	 the	 rewarding	
factor	of	pain	relief	(Remeniuk,	Sukhtankar	et	al.	2015).	In	addition	to	this	Remenuik	et	al.	2015	
also	demonstrated	that	whereas	the	NSAID	diclofenac	fails	to	alleviate	ongoing	pain,	morphine	
successfully	 does	 so.	 This	 being	 a	 direct	 translation	 from	 bed	 to	 bench	 of	 investigating	 CIBP	
using	 CPP	 to	 pain	 relief.	 Remenuik	 et	 al.	 2018	 also	 demonstrated	 that	 the	 inflammatory	
mediator	 IL-6	 plays	 a	 critical	 role	 in	 the	 development	 and	 establishment	 of	 cancer-induced	
ongoing	pain	(Remeniuk,	King	et	al.	2018).	To	my	knowledge	these	are	the	only	two	papers	using	
conditioned	 place	 preference	 to	 pain	 relief	 in	 the	 CIBP	 literature,	 however	work	 investigating	
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orofacial	cancer	pain	has	also	demonstrated	CPP	to	pain	relief	in	animals	with	cancer	(Gambeta,	
Kopruszinski	et	al.	2017).	
	 Work	presented	here	solidifies	 the	expected	 role	 that	Nav1.8	expressing	 fibers	play	 in	
transducing	 ongoing	 CIBP.	 As	 in	many	 other	models	 investigating	 the	 role	 of	 Nav1.8	 fibers	 in	
models	of	pain	we	demonstrate	that	using	a	novel	paradigm	of	Nav1.8	fiber	 inhibition,	we	can	
successfully	 induce	 CPP	 to	 pain	 relief	 in	mice	 bearing	 tumors	 in	 their	 femur.	 The	 observation	
that	inhibition	of	Nav1.8	fibers	in	cancer	bearing	but	not	sham	animals	induces	CPP	diminishes	
the	 likelihood	 that	 inhibition	 of	 Nav1.8	 fibers	 itself	 is	 rewarding,	 implying	 the	 likelihood	 that	
these	fibers	are	quiet	under	“normal”	conditions.	Silencing	these	fibers	at	the	level	of	the	spinal	
cord	dorsal	horn	 in	cancer-bearing	animals	blocks	the	transduction	of	nociceptive	signals	 from	
the	periphery,	 similar	 to	a	peripheral	nerve	block	which	has	been	previously	demonstrated	 to	
induce	CPP	to	pain	relief	(Remeniuk,	Sukhtankar	et	al.	2015).	This	is	an	intuitive	interpretation	of	
these	 results	 as	 it	 is	 well	 described	 and	 known	 that	 as	 a	 result	 of	 tumor	 growth	 and	 tumor-
induced	 destruction	 of	 the	 bone,	 fibers	 in	 this	 tissue	 are	 constantly	 being	 bombarded	with	 a	
slew	of	inflammatory	mediators	that	can	directly	activate	and	drive	signals	in	Nav1.8	expressing	
fibers	 (Mantyh	 2014,	Mantyh	 2014).	 As	 the	 Nav1.8	 fiber	 population	 includes	 the	 peptidergic	
population	of	nociceptive	neurons,	which	have	been	previously	demonstrated	 to	be	 critical	 in	
transducing	 nociceptive	 stimuli,	 it	 is	 very	 likely	 Nav1.8	 fibers	 are	 present	 in	 the	 bone	 and	
periosteum	and	undergo	changes	similar	to	those	described	in	the	peptidergic	fibers	described	
by	 others	 (Mach,	 Rogers	 et	 al.	 2002,	 Jimenez-Andrade,	 Bloom	 et	 al.	 2010,	 Bloom,	 Jimenez-
Andrade	 et	 al.	 2011,	 Castaneda-Corral,	 Jimenez-Andrade	 et	 al.	 2011).	 These	 observations	
contribute	to	the	body	of	work	using	optogenetics	to	 investigate	the	theory	that	Nav1.8	fibers	
are	critical	in	transducing	painful	stimuli	from	the	periphery.	
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	 Perhaps	the	most	 intriguing	results	 included	 in	this	body	of	work	 is	the	demonstration	
that	 ArchT	 induced	 silencing	 of	 MrgD	 expressing	 fibers	 in	 animals	 bearing	 tumors	 results	 in	
conditioned	 place	 preference.	 These	 data	 indicate	 that	 blockade	 of	MrgD	 expressing	 sensory	
fibers	likely	blocks	ongoing	CIBP	as	no	previous	interventions	have	induced	CPP	in	sham	animals.	
Additional	 studies	 are	 planned	 once	 the	 colony	 is	 re-established	 to	 verify/replicate	 this	
observation	 in	a	study	with	a	 larger	sample	size	and	 include	MrgD	sham	controls	as	 the	 initial	
study	only	 included	Nav1.8	 sham	controls.	As	mentioned	previously,	only	correlative	evidence	
exists	 using	 IHC	 methods	 staining	 for	 P2X3,	 staining	 with	 fluorescent	 IB4-conjugates,	 and	
transgenic	reporter	animals	that	demonstrates	a	lack	of	the	presence	of	these	fibers	in	the	naïve	
and	 cancer-afflicted	 femur	 (Mach,	 Rogers	 et	 al.	 2002,	 Jimenez-Andrade,	Mantyh	 et	 al.	 2010).	
Additionally,	 blockade	 or	 antagonism	 of	 P2X3	 with	 antibody	 or	 antagonist	 has	 been	
demonstrated	to	play	a	role	in	measures	of	CIBP	such	as	tactile	hypersensitivity.	Notably,	these	
measures	do	not	necessarily	measure	ongoing	pain	 (Kaan,	Yip	et	al.	2010,	Wu,	Xu	et	al.	2012,	
Guedon,	Longo	et	al.	2016).		
In	addition,	blocking	a	single	channel	on	a	fiber	differs	from	blocking	the	activity	of	the	
entire	neuron	as	we	do	by	 stimulating	ArchT	 in	 the	MrgD	expressing	neurons.	 Therefore,	 this	
may	account	for	differential	effects	observed	between	our	studies	and	those	selectively	blocking	
the	 P2X3	 channel.	 As	 such,	 whether	 MrgD	 fibers	 play	 a	 role	 in	 ongoing	 pain	 was	 an	 open	
question.	 Our	 work	 indicates	 that	 blocking	 MrgD	 fibers	 blocks	 ongoing	 pain	 both	 in	
acute/transient	 pain	 states	 as	 indicated	by	 our	AITC	 findings	 and	 likely	 in	 CIBP.	We	note	 that	
others	have	demonstrated	that	driving	MrgD	fibers	fails	to	induce	pain-like	behaviors	indicating	
that	driving	these	fibers	alone	may	not	be	sufficient	to	induce	pain	(Beaudry,	Daou	et	al.	2017).	
One	 limitation	of	previous	 imaging	studies	examining	whether	MrgD	expressing	or	 IB4-binding	
fibers	innervate	the	bone	is	that	identification,	 imaging	and	the	treatment	of	decalcified	tissue	
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as	well	as	the	periosteum	can	cause	loss	of	antigen	and	general	abuse	to	the	tissue,	resulting	in	
a	very	challenging	endeavor,	and	potentially	leading	to	a	false	negative	result	(Mach,	Rogers	et	
al.	2002,	Akkiraju,	Bonor	et	al.	2016).	These	reservations	of	previous	work	lend	some	in	the	field	
to	 believe	 there	may	 yet	 be	 a	 subpopulation	 of	 non-peptidergic	 fibers	 that	 does	 exist	 in	 the	
bone	but	has	not	been	discovered	or	reported.	
	 There	are	alternative	explanations	that	would	explain	CPP	to	inhibition	of	MrgD	fibers	in	
tumor	 bearing	 animals.	 Due	 to	 the	 rapid	 nature	 of	 how	 quickly	 optogenetic	 tools	 can	 inhibit	
neurons,	 and	 how	 quickly	 this	 electrochemical	 effect	 wears	 off,	 it	 is	 unlikely	 that	 ArchT	
mediated	inhibition	of	MrgD	fibers	results	in	a	proteomic	or	genetic	shift	in	cellular	activity	that	
could	produce	CPP.	This	begins	the	conundrum	of	interpreting	and	discussing	these	results	if,	as	
the	 field	 currently	 reports,	 MrgD	 fibers	 do	 not	 innervate	 the	 cancer	 afflicted	 femur	 or	
periosteum.	The	question	becomes	how	does	inhibiting	this	class	of	fibers	that	do	not	innervate	
the	 site	of	ongoing	 tumor	pathology,	 result	 in	a	positive	affective	condition	 for	 the	animals?	 I	
propose	 that	 the	 pain	 signal	 maintaining	 and	 generating	 ongoing	 pain	 originates	 from	 fibers	
either	in	the	bone	or	the	periosteum	surrounding	the	bone,	rather	than	a	secondary	site	such	as	
the	skin.	This	does	leave	the	possibility	that	sensitization	of	fibers	in	surrounding	or	anatomically	
relevant	 tissue	 can	 occur	 (i.e.	 peripheral	 and	 central	 sensitization)	 which	 may	 result	 in	
pathological	pain	originating	from	fibers	other	than	those	in	the	bone.	
One	attractive	hypothesis	is	that	if	indeed	MrgD	expressing	fibers	do	not	innervate	the	
bone	or	periosteum,	perhaps	activation	of	nociceptive	fibers	that	do	innervate	the	bone	in	one	
way	or	another	lead	to	the	generation	of	an	antidromic	signal	from	the	spinal	cord	that	leads	to	
the	 sensitization	of	MrgD	expressing	 fibers.	 Ferrari	et	al.	 2015,	elegantly	describes	 just	 such	a	
situation	 where	 hyperalgesic	 priming	 induced	 at	 the	 level	 of	 the	 spinal	 cord	 generates	 an	
antidromic	 signal,	 potentially	 CPEB	 mRNA,	 that	 induced	 hyperalgesia	 in	 peripheral	 sensory	
147	
	
fibers,	and	may	be	unique	to	the	non-peptidergic	population	of	nociceptors	(Ferrari,	Araldi	et	al.	
2015).	Origin	of	this	signal	 is	 likely	beyond	the	scope	of	this	body	of	work,	but	may	result	as	a	
cause	of	cancer-induced	hypertrophy	of	astrocytes	within	the	spinal	cord	as	reported	by	others	
(Sabino,	Luger	et	al.	2003).	Interestingly	in	a	side	by	side	comparison	of	the	effects	of	different	
cancer	cell	 lines,	out	of	the	sarcoma,	melanoma,	and	colon	tumors	compared,	melanoma	cells	
didn’t	 induce	drastic	bone	degradation,	did	not	 result	 in	ambulatory	movement	 induced	pain,	
and	 did	 not	 induce	 astrocyte	 hypertrophy	 in	 the	 spinal	 cord	 (Sabino,	 Luger	 et	 al.	 2003).	
Potentially	 indicating	a	necessary	role	of	astrocyte	hypertrophy	in	driving	measures	of	ongoing	
and	 ambulatory	 movement-induced	 pain.	 Interestingly,	 recent	 work	 using	 optogenetic	
activation	of	astrocytes	in	the	spinal	cord,	believed	to	induce	release	of	ATP	(an	activator	of	the	
P2X3	 receptor	 found	 on	 non-peptidergic	 fibers)	 has	 been	 shown	 to	 induce	 measures	 of	
nociception	from	the	hind	paw	(Nam,	Kim	et	al.	2016).	Perhaps	astrocytes	within	the	spinal	cord	
are	producing	a	signal	that	causes	changes	in	the	MrgD	expressing	population	of	neurons	in	an	
antidromic	fashion.	To	date	no	one	has	reported	whether	or	not	the	 induction	of	hyperalgesic	
priming	 results	 in	 a	 prolonged	 ongoing	 pain	 state	 that	 can	 be	 assessed	 by	 using	 CPP	 to	 pain	
relief.	 However,	 work	 by	 Okun	 et	 al.	 2011	 has	 demonstrated	 that	 while	 mechanical	
hypersensivity	persists,	 the	ongoing	pain	 from	CFA	 injection	 into	 the	hind	paw	does	diminish,	
and	previous	work	has	demonstrated	that	CFA	can	induce	hyperalgesic	priming	in	the	periphery.		
This	 observation	 does	 not	 entirely	 exclude	 the	 possibility	 that	 astrocytes	 are	 inducing	
some	form	of	sensitization	that	results	in	hyperalgesia,	or	some	form	of	activity	that	leads	to	an	
ongoing	pain	signal	 from	the	MrgD	expressing	neurons.	Not	only	are	mechanisms	of	 induction	
from	 the	 periphery	 different	 than	 signals	 from	 the	 spinal	 cord,	 cancer-induced	 activation	 of	
nociceptors	is	a	chronic	and	increasingly	intense	stimulus.	If	this	is	driving	pathology	capable	of	
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causing	sensitization,	it	is	likely	different	in	effect	compared	to	a	single	priming	stimulus,	not	to	
mention	different	in	nature	to	the	second	hyperalgesia	precipitating	stimulus.	 	
	
4.3.	Limitations	and	Lingering	Questions	
Role	of	TRPV1	and	IB4-binding	neurons	in	Ongoing	Pain	in	the	Rat.	While	the	objective	
of	 our	 work	 in	 the	 rat	 was	 to	 establish	 a	 model	 of	 BTP	 and	 investigate	 primary	 nociceptor	
populations	 in	said	model,	 it	would	have	been	exciting	 to	examine	whether	or	not	ablation	of	
TRPV1	or	IB4-binding	fibers	had	a	differential	effect	on	ongoing	pain.	Based	on	the	literature	at	
the	time,	with	the	overwhelmingly	demonstrated	role	for	peptidergic	fibers	in	classic	measures	
of	CIBP	pain	we	hypothesized	that	ablation	of	TRPV1	expressing	fibers	would	eliminate	ongoing	
pain,	whereas	ablation	of	IB4-binding	fibers	would	not.	With	the	addition	of	our	paper,	Havelin	
et	al.	 2017,	and	 the	work	provided	here	 in	 the	mouse,	 it	 is	possible	we	would	have	observed	
something	 different.	 One	 limitation	 to	 consider	 during	 this	 approach	 is	 that	 in	 the	 rat,	 the	
classical	 “peptidergic”	 and	 “non-peptidergic”	 populations	 of	 nociceptive	 fibers	 have	 been	
demonstrated	to	be	more	overlapping	than	what	is	observed	in	the	mouse,	and	in	the	rat	small	
numbers	 of	 fibers	 both	 bind	 IB4	 and	 express	 markers	 of	 peptidergic	 fibers	 (Price	 and	 Flores	
2007).	This	 can	confound	 the	 translatability	of	 results	between	 the	mouse	and	 rat,	where	 the	
ablation	of	 IB4-binding	fibers	 (non-peptidergic)	actually	results	 in	ablation	of	some	peptidergic	
fibers,	 and	 vice	 versa.	 While	 the	 minutia	 of	 this	 does	 not	 ultimately	 change	 the	 results	 of	
ablating	“all”	 fibers	of	one	category	or	the	other,	 it	could	hinder	steps	towards	 isolating	these	
populations	and	searching	for	targets	for	pharmacological	compounds.	Second,	the	approach	of	
ablating	fibers	can	 inevitably	 lead	to	the	development	of	compensatory	effects	of	the	nervous	
system.	Whether	 this	 be	 fiber	 populations	 growing	 into	 areas	 they	were	 previously	 restricted	
from,	or	perhaps	compensatory	signaling	where	fiber	terminals	once	were,	not	to	mention	the	
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potential	for	altered	signaling	properties	as	a	result	of	degenerated	neurons	both	in	the	spinal	
cord	and	in	the	dorsal	root	ganglion.	
Definitive	Role	of	MrgD	Expressing	Fibers	in	Ongoing	Pain	in	the	Mouse.	While	inhibition	
of	Nav1.8	 fibers	 in	 the	 sham	group	did	 not	 result	 in	 CPP,	 it	 is	worth	 examining	 the	 effects	 of	
inhibiting	just	the	MrgD	population	in	naïve	or	sham	treated	animals.	Inhibition	of	Nav1.8	fibers	
likely	results	 in	the	simultaneous	 inhibition	of	both	the	peptidergic	and	non-peptidergic	 fibers,	
which	has	been	demonstrated	here	to	be	neither	inherently	averse	nor	rewarding.	However	it	is	
beyond	 this	body	of	work	 to	hypothesize	 the	differences	 that	may	occur	during	 simultaneous	
inhibition	of	both,	or	inhibition	of	singular	populations,	this	contributes	to	the	necessity	to	test	
the	effects	of	independent	inhibition	of	the	MrgD	population.		
It	would	also	be	very	 interesting	to	utilize	the	recently	published	CGRP-cre	mouse	that	
would	allow	for	inhibition	of	the	peptidergic	population	in	our	approach	(Cowie,	Moehring	et	al.	
2018).	Based	solely	on	the	literature	surrounding	CIBP,	I	hypothesize	we	would	also	see	CPP	to	
pain	relief	by	 inhibiting	the	peptidgeric	population	of	 fibers.	 If	 this	were	to	end	up	being	true,	
many,	many	grants	could	be	written	proposing	ideas	to	investigate	signaling	at	the	level	of	the	
spinal	cord	and	DRG	examining	converging	or	diverging	roles	for	these	populations.	
Steps	 to	 Investigate	 Rearing	 and	 Movement	 as	 Measures	 of	 BTP	 in	 the	 Mouse	 and	
Utilizing	Optogenetics	to	Tease	out	Fibers’	Roles	in	BTP.	We	provide	here	at	least	2	measures	of	
behaviors	that	are	altered	in	cancer	bearing	animals	that	are	not	 in	sham	animals,	and	several	
others	 that	 may	 reflect	 anxiety	 behaviors	 in	 cancer-bearing	 mice.	 There	 are	 many	 more	
parameters	and	behaviors	that	can	be	observed	and	measured	using	locomotor	chambers.	The	
telltale	examination	to	prove	that	rearing	and	distance	traveled	may	be	used	as	measures	of	BTP	
would	be	to	demonstrate	that	hind	limb	movement	induced	decrease	in	behaviors	persists	while	
a	MOR	 agonist	 is	 onboard.	We	 did	 in	 fact	 try	 this	 using	 25mg	morphine	 pellets,	 however	 24	
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hours	post	morphine	pellet	implantation	our	wildtype	mice	still	exhibited	stereotypical	signs	of	
high	 dose	 MOR	 agonists,	 i.e.	 straub	 tail,	 hyperlocomotion	 and	 circling	 patterns.	 Specifically,	
hyperlocomotion	 and	 circling	 patterned	 behavior	 resulted	 in	 an	 inability	 to	 use	 distance	
travelled	or	rearing	as	a	measure	of	behavior,	the	mice	treated	with	morphine	demonstrated	an	
immense	increase	in	movement,	and	in	addition	to	this	they	spent	very	little	time	rearing.	
	 We	also	began	to	investigate	whether	or	not	inhibition	of	Nav1.8	or	MrgD	fibers	blocked	
hind	 limb	 movement	 decreases	 in	 distance	 travelled	 and	 rearing,	 however,	 we	 met	 several	
technical	challenges	that	stopped	these	results	from	being	completed	and	included	in	this	body	
of	work.	The	approach	we	took	while	doing	this	was	by	inhibiting	either	population	of	neurons	
for	2	minutes	prior	to	hind	limb	movement,	the	2	minutes	during	hind	limb	movement	and	then	
were	placed	into	a	chamber	with	laser	activation	of	2	minutes	ON	and	1	minute	OFF	for	the	30-
minute	duration	of	testing.	The	first	challenge	in	doing	this	is	restraining	the	animal	while	it	has	
a	 laser	 cord	 attached	 to	 its	 head.	 This	 occasionally	 resulted	 in	 abrupt	 disruption	 of	 the	 fiber	
implant	 rendering	 it	useless,	blocking	our	 ability	 to	 successfully	expose	neuron	populations	 to	
our	 520nm	 laser,	 and	 inhibiting	 them.	 In	 the	 animals	we	 did	 successfully	 expose	 to	 our	 laser	
paradigm	we	 did	 not	 see	 a	 reversal	 of	 behaviors.	 This	 could	 be	 the	 result	 of	 any	 number	 of	
things.	A	few	thoughts	and	examples	I	have	had	are	that	pre-exposure	to	the	laser	may	not	have	
been	 long	 enough	 to	 inhibit	 or	 outcompete	 signals	 being	 generated	 in	 the	 periphery,	 or	 that	
unavoidable	complications	persist	with	our	approach	 to	having	 the	mice	attached	 to	 the	 laser	
source.	The	implementation	of	wireless	optogenetics	may	allow	for	a	path	around	some	of	these	
potential	complications.	
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4.4.	Future	Directions	
Complexities	 of	 the	 fiber	 implant	 surgery,	 timing	of	 CIBP	with	 the	health	of	 the	mice,	
and	 mouse	 colony	 challenges	 stopped	 us	 from	 investigating	 whether	 transient	 inhibition	 of	
MrgD	 fibers	 blocks	 tactile	 hypersensitivity.	 It	 will	 be	 interesting	 to	 investigate	 this	 when	 the	
MrgD-ArchT	colony	of	mice	 is	reestablished.	 If	reversal	of	tactile	hypersensitivity	 is	observed	it	
would	emphasize	a	role	of	the	MrgD	(non-peptidergic)	fibers	in	transducing	mechanical	modality	
of	nociception.		
Investigating	GABAergic	signaling	in	the	lumbar	spinal	cord	in	BTP.	Current	work	in	the	
laboratory	 is	 investigating	 the	 role	 for	 GABAergic	 signaling	 in	 the	 lumbar	 spinal	 cord	 both	
utilizing	pharmacological	and	optogenetic	 interventions.	This	direction	 follows	 the	observation	
that	lidocaine	before	hind	limb	movement	blocks	BTP	while,	lidocaine	post	hind	limb	movement	
fails	 to	do	so.	This	dichotomy	raises	 interesting	questions	about	what	may	be	occurring	at	the	
level	of	 the	spinal	cord	or	supraspinal	 in	 terms	of	maintaining	the	experience	of	BTP.	 It	would	
also	be	 interesting	 to	 investigate	 the	role	 the	rACC	or	RVM	may	be	playing	 in	maintaining	 the	
unpleasant	affective	component	of	hind	limb	induced	BTP.	
	
Immunohistochemical	Analysis	of	Tissues.	Current	work	in	the	lab	is	investigating	of	the	effects	
cancer-induced	bone	remodeling	and	pain	has	on	peripheral	nerves	in	the	bone	and	periosteum,	
as	well	as	sensory	nerve	terminals	in	the	spinal	cord	dorsal	horn.	We	are	currently	performing	a	
number	of	comparisons	between	naïve,	sham	treated	and	cancer	treated	animals.		
The	 first	 investigation	we	are	performing	 is	 to	 identify	whether	Nav1.8	or	MrgD	fibers	
are	undergoing	sprouting	in	the	bone	or	periosteum.	Although	several	publications	have	already	
investigated	fiber	sprouting	in	the	bone,	we	have	collected	bones	from	animals	that	expressed	
tdtomato	in	either	Nav1.8	expressing	or	MrgD	expressing	cells,	with	the	goal	of	identifying	their	
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location	 in	 the	 bone,	 and	 what	 changes	 they	may	 undergo	 during	 cancer.	We	 expect	 to	 see	
pathological	 sprouting	of	Nav1.8	 fibers	 in	animals	 that	have	 tumor	growth	within	 their	bones,	
while	 observing	 relatively	 normal	 morphology	 of	 fiber	 endings	 in	 naïve	 and	 sham	 treated	
animals.	This	would	replicate	previous	work	by	Pat	Mantyh	as	the	Nav1.8	fibers	should	contain	
peptidergic	 fibers	that	have	been	extensively	demonstrated	to	undergo	pathological	growth	 in	
the	presence	of	cancer.	Given	our	 results	 that	demonstrated	CPP	to	 inhibition	of	MrgD	 fibers,	
we	 aren’t	 sure	 if	 we	 will	 see	 MrgD-tdtomato	 fibers	 undergo	 pathological	 sprouting	 into	 the	
bone.	Presumably	based	on	the	literature,	there	will	be	no	MrgD-tdtomato	fibers	in	the	bone	or	
periosteum	of	naïve	or	 sham	animals.	Despite	 results	published	 in	 the	mouse,	 there	 is	always	
the	slight	possibility	that	different	cancer	lines	and	different	strains	of	mice	respond	differently	
to	this	procedure.	Most	of	the	previous	work	in	mice	has	been	with	immunocompromised	mice,	
C3H	mice	or	BalbC	strains	of	mice,	and	different	cell	lines	than	the	LLC	line	we	used.	
Secondly	 we	 are	 investigating	 the	 correlation	 between	 ATF3	 expression	 and	 fiber	
subtypes	in	L2	and	L4	DRG	in	naïve,	sham	and	cancer	treated	animals.	Previous	reports	by	Peters	
et	 al.	 2005	 and	 King	 et.	 Al	 2007	 demonstrated	 increased	 ATF3	 expression	 in	 cancer	 bearing	
animals	to	differing	degrees.	We	would	like	to	understand	if	ATF3	expression	occurs	to	a	higher	
degree	 in	 Nav1.8+	 cells	 than	 Nav1.8-	 negative	 cells,	 or	 if	 ATF3	 is	 induced	 evenly	 amongst	
different	 cell	 types.	 If	 ATF3	 is	 selectively,	 or	 at	 least	 correlated	 to	 be	 expressed	 more	 so	 in	
Nav1.8	cells,	it	might	mean	that	nerve	injury	may	be	driving	some	degree	of	neuropathic	pain	in	
this	 model.	 We	 ask	 the	 same	 question	 in	 MrgD	 expressing	 cells.	 ATF3	 expression	 in	 MrgD-
tdtomato+	 cells	may	mean	 that	 cancer-induced	bone	 remodeling	or	 pain	 is	 somehow	 causing	
nerve	 damage	 to	 this	 cell	 population	 that	 has	 classically	 been	demonstrated	 to	 innervate	 the	
skin.		
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4.5	Concluding	Remarks	
In	 conclusion,	 this	 body	 of	 work	 contains	 novel	 implications	 of	 the	 role	 of	 subpopulations	 of	
sensory	 neurons	 contributing	 to	 cancer-induced	 bone	 pain.	 Additionally	 this	 body	 of	 work	
contributes	 to	 the	 body	 of	 work	 emphasizing	 the	 heterogeneity,	 and	 therefore	 difficulty	 of	
uncovering	critical	mechanisms	driving	cancer-induced	bone	pain.	Work	here	also	supports	the	
differential	 roles	 of	 subpopulations	 of	 sensory	 fibers,	 and	demonstrates	 a	 unique	 role	 for	 the	
non-peptidergic,	 specifically	MrgD	expressing,	 fibers	 in	 transducing	 cancer-induced	bone	pain.	
Future	work	involving	the	study	of	cancer-induced	bone	pain	should	not	discount	and	continue	
to	 study	 the	 potentially	 critical	 role	 that	 MrgD	 expressing	 fibers	 may	 be	 playing	 in	 cancer-
induced	bone	pain,	as	work	in	the	field	has	and	likely	currently	is	being	done.		It	is	my	hope	that	
these	novel	findings	contribute	to	the	future	work	and	discovery	of	more	optimal	treatments	for	
those	who	are	unfortunate	enough	to	suffer	from	cancer	pain,	and	cancer-induced	bone	pain.	
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